 EXHIBIT 2.1      



  

Exhibit 2.1

   



  

EXECUTION VERSION

  



  

AGREEMENT AND PLAN OF MERGER

  



  

among

  



  

DENTSPLY International Inc.,

  



  

Sirona Dental Systems, Inc.,

  



  

and

  



  

Dawkins Merger Sub Inc.

  



  

Dated as of September 15, 2015

  



    



 



    



  

TABLE OF CONTENTS

  



       |   | Page 
---|---|--- 
     | 
   ARTICLE 1 The Merger  | 2 
     |   | 
   1.1  | The Merger  | 2 
   1.2  | Closing  | 2 
   1.3  | Effective Time  | 2 
   1.4  | Charters and Bylaws  | 2 
   1.5  | Directors and Officers of the Surviving Corporation  | 3 
   1.6  | Directors and Officers of DENTSPLY  | 3 
   1.7  | Headquarters  | 4 
   1.8  | Tax Treatment  | 4 
     | 
   ARTICLE 2 Conversion of Securities IN THE MERGER  | 4 
     |   | 
   2.1  | Effect on Capital Stock of Sirona and Merger Sub  | 4 
   2.2  | Effect on DENTSPLY Common Stock  | 5 
   2.3  | Certain Adjustments  | 5 
   2.4  | Fractional Shares  | 5 
   2.5  | Exchange of Certificates and Book-Entry Shares  | 6 
   2.6  | Sirona Stock Options and Stock-Based Awards  | 9 
   2.7  | Withholding Rights  | 10 
     | 
   ARTICLE 3 Representations and Warranties of Sirona  | 10 
     |   | 
   3.1  | Corporate Organization  | 11 
   3.2  | Sirona Capitalization  | 11 
   3.3  | Authority; Execution and Delivery; Enforceability  | 13 
   3.4  | No Conflicts  | 13 
   3.5  | SEC Documents; Financial Statements; Undisclosed Liabilities  |
14 
   3.6  | Absence of Certain Changes or Events  | 16 
   3.7  | Information Supplied  | 16 
   3.8  | Legal Proceedings  | 17 
   3.9  | Compliance with Laws  | 17 
   3.10  | Permits  | 18 
   3.11  | Employee Benefit Plans  | 19 
   3.12  | Employee and Labor Matters  | 21 
   3.13  | Environmental Matters  | 22 
   3.14  | Real Property  | 23 
   3.15  | Tax Matters  | 23 
   3.16  | Material Contracts  | 26 
   3.17  | Intellectual Property  | 28 
   3.18  | Healthcare Compliance Matters  | 30 
   3.19  | Broker's Fees  | 32 
   3.20  | Opinion of Financial Advisor  | 32 
   3.21  | Ownership of DENTSPLY Common Stock  | 33 
   3.22  | Insurance  | 33 
  



    

i

 



    



     3.23  | No Other Representations or Warranties  | 33 
---|---|--- 
     | 
   ARTICLE 4 Representations and Warranties of DENTSPLY AND MERGER SUB  |
33 
     |   | 
   4.1  | Corporate Organization  | 34 
   4.2  | DENTSPLY Capitalization  | 34 
   4.3  | Authority; Execution and Delivery; Enforceability  | 36 
   4.4  | No Conflicts  | 37 
   4.5  | SEC Documents; Financial Statements; Undisclosed Liabilities  |
37 
   4.6  | Absence of Certain Changes or Events  | 39 
   4.7  | Information Supplied  | 40 
   4.8  | Legal Proceedings  | 40 
   4.9  | Compliance with Laws  | 40 
   4.10  | Permits  | 41 
   4.11  | Employee Benefit Plans  | 42 
   4.12  | Employee and Labor Matters  | 44 
   4.13  | Environmental Matters  | 45 
   4.14  | Real Property  | 46 
   4.15  | Tax Matters  | 47 
   4.16  | Material Contracts  | 49 
   4.17  | Intellectual Property  | 51 
   4.18  | Healthcare Compliance Matters  | 54 
   4.19  | Broker's Fees  | 56 
   4.20  | Opinion of Financial Advisor  | 56 
   4.21  | Ownership of Sirona Common Stock  | 56 
   4.22  | Insurance  | 56 
   4.23  | Merger Sub  | 57 
   4.24  | No Other Representations or Warranties  | 57 
     | 
   ARTICLE 5 Covenants  | 57 
     |   | 
   5.1  | Conduct of Business by Sirona Pending the Effective Time  | 57 
   5.2  | Conduct of Business by DENTSPLY Pending the Effective Time  | 61 
   5.3  | Preparation of the Form S-4 and the Joint Proxy Statement;
Shareholders Meetings  | 65 
   5.4  | No Solicitation of Transactions  | 68 
   5.5  | Access to Information; Confidentiality  | 73 
   5.6  | Appropriate Action  | 73 
   5.7  | Certain Notices  | 76 
   5.8  | Public Announcements  | 76 
   5.9  | Indemnification  | 77 
   5.10  | Financing Matters  | 78 
   5.11  | Stock Exchange Listing  | 79 
   5.12  | Section 16 Matters  | 79 
   5.13  | Shareholder Litigation  | 79 
   5.14  | Tax Matters  | 79 
   5.15  | Employee Matters  | 80 
  



    

ii

 



    



     5.16  | Cooperation  | 82 
---|---|--- 
     | 
   ARTICLE 6 Conditions to Consummation of the Merger  | 82 
     |   | 
   6.1  | Conditions to Obligations of Each Party Under This Agreement  |
82 
   6.2  | Conditions to Obligations of DENTSPLY and Merger Sub Under This
Agreement  | 83 
   6.3  | Conditions to Obligations of Sirona Under This Agreement  | 84 
     | 
   ARTICLE 7 Termination, Amendment and Waiver  | 85 
     |   | 
   7.1  | Termination  | 85 
   7.2  | Effect of Termination  | 86 
   7.3  | Termination Fee; Expenses  | 87 
   7.4  | Amendment or Supplement  | 89 
   7.5  | Extension of Time; Waiver  | 90 
     | 
   ARTICLE 8 General Provisions  | 90 
     |   | 
   8.1  | Non-Survival of Representations and Warranties  | 90 
   8.2  | Notices  | 90 
   8.3  | Certain Definitions  | 91 
   8.4  | Terms Defined Elsewhere  | 99 
   8.5  | Headings  | 103 
   8.6  | Severability  | 103 
   8.7  | Entire Agreement  | 103 
   8.8  | Assignment  | 103 
   8.9  | Parties in Interest  | 103 
   8.10  | Mutual Drafting; Interpretation  | 104 
   8.11  | Governing Law; Consent to Jurisdiction; Waiver of Trial by
Jury  | 104 
   8.12  | Counterparts  | 105 
   8.13  | Delivery by Facsimile or Email  | 105 
   8.14  | Specific Performance  | 105 
   8.15  | Disclosure Schedules  | 105 
  



     Exhibit A  | Form of Certificate of Incorporation of the Surviving
Corporation 
---|--- 
   Exhibit B  | Form of Amended and Restated Certificate of Incorporation
of DENTSPLY 
   Exhibit C  | Form of Amended and Restated Bylaws of DENTSPLY SIRONA Inc. 
   Exhibit D  | Form of Corporate Governance Policies/Guidelines of
DENTSPLY SIRONA Inc. 
  



    

iii

 



    



  

AGREEMENT AND PLAN OF MERGER

  



  

THIS AGREEMENT AND PLAN OF MERGER (this " _Agreement_ ") is dated as of
September 15, by and among DENTSPLY International Inc., a
Delaware corporation (" _DENTSPLY_ "), Sirona Dental Systems, Inc., a
Delaware corporation (" _Sirona_ "), and Dawkins Merger Sub Inc., a Delaware
corporation and a wholly-owned subsidiary of DENTSPLY (" _Merger Sub_ ").

  



  

recitals

  



  

WHEREAS, each of DENTSPLY, Sirona and Merger Sub desire, following the
satisfaction or waiver of the conditions set forth in _Article 6_, to
effect the Merger upon the terms and conditions set forth in this Agreement
pursuant to which Merger Sub shall be merged with and into Sirona, with
Sirona as the surviving entity in the Merger and becoming a wholly-owned
subsidiary of DENTSPLY;

  



  

WHEREAS, the Boards of Directors of each of DENTSPLY, Sirona and Merger Sub
have each approved and declared advisable this Agreement and the
Transactions, including the Merger, and determined that it is advisable and
in the best interests of their respective companies and shareholders to
consummate the Merger and the Transactions on the terms and conditions set
forth in this Agreement;

  



  

WHEREAS, the Board of Directors of DENTSPLY has, subject to _Section 5.4_,
unanimously resolved to recommend the approval of the DENTSPLY Share Issuance
and the Amended and Restated DENTSPLY Charter by the DENTSPLY shareholders,
and following the execution and delivery of this Agreement, DENTSPLY shall
adopt and approve this Agreement and the Merger as the sole shareholder of
Merger Sub;

  



  

WHEREAS, the Board of Directors of Sirona has, subject to _Section 5.4_,
unanimously resolved to recommend the adoption of this Agreement by the
Sirona shareholders;

  



  

WHEREAS, for U.S. federal income Tax purposes, it is intended that the Merger
qualify as a "reorganization" within the meaning of Section 368(a) of the
Code, and the regulations promulgated thereunder, that this Agreement will
constitute a "plan of reorganization" for purposes of Sections 354 and 361 of
the Code, and that Sirona, Merger Sub and DENTSPLY will each be a "party to
the reorganization" within the meaning of Section 368(b) of the Code; and

  



  

WHEREAS, DENTSPLY, Sirona and Merger Sub desire to make certain
representations, warranties, covenants and agreements in connection with the
Merger and also to prescribe various conditions to the Merger.

  



  

agreement

  



  

NOW, THEREFORE, in consideration of the mutual covenants and premises
contained in this Agreement and for other good and valuable consideration, the
receipt and adequacy of which are hereby acknowledged, the parties to this
Agreement agree as follows:

  



    



 



    



  

ARTICLE 1 
 The Merger

  



  

1.1 _The Merger_.

  



  

(a) At the Effective Time, Merger Sub shall be merged with and into
Sirona (the " _Merger_ ") in accordance with the DGCL, and upon the terms and
conditions set forth in this Agreement, whereupon the separate existence of
Merger Sub shall cease and Sirona shall continue as the surviving corporation
(the " _Surviving Corporation_ "). As a result of the Merger, the
Surviving Corporation shall become a wholly-owned subsidiary of DENTSPLY. The
Merger and other transactions contemplated by this Agreement are referred to
herein as the " _Transactions_." References herein to "Sirona" with respect to
the period from and after the Effective Time shall be deemed to be references
to the Surviving Corporation.

  



  

(b) The Merger shall have the effects specified in the DGCL. From
and after the Effective Time, the Surviving Corporation shall possess all the
rights, powers, privileges and franchises and be subject to all of the
obligations, liabilities and duties of Sirona and Merger Sub, all as provided
under the DGCL.

  



  

1.2 _Closing_. The closing of the Merger (the " _Closing_ ") shall
take place at the offices of Latham and Watkins LLP, 885 Third Avenue, New
York, New York, 10022-4834 at 9:00 a.m. local time, as soon as practicable
(and, in any event, within three (3) Business Days) after satisfaction or, to
the extent permitted hereunder, waiver of all applicable conditions set
forth in _Article 6 _(except for any conditions that by their nature can
only be satisfied at the Closing, but subject to the satisfaction of such
conditions or waiver by the party entitled to waive such conditions) or at
such other time and place as DENTSPLY and Sirona shall agree. The date and
time at which the Closing occurs is referred to herein as the "
_Closing Date_."

  



  

1.3 _Effective Time_.

  



  

(a) On the Closing Date, Sirona and Merger Sub shall file a
certificate of merger relating to the Merger (the " _Certificate of Merger_
") with the Secretary of State of the State of Delaware in accordance with the
relevant provisions of the DGCL and shall make all other filings or
recordings required under the DGCL.

  



  

(b) The Merger shall become effective at the time the Certificate of
Merger shall have been duly filed with the Secretary of State of the State of
Delaware, or such later time as Sirona and DENTSPLY shall agree and specify in
the Certificate of Merger (such time as the Merger becomes effective being
the " _Effective Time_ ").

  



  

1.4 _Charters and Bylaws_.

  



  

(a) _Surviving Corporation Certificate of Incorporation and
Bylaws_. At the Effective Time, the certificate of incorporation of the
Surviving Corporation shall be amended and restated pursuant to the Merger in
its entirety as set forth on _Exhibit A_ , until thereafter changed or
amended as provided therein or by applicable Law. The name of the Surviving
Corporation immediately after the Effective Time shall be "Sirona Dental
Systems, Inc." At the Effective Time, the bylaws of the Surviving Corporation
shall be amended and restated in their entirety so as to be identical to the
bylaws of Merger Sub as in effect immediately prior to the Effective Time
(except that the name of the Surviving Corporation shall be reflected as
"Sirona Dental Systems, Inc.") until thereafter changed or amended as
provided therein or by applicable Law.

  



    

 | 2| 
---|---|--- 

 



    



  

(b) _DENTSPLY Certificate of Incorporation and Bylaws; Name_.
Subject to the receipt of the DENTSPLY Shareholder Approval, at the
Effective Time, the certificate of incorporation of DENTSPLY (as in effect
immediately prior to the Effective Time) shall be amended and restated in its
entirety as set forth on _Exhibit B_ (the " _Amended and Restated DENTSPLY
Charter_ "), until thereafter changed or amended as provided therein or by
applicable Law. At the Effective Time, the DENTSPLY Bylaws shall be
amended and restated in their entirety as set forth on _Exhibit C_ and the
DENTSPLY Corporate Governance Guidelines/Policies shall be amended and
restated in their entirety as set forth on _Exhibit D_. As set forth in the
Amended and Restated DENTSPLY Charter, the name of DENTSPLY shall be
"DENTSPLY SIRONA Inc."

  



  

1.5 _Directors and Officers of the Surviving Corporation_. From and
after the Effective Time, until successors are duly elected or appointed and
qualified in accordance with applicable Law, (i) the directors of the
Surviving Corporation shall be the directors as set forth in _Section 1.5_
of the Sirona Disclosure Schedule and (ii) the officers of the Surviving
Corporation shall be the officers as set forth in _Section 1.5_ of the Sirona
Disclosure Schedule.

  



  

1.6 _Directors and Officers of DENTSPLY_.

  



  

(a) Effective at the Effective Time, unless otherwise agreed by
Sirona and DENTSPLY in writing, DENTSPLY shall take all necessary action to
cause the size of the DENTSPLY Board to be increased to eleven (11) members,
five (5) of which shall be designated by the Board of Directors of Sirona and
each of which shall be a director of Sirona immediately prior to the Effective
Time, and six (6) of which shall be designated by the Board of Directors of
DENTSPLY and each of which shall be a director of DENTSPLY immediately prior
to the Effective Time. One of Sirona's director designees shall be the chief
executive officer of Sirona immediately prior to the Effective Time and one
of DENTSPLY director designees shall be the chief executive officer of
DENTSPLY immediately prior to the Effective Time. All other director
designees shall qualify as an "independent director", as such term is defined
in NASDAQ Equity Rule 5605(a)(2); _provided_ , that at least two of the
Sirona designees and two of the DENTSPLY designees shall meet the
minimum requirements to serve on Sirona's audit committee under the NASDAQ
Marketplace Rules. Effective at the Effective Time, unless otherwise agreed
by Sirona and DENTSPLY in writing, DENTSPLY shall take all necessary action to
cause (i) Bret W. Wise to be appointed to act as executive chairman of the
DENTSPLY Board, (ii) the directors designated by Sirona and DENTSPLY
respectively to be appointed to the DENTSPLY Board, (iii) the audit committee
of the DENTSPLY Board to be comprised of two directors designated by
DENTSPLY and one director designated by Sirona, with one such director
designated by DENTSPLY to act as the chairperson of the audit committee of
the DENTSPLY Board, (iv) the compensation committee of the DENTSPLY Board to
be comprised of two directors designated by DENTSPLY and two directors
designated by Sirona, with one such director designated by Sirona to act as
the chairperson of the compensation committee of the DENTSPLY Board, (v) the
nominating and corporate governance committee of the DENTSPLY Board to be
comprised of two directors designated by DENTSPLY and two directors
designated by Sirona, with one such director designated by DENTSPLY to act as
the chairperson of the nominating and corporate governance committee of the
DENTSPLY Board and (vi) one director designated by Sirona to be appointed as
lead independent director.

  



    

 | 3| 
---|---|--- 

 



    



  

(b) Effective at the Effective Time, DENTSPLY shall take all
necessary action to cause Jeffrey T. Slovin to be appointed as chief executive
officer of DENTSPLY and to designate the other officers of DENTSPLY as may be
agreed by DENTSPLY and Sirona prior to the Effective Time, such officers to
serve from and after the Effective Time until successors are duly elected or
appointed and qualified in accordance with applicable Law.

  



  

1.7 _Headquarters_. At the Effective Time, the global headquarters
and related corporate functions for DENTSPLY and its Subsidiaries will be
located in York, Pennsylvania, and the international headquarters and related
international corporate functions for DENTSPLY and its Subsidiaries will be
located in Salzburg, Austria.

  



  

1.8 _Tax Treatment_. For U.S. federal income Tax purposes, it is
intended that the Merger qualify as a "reorganization" within the meaning of
Section 368(a) of the Code, and the regulations promulgated thereunder, that
this Agreement will constitute a "plan of reorganization" for purposes of
Sections 354 and 361 of the Code, and that Sirona, Merger Sub and
DENTSPLY will each be a "party to the reorganization" within the meaning of
Section 368(b) of the Code.

  



  

ARTICLE 2 
 Conversion of Securities IN THE MERGER

  



  

2.1 _Effect on Capital Stock of Sirona and Merger Sub_. At the
Effective Time, by virtue of the Merger and without any action on the part of
DENTSPLY, Sirona, Merger Sub or any holder of any shares of Sirona common
stock, $0.01 par value per share (" _Sirona Common Stock_ "):

  



  

(a) All shares of Sirona Common Stock that are owned by DENTSPLY,
Sirona or Merger Sub immediately prior to the Effective Time shall cease to
be outstanding and shall be cancelled and retired and shall cease to exist,
and no consideration shall be delivered in exchange therefor.

  



  

(b) Subject to _Section 2.1(a)_ , _Section 2.3_ and _Section 2.6_ ,
each share of Sirona Common Stock issued and outstanding immediately prior to
the Effective Time shall be converted into and thereafter represent the right
to receive that number of validly issued, fully paid and non-assessable
shares of DENTSPLY common stock, $0.01 par value per share (" _DENTSPLY Common
Stock_ "), equal to the Exchange Ratio. The shares of DENTSPLY Common Stock
to be issued upon the conversion of shares of Sirona Common Stock pursuant to
this _Section 2.1_ are referred to collectively as the " _Merger
Consideration_." For purposes of this Agreement, " _Exchange Ratio_ " means
1.8142.

  



    

 | 4| 
---|---|--- 

 



    



  

(c) All of the shares of Sirona Common Stock shall be converted into
shares of DENTSPLY Common Stock pursuant to this _Section 2.1_ and shall
cease to be outstanding and shall cease to exist and, as of the Effective
Time, each holder of a certificate representing any such shares of Sirona
Common Stock (a " _Sirona Certificate_ ") or shares of Sirona Common Stock
held in book entry form (" _Sirona Book-Entry Shares_ ") shall cease to have
any rights with respect thereto, except the right to receive, in accordance
with _Section 2.1(b)_, the Merger Consideration, upon surrender of such
Sirona Certificate or Sirona Book-Entry Share.

  



  

(d) Each share of common stock, par value $0.01 per share, of Merger
Sub issued and outstanding immediately prior to the Effective Time shall be
converted into one share of common stock, par value $0.01 per share, of
Surviving Corporation.

  



  

2.2 _Effect on DENTSPLY Common Stock_. At the Effective Time, each
share of DENTSPLY Common Stock issued and outstanding immediately prior to
the Effective Time shall remain outstanding. Immediately following the
Effective Time, shares of DENTSPLY Common Stock owned by Surviving
Corporation or any wholly-owned Subsidiary of Surviving Corporation shall be
surrendered to DENTSPLY without payment therefor.

  



  

2.3 _Certain Adjustments_. Notwithstanding anything in this
Agreement to the contrary, if, from the date of this Agreement until the
Effective Time, the outstanding shares of DENTSPLY Common Stock or Sirona
Common Stock shall have been changed into a different number of shares or a
different class by reason of any reclassification, stock split (including a
reverse stock split), recapitalization, split-up, combination, exchange of
shares, readjustment, or other similar transaction, or a stock dividend or
stock distribution thereon shall be declared with a record date within said
period, the Merger Consideration and the Exchange Ratio and any
other similarly dependent items, as the case may be, shall be equitably
adjusted to provide the holders of Sirona Common Stock the same economic
effect as contemplated by this Agreement prior to such event.

  



  

2.4 _Fractional Shares_.

  



  

(a) No fractional shares of DENTSPLY Common Stock shall be issued in
the Merger, but in lieu thereof each holder of Sirona Common Stock otherwise
entitled to a fractional share of DENTSPLY Common Stock will be entitled to
receive, from the Exchange Agent in accordance with the provisions of this
_Section 2.4_ , a cash payment in lieu of such fractional share of DENTSPLY
Common Stock representing such holder's proportionate interest, if any, in
the proceeds from the sale by the Exchange Agent (reduced by any fees of the
Exchange Agent attributable to such sale) in one or more transactions of
shares of DENTSPLY Common Stock equal to the excess of (A) the aggregate
number of shares of DENTSPLY Common Stock to be delivered to the Exchange
Agent by DENTSPLY pursuant to _Section 2.5(a)(i)_ over (B) the aggregate
number of whole shares of DENTSPLY Common Stock to be distributed to the
holders of shares of Sirona Common Stock pursuant to _Section 2.5(b)_ (such
excess, the " _Excess Shares_ "). Sirona, DENTSPLY and the Merger Sub
acknowledge that payment of the cash consideration in lieu of issuing
fractional shares of DENTSPLY Common Stock was not separately bargained-for
consideration but merely represents a mechanical rounding off for purposes of
avoiding the expense and inconvenience to DENTSPLY that would otherwise be
caused by the issuance of fractional shares of DENTSPLY Common Stock. As soon
as practicable after the Effective Time, the Exchange Agent, as agent for the
holders of Sirona Common Stock that would otherwise receive fractional shares
of DENTSPLY Common Stock, shall sell the Excess Shares at then prevailing
prices on the NASDAQ in the manner provided in the following paragraph.

  



    

 | 5| 
---|---|--- 

 



    



  

(b) The sale of the Excess Shares by the Exchange Agent, as agent
for the holders of Sirona Common Stock that would otherwise receive
fractional shares of DENTSPLY Common Stock, shall be executed on the NASDAQ
and shall be executed in round lots to the extent practicable. Until the
proceeds of such sale or sales have been distributed to the holders of Sirona
Common Stock, the Exchange Agent shall hold such proceeds in trust for the
holders of Sirona Common Stock that would otherwise receive fractional shares
of DENTSPLY Common Stock (the " _Common Shares Trust_ "). The Exchange Agent
shall determine the portion of the Common Shares Trust to which each holder
of Sirona Common Stock shall be entitled, if any, by multiplying the amount of
the aggregate proceeds comprising the Common Shares Trust by a fraction, the
numerator of which is the amount of the fractional share interest to which
such holder of Sirona Common Stock would otherwise be entitled and the
denominator of which is the aggregate amount of fractional share interests to
which all holders of Sirona Common Stock would otherwise be entitled (the "
_Fractional Shares Cash Amount_ ").

  



  

(c) As soon as practicable after the determination of the amount of
cash, if any, to be paid to holders of Sirona Common Stock in lieu of any
fractional shares of DENTSPLY Common Stock, the Exchange Agent shall make
available such amounts to such holders of shares of Sirona Common Stock
without interest, subject to and in accordance with _Section 2.5_.

  



  

2.5 _Exchange of Certificates and Book-Entry Shares_.

  



  

(a) Prior to the dissemination of the Joint Proxy Statement to the
shareholders of Sirona and the shareholders of DENTSPLY, DENTSPLY
shall appoint a nationally recognized financial institution reasonably
acceptable to Sirona to act as exchange agent (the " _Exchange Agent_ ") for
the payment and delivery of the Merger Consideration. At or prior to the
Effective Time, DENTSPLY shall deposit, in trust for the benefit of the
holders of Sirona Common Stock, with the Exchange Agent for exchange in
accordance with this _Article 2_, (i) a number of shares of DENTSPLY Common
Stock equal to the total shares of DENTSPLY Common Stock issuable pursuant to
_Section 2.1_ and (ii) cash sufficient to make payments of any dividends or
other distributions declared or made prior to the Effective Time with a
record date after the Effective Time to such holders (collectively, together
with the Fractional Shares Cash Amount, the " _Exchange Fund_ "). The
Exchange Agent shall, pursuant to irrevocable instructions, deliver the whole
shares of DENTSPLY Common Stock contemplated to be issued pursuant to
_Section 2.1_ and the Fractional Shares Cash Amount out of the Exchange Fund.
The Exchange Fund shall not be used for any other purpose.

  



    

 | 6| 
---|---|--- 

 



    



  

(b) _Exchange Procedures_. As promptly as practicable after the
Effective Time (but in no event later than three (3) Business Days
thereafter), DENTSPLY shall cause the Exchange Agent to mail to each holder
of record of a Sirona Certificate or Sirona Book-Entry Share, in each case
which shares were converted into the right to receive the Merger Consideration
at the Effective Time pursuant to this Agreement: (i) a letter of
transmittal, which shall specify that delivery shall be effected, and risk of
loss and title to the Sirona Certificates shall pass, only upon delivery of
the Sirona Certificates to the Exchange Agent, and shall otherwise be in such
form and have such other provisions as DENTSPLY, Sirona and the Exchange Agent
may reasonably specify, and (ii) instructions for effecting the surrender of
the Sirona Certificates or Sirona Book-Entry Shares in exchange for the Merger
Consideration, as applicable, and the method of payment of such holder\'s
Fractional Shares Cash Amount. Upon surrender of Sirona Certificates
and Sirona Book-Entry Shares for cancellation to the Exchange Agent or to
such other agent or agents as may be appointed by Sirona and DENTSPLY, and
upon delivery of a letter of transmittal, duly executed and in proper form
with all required enclosures and attachments, with respect to such Sirona
Certificates or Sirona Book-Entry Shares, the holder of such Sirona
Certificates or Sirona Book-Entry Shares shall be entitled to receive the
whole shares of DENTSPLY Common Stock that such holder is entitled to receive
pursuant to _Section 2.1_ and, if applicable, the Fractional Shares Cash
Amount for each share of Sirona Common Stock formerly represented by such
Sirona Certificates and for each Sirona Book-Entry Share. Any Sirona
Certificates and Sirona Book-Entry Shares so surrendered shall forthwith be
cancelled. If payment of the Merger Consideration is to be made to a Person
other than the Person in whose name any surrendered Sirona Certificate is
registered, it shall be a condition precedent to payment that the Sirona
Certificate so surrendered shall be properly endorsed or shall be otherwise
in proper form for transfer, and the Person requesting such payment shall
have paid any transfer and other similar Taxes required by reason of the
delivery of the Merger Consideration, as applicable, to a Person other than
the registered holder of the Sirona Certificate so surrendered and shall have
established to the satisfaction of Sirona that such Taxes either have been
paid or are not required to be paid. Delivery of the Merger Consideration with
respect to Sirona Book-Entry Shares shall only be made to the Person in whose
name such Sirona Book-Entry Shares are registered. Until surrendered as
contemplated hereby, each Sirona Certificate or Sirona Book-Entry Share shall
be deemed at any time after the Effective Time to represent only the right to
receive the Merger Consideration as provided in this Agreement.

  



  

(c) _Transfer Books_. At the Effective Time, the stock transfer
books of Sirona shall be closed and thereafter there shall be no further
registration of transfers of shares of Sirona Common Stock on the records of
Sirona. From and after the Effective Time, the holders of Sirona Certificates
and Sirona Book-Entry Shares representing shares of Sirona Common Stock
outstanding immediately prior to the Effective Time shall cease to have any
rights with respect to such shares except as otherwise provided for herein or
by applicable Law. If, after the Effective Time, Sirona Certificates
representing shares of Sirona Common Stock are presented to the Surviving
Corporation for any reason, they shall be cancelled and exchanged for the
whole shares of DENTSPLY Common Stock that such holder is entitled to receive
pursuant to _Section 2.1_ and, if applicable, the Fractional Shares Cash
Amount as provided in this Agreement.

  



    

 | 7| 
---|---|--- 

 



    



  

(d) _Termination of Fund; Abandoned Property_. At any time
following six months after the Closing Date, DENTSPLY shall be entitled to
require the Exchange Agent to deliver to it any shares of DENTSPLY Common
Stock or cash remaining in the Exchange Fund made available to the Exchange
Agent and not delivered to holders of Sirona Certificates or Sirona Book-Entry
Shares, and thereafter such holders shall be entitled to look only to
DENTSPLY (subject to abandoned property, escheat or other similar Laws) only
as general creditors thereof with respect to the Merger Consideration payable
upon due surrender of their Sirona Certificates or Sirona Book-Entry
Shares and compliance with the procedures in _Section 2.5_. If, prior to six
years after the Closing Date (or otherwise immediately prior to such time on
which any payment in respect hereof would escheat to or become the property of
any Governmental Entity pursuant to any applicable abandoned property,
escheat or similar Laws), any holder of Sirona Certificates or Sirona Book-
Entry Shares has not complied with the procedures in _Section 2.5_ to
receive the Merger Consideration to which such holder would otherwise be
entitled, the Merger Consideration to which such holder would otherwise be
entitled in respect of such Sirona Certificates or Sirona Book-Entry Shares
shall, to the extent permitted by applicable Law, become the property of
DENTSPLY, free and clear of all claims or interest of any Person previously
entitled thereto. Notwithstanding the foregoing, none of DENTSPLY, the
Surviving Corporation or the Exchange Agent, or any Representative or
affiliate thereof, shall be liable to any holder of a Sirona Certificate or
Sirona Book-Entry Shares for Merger Consideration delivered to a public
official pursuant to any applicable abandoned property, escheat or similar
Law.

  



  

(e) _Lost, Stolen or Destroyed Certificates_. In the event that any
Sirona Certificates shall have been lost, stolen or destroyed, the Exchange
Agent shall issue in exchange for such lost, stolen or destroyed Sirona
Certificates, upon the making of an affidavit of that fact by the holder
thereof, the Merger Consideration payable in respect thereof pursuant to
_Section 2.1(b)_;  _provided_ , _however_ , that DENTSPLY or the Exchange
Agent may, in its reasonable discretion and as a condition precedent to the
payment of the Merger Consideration, require the owners of such lost, stolen
or destroyed Sirona Certificates to deliver a bond in such sum as it may
reasonably direct as indemnity against any claim that may be made against
DENTSPLY, the Surviving Corporation or the Exchange Agent with respect to the
Sirona Certificates alleged to have been lost, stolen or destroyed.

  



  

(f) _Distributions with Respect to Unexchanged DENTSPLY Common
Stock_. No dividends or other distributions declared or made after the
Effective Time with respect to DENTSPLY Common Stock with a record date after
the Effective Time shall be paid to the holder of any unsurrendered Sirona
Certificate or Sirona Book-Entry Share with respect to the shares of DENTSPLY
Common Stock represented thereby, and, if applicable, no portion of the
Fractional Shares Cash Amount shall be paid to any such holder pursuant to
_Section 2.4_, unless and until the holder of such Sirona Certificate or
Sirona Book-Entry Share shall surrender such Sirona Certificate or
Sirona Book-Entry Share. Subject to the effect of escheat, Tax or other
applicable Laws, following surrender of any such Sirona Certificate, there
shall be paid by DENTSPLY to the holder of the certificates representing whole
shares of DENTSPLY Common Stock issued in exchange therefor, without
interest, (i) promptly, the portion of the Fractional Shares Cash Amount, if
applicable, payable with respect to a fractional share of DENTSPLY Common
Stock to which such holder is entitled pursuant to _Section 2.4_ and
the amount of dividends or other distributions with a record date after the
Effective Time theretofore paid with respect to such whole shares of DENTSPLY
Common Stock and (ii) at the appropriate payment date, the amount of dividends
or other distributions, with a record date after the Effective Time but prior
to surrender and a payment date occurring after surrender, payable with
respect to such whole shares of DENTSPLY Common Stock.

  



    

 | 8| 
---|---|--- 

 



    



  

2.6 _Sirona Stock Options and Stock-Based Awards_.

  



  

(a) _Treatment of Sirona Stock Options_. As of the Effective Time,
each option to acquire shares of Sirona Common Stock (a " _Sirona Stock
Option_ ") granted under the Sirona Stock Plans that is outstanding and
unexercised immediately prior to the Effective Time, whether or not then
vested or exercisable, shall be assumed by DENTSPLY and shall be converted
into an option (a " _DENTSPLY Stock Option_ ") to acquire shares of DENTSPLY
Common Stock in accordance with this _Section 2.6_. Each such DENTSPLY Stock
Option as so assumed and converted shall continue to have, and shall be
subject to, the same terms and conditions as applied to the Sirona Stock
Option immediately prior to the Effective Time (but taking into account any
changes thereto provided for in the applicable Sirona Stock Plan, in any
award agreement or in such Sirona Stock Option by reason of this Agreement or
the Transactions). As of the Effective Time, each such DENTSPLY Stock Option
as so assumed and converted shall be an option to acquire that number of
whole shares of DENTSPLY Common Stock (rounded down to the nearest whole
share) equal to the product of (i) the number of shares of Sirona Common
Stock subject to such Sirona Stock Option and (ii) the Exchange Ratio, at an
exercise price per share of DENTSPLY Common Stock (rounded up to the nearest
whole cent) equal to the quotient obtained by dividing (x) the exercise price
per share of Sirona Common Stock of such Sirona Stock Option by (y) the
Exchange Ratio; _provided_ , that the exercise price and the number of shares
of DENTSPLY Common Stock subject to the DENTSPLY Stock Option shall be
determined in a manner consistent with the requirements of Section 409A of
the Code, and, in the case of Sirona Stock Options that are intended to
qualify as incentive stock options within the meaning of Section 422 of the
Code, consistent with the requirements of Section 424 of the Code.

  



  

(b) _Treatment of Sirona Restricted Stock Units_. As of the
Effective Time, each restricted stock unit award granted under the applicable
Sirona Stock Plan (a " _Sirona RSU_ ") that is outstanding immediately prior
to the Effective Time and that is not vested by its terms as of the Effective
Time shall be assumed by DENTSPLY and shall be converted into a restricted
stock unit award (a " _DENTSPLY RSU_ ") to acquire DENTSPLY Common Stock in
accordance with this _Section 2.6_. Each such DENTSPLY RSU as so assumed and
converted shall continue to have, and shall be subject to, the same terms and
conditions as applied to the Sirona RSU immediately prior to the Effective
Time (but taking into account any changes thereto provided for in the
applicable Sirona Stock Plan, in any award agreement or in such Sirona RSU by
reason of this Agreement or the Transactions). As of the Effective Time, each
such DENTSPLY RSU as so assumed and converted shall be a restricted stock unit
award for that number of shares of DENTSPLY Common Stock (rounded down to the
nearest whole share) equal to the product of (i) the number of shares of
Sirona Common Stock underlying such Sirona RSU multiplied by (ii) the
Exchange Ratio. As of the Effective Time, each restricted stock unit award
granted under the applicable Sirona Stock Plan that is outstanding
immediately prior to the Effective Time and that vests as of the
Effective Time in accordance with its terms shall be canceled as of the
Effective Time and converted into the right to receive the
Merger Consideration in respect of each share of Sirona Common Stock subject
thereto as of immediately before the Effective Time.

  



    

 | 9| 
---|---|--- 

 



    



  

(c) Not later than the Closing Date, DENTSPLY shall deliver to the
holders of Sirona Stock Options and Sirona RSUs any required notices setting
forth such holders' rights pursuant to the relevant Sirona Stock Plan and
award documents and stating that such Sirona Stock Options or Sirona RSUs
have been assumed by DENTSPLY and shall continue in effect on the same terms
and conditions subject, in each case, to the adjustments required by this
_Section 2.6_ after giving effect to the Merger and the terms of
the relevant Sirona Stock Plan.

  



  

(d) Prior to the Effective Time, Sirona shall take all necessary
action for the adjustment of Sirona Stock Options and Sirona RSUs under this
_Section 2.6_. DENTSPLY shall reserve for future issuance a number of shares
of DENTSPLY Common Stock at least equal to the number of shares of DENTSPLY
Common Stock that will be subject to DENTSPLY Stock Options and DENTSPLY RSUs
as a result of the actions contemplated by this _Section 2.6_. Not later
than the Closing Date, DENTSPLY shall file an effective
registration statement on Form S-8 (or other applicable form) with respect to
the DENTSPLY Common Stock subject to such DENTSPLY Stock Options and DENTSPLY
RSUs and shall distribute a prospectus relating to such Form S-8, and DENTSPLY
shall use reasonable best efforts to maintain the effectiveness of such
registration statement or registration statements (and maintain the current
status of the prospectus or prospectuses contained therein) for so long as
such DENTSPLY Stock Options and DENTSPLY RSUs remain outstanding.

  



  

(e) Immediately after the Effective Time, Sirona shall take all
necessary actions necessary to terminate the Sirona Stock Plans, and no
additional equity-based awards shall be issued thereunder.

  



  

2.7 _Withholding Rights_. Each of DENTSPLY, the Surviving
Corporation, Sirona, Merger Sub and the Exchange Agent shall be entitled to
deduct and withhold from any consideration otherwise payable pursuant to this
Agreement to any holder of a Sirona Certificate or Sirona Book-Entry Share or
any other Person who is entitled to receive the Merger Consideration or
Fractional Shares Cash Amount, such amounts as are required to be deducted
and withheld under the Code, Treasury Regulations promulgated under the Code
or any provisions of applicable state, local or non-U.S. Tax Law. To the
extent that amounts are so deducted and withheld and paid over to the
applicable Governmental Entity, such deducted and withheld amounts shall be
treated for all purposes of this Agreement as having been paid to the
person(s) in respect of which such deduction and withholding was made.

  



  

ARTICLE 3 
 Representations and Warranties of Sirona

  



  

Except (a) as set forth in the Sirona Disclosure Schedule (subject to
_Section 8.15_) and (b) as otherwise disclosed or identified in the
Sirona SEC Documents publicly filed or furnished after September 30, 2013 and
prior to the date hereof (other than (i) any forward-looking disclosures
contained in the "Forward Looking Statements" and "Risk Factors" sections of
the Sirona SEC Documents and any other disclosures included therein to the
extent they are primarily predictive, cautionary or forward looking in nature
and (ii) information included in, or incorporated by reference as, exhibits
and schedules to any Sirona SEC Document, and provided that the exception
provided for in this clause (b) shall be applied if, and only if, the nature
and content of the applicable disclosure in any such Sirona SEC Document
publicly filed or furnished prior to the date hereof is reasonably
specific as to matters and items such that the subject matter of such
disclosure is reasonably apparent on the face of the text of such disclosure
to be applicable to the representation set forth herein), Sirona hereby
represents and warrants to DENTSPLY as follows:

  



    

 | 10| 
---|---|--- 

 



    



  

3.1 _Corporate Organization_. Each of Sirona and, except where the
failure to be in good standing has not had and would not reasonably
be expected to have, individually or in the aggregate, a Sirona Material
Adverse Effect, its Subsidiaries is a corporation or other entity duly
organized, validly existing and, to the extent applicable, in good standing
under the laws of the jurisdiction of its organization and has the requisite
corporate or other entity power and authority to own or lease all of its
properties and assets and to carry on its business as it is now being
conducted. Each of Sirona and its Subsidiaries is duly licensed or
qualified to do business in each jurisdiction in which the nature of the
business conducted by it or the character or location of the properties and
assets owned or leased by it makes such licensing or qualification necessary,
except where the failure to be so licensed or qualified, has not had and
would not reasonably be expected to have, individually or in the aggregate, a
Sirona Material Adverse Effect. The copies of the Amended and Restated
Certificate of Incorporation, as amended (the " _Sirona Charter_"), and By-
Laws of Sirona (the " _Sirona Bylaws_ ") as most recently filed with the
Sirona SEC Documents are true, complete and correct copies of such documents
as in effect as of the date of this Agreement. Sirona is not in violation of
any of the provisions of the Sirona Charter. True and complete copies of all
minute books of Sirona since January 1, 2013 have been made available by
Sirona to DENTSPLY, except for such portions of the minutes subject to
attorney-client privilege or with respect to the consideration of a possible
acquisition or business combination involving Sirona.

  



  

3.2 _Sirona Capitalization_.

  



  

(a) The authorized capital stock of Sirona consists of ninety-five
million (95,000,000) shares of Sirona Common Stock and five
million (5,000,000) shares of preferred stock, par value $0.01 per share ("
_Sirona Preferred Stock_ "). As of September 11, 2015, (i) 55,896,586 shares
of Sirona Common Stock (other than treasury shares) were issued and
outstanding, all of which were validly issued and fully paid, nonassessable
and free of preemptive rights, (ii) 2,471,499 shares of Sirona Common
Stock were held in the treasury of Sirona or by its Subsidiaries, (iii)
1,480,768 shares of Sirona Common Stock were issuable (and such number was
reserved for issuance) upon exercise of Sirona Stock Options granted under a
Sirona Stock Plan, Sirona RSUs granted under the Sirona Stock Plans and
performance-based stock unit awards (the " _Sirona Performance Units_ ")
granted under a Sirona Stock Plan outstanding as of such date and (iv) no
shares of Sirona Preferred Stock were issued and outstanding. Except for
Sirona Stock Options, Sirona RSUs and Sirona Performance Units to purchase not
more than 1,480,768 shares of Sirona Common Stock, there are no options,
warrants or other rights, agreements, arrangements or commitments of any
character to which Sirona or any of its Subsidiaries is a party or by which
Sirona or any of its Subsidiaries is bound relating to the issued or
unissued capital stock or other Equity Interests of Sirona or any of its
Subsidiaries, or securities convertible into or exchangeable for such capital
stock or other Equity Interests, or obligating Sirona or any of its
Subsidiaries to issue or sell any shares of its capital stock or other Equity
Interests, or securities convertible into or exchangeable for such capital
stock of, or other Equity Interests in, Sirona or any of its Subsidiaries.
Since September 11, 2015, Sirona has not issued any shares of its
capital stock or other Equity Interests, or securities convertible into or
exchangeable for such capital stock or other Equity Interests, other than
those shares of capital stock reserved for issuance described in this _Section
3.2(a)_. Sirona has previously provided DENTSPLY with a true and complete
list, as of the date hereof, of the prices at which each outstanding Sirona
Stock Option, Sirona RSU and Sirona Performance Unit may be exercised under
the applicable Sirona Stock Plan, the number of Sirona Stock Options, Sirona
RSUs and Sirona Performance Units outstanding at each such price and the
vesting schedule of the Sirona Stock Options, Sirona RSUs and Sirona
Performance Units. None of the Sirona Stock Options are "incentive stock
options" within the meaning of Section 422 of the Code. All shares of Sirona
Common Stock subject to issuance under a Sirona Stock Plan, upon issuance
prior to the Effective Time on the terms and conditions specified in the
instruments pursuant to which they are issuable, will be duly authorized,
validly issued, fully paid, nonassessable and free of preemptive rights. There
are no bonds, debentures, notes or other indebtedness of Sirona having the
right to vote on any matters on which shareholders of Sirona may vote. Neither
Sirona nor any of its Subsidiaries is a party to any voting agreement with
respect to the voting of any Equity Interests of Sirona or any of
its Subsidiaries.

  



    

 | 11| 
---|---|--- 

 



    



  

(b) Except with respect to Sirona RSUs and Sirona Performance Units,
there are no outstanding contractual obligations of Sirona or any of its
Subsidiaries (i) restricting the transfer of, (ii) affecting the voting rights
of, (iii) requiring the repurchase, redemption or disposition of, or
containing any right of first refusal with respect to, (iv) requiring the
registration for sale of, or (v) granting any preemptive or antidilutive
right with respect to, any shares of Sirona Common Stock or any capital stock
of, or other Equity Interests in, Sirona or any of its Subsidiaries.

  



  

(c) _Section 3.2(c)_ of the Sirona Disclosure Schedule sets forth a
true and complete list of all of the Subsidiaries of Sirona and the
jurisdiction of organization of each such Subsidiary. Except as set forth in
_Section 3.2(c)_ of the Sirona Disclosure Schedule, none of Sirona or any of
its Subsidiaries holds an Equity Interest in any other Person. Each
outstanding share of capital stock or other Equity Interest in each
Subsidiary of Sirona is duly authorized, validly issued, fully paid,
nonassessable and free of preemptive rights and is owned, beneficially and of
record, by Sirona or one or more of its wholly-owned Subsidiaries free and
clear of all Liens. There are no outstanding contractual obligations of
Sirona or any of its Subsidiaries to provide funds to, or make any
investment (in the form of a loan, capital contribution or otherwise) in, any
Subsidiary of Sirona (in excess of $5 million) or any other Person, other
than guarantees by Sirona of any indebtedness or other obligations of any
wholly-owned Subsidiary of Sirona.

  



    

 | 12| 
---|---|--- 

 



    



  

3.3 _Authority; Execution and Delivery; Enforceability_.

  



  

(a) Sirona has all necessary power and authority to execute and
deliver this Agreement, to perform and comply with each of its
obligations under this Agreement and, subject to the receipt of the Sirona
Shareholder Approval, to consummate the Transactions applicable to Sirona.
The execution and delivery by Sirona of this Agreement, the performance and
compliance by Sirona with each of its obligations herein and the consummation
by Sirona of the Transactions applicable to it have been duly authorized by
all necessary corporate action on the part of Sirona, subject to receipt of
the Sirona Shareholder Approval, and no other corporate proceedings on
the part of Sirona and no shareholder votes are necessary to authorize this
Agreement or the consummation by Sirona of the Transactions to which it is a
party. Sirona has duly and validly executed and delivered this Agreement and,
assuming the due authorization, execution and delivery by DENTSPLY and Merger
Sub of this Agreement, this Agreement constitutes its legal, valid and binding
obligation, enforceable against it in accordance with its terms, except as
limited by Laws affecting the enforcement of creditors' rights generally, by
general equitable principles or by the discretion of any Governmental Entity
before which any Proceeding seeking enforcement may be brought.

  



  

(b) The Board of Directors of Sirona (the " _Sirona Board_ "), at a
meeting duly called and held, unanimously adopted resolutions (i) approving
this Agreement and the consummation of the Transactions upon the terms and
subject to the conditions set forth in this Agreement, (ii) determining that
the terms of the Agreement, the Merger and the other Transactions are fair to,
and in the best interests of, Sirona and its shareholders, (iii) directing
that this Agreement be submitted to the shareholders of Sirona for adoption,
(iv) recommending that its shareholders adopt this Agreement and (v) declaring
that this Agreement is advisable (the " _Sirona Recommendation_ ").

  



  

(c) Assuming the accuracy of the representations and warranties in
_Section 4.21_, to the Knowledge of Sirona, no takeover, anti-
takeover, business combination, control share acquisition or similar Law
applies to the Merger or the other Transactions. The only vote of holders of
any class or series of Sirona Common Stock or other Equity Interests of Sirona
necessary to adopt this Agreement is the adoption of this Agreement by the
holders of a majority of the shares of Sirona Common Stock outstanding and
entitled to vote thereon at the Sirona Shareholders Meeting (the " _Sirona
Shareholder Approval_ "). No other vote of the holders of Sirona Common Stock
or any other Equity Interests of Sirona is necessary to consummate the
Transactions.

  



  

3.4 _No Conflicts_.

  



  

(a) The execution and delivery of this Agreement by Sirona does not
and will not, and the performance of this Agreement by Sirona and
the consummation of the Transactions will not, (i) assuming the Sirona
Shareholder Approval is obtained, conflict with or violate any provision of
the Sirona Charter or the Sirona Bylaws or any equivalent organizational
documents of any Subsidiary of Sirona, (ii) assuming that all consents,
approvals, authorizations and permits described in _Section 3.4(b)_ have been
obtained and all filings and notifications described in _Section 3.4(b)_ have
been made and any waiting periods thereunder have terminated or expired,
conflict with or violate any Law applicable to Sirona or any of its
Subsidiaries or by which any property or asset of Sirona or any of its
Subsidiaries is bound or affected or (iii) require any consent or approval
under, result in any breach of or any loss or impairment of any benefit
under, constitute a change of control or default (or an event which with
notice or lapse of time or both would become a default) under or give to
others any right of termination, vesting, amendment, acceleration or
cancellation of, or result in the creation of a Lien on any property or asset
of Sirona or any of its Subsidiaries pursuant to, any Contract or Permit,
except, with respect to clauses (ii) and (iii), for any such conflicts,
violations, breaches, defaults or other occurrences which would not,
individually or in the aggregate, reasonably be expected to (A) prevent or
delay beyond the Outside Date consummation of the Merger, (B) otherwise
prevent or delay beyond the Outside Date performance by Sirona of any of its
material obligations under this Agreement or (C) have a Sirona Material
Adverse Effect.

  



    

 | 13| 
---|---|--- 

 



    



  

(b) The execution and delivery of this Agreement by Sirona do not
and will not, and the consummation by Sirona of the Transactions
and compliance by Sirona with any of the terms or provisions hereof will not,
require any consent, approval, authorization or permit of, or filing with or
notification to, any Governmental Entity or any other Person, except
(i) under the Exchange Act, Securities Act, any applicable blue sky Law, and
the rules and regulations of the NASDAQ, (ii) under the HSR Act, the EU
Merger Regulation or other applicable foreign, federal, state or supranational
antitrust, competition, fair trade or similar applicable Laws, (iii) the
filing of the Certificate of Merger as required by the DGCL and (iv) where
failure to obtain such consents, approvals, authorizations or permits, or to
make such filings or notifications to a Person other than a Governmental
Entity, would not, individually or in the aggregate, reasonably be
expected to (A) prevent or delay beyond the Outside Date consummation of the
Merger or other Transactions, (B) otherwise prevent or delay beyond the
Outside Date performance by Sirona of any of its material obligations under
this Agreement or (C) have a Sirona Material Adverse Effect.

  



  

3.5 _SEC Documents; Financial Statements; Undisclosed Liabilities_.

  



  

(a) Sirona has filed or furnished all reports, schedules, forms,
statements, registration statements, prospectuses and other documents
required to be filed or furnished by Sirona with the SEC under the Securities
Act or the Exchange Act since October 1, 2012 (the " _Sirona SEC Documents_
"). None of the Subsidiaries of Sirona is required to make or makes any
filings with the SEC.

  



  

(b) As of its respective filing date, and, if amended, as of the
date of the last amendment prior to the date of this Agreement, each Sirona
SEC Document complied in all material respects with the requirements of the
Exchange Act or the Securities Act, as the case may be, and the rules and
regulations of the SEC promulgated thereunder applicable to such Sirona SEC
Document and did not contain any untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary in order
to make the statements therein, in light of the circumstances under which
they were made, not misleading.

  



  

(c) The consolidated financial statements of Sirona included in the
Sirona SEC Documents (including, in each case, any notes or
schedules thereto) and all related compilations, reviews and other reports
issued by Sirona's accountants with respect thereto (the " _Sirona SEC
Financial Statements_ "), comply as to form in all material respects with
applicable accounting requirements and the published rules and regulations of
the SEC with respect thereto. The Sirona SEC Financial Statements fairly
present, in all material respects, the financial condition and the results of
operations, cash flows and changes in shareholders' equity of Sirona (on a
consolidated basis) as of the respective dates of and for the periods referred
to in the Sirona SEC Financial Statements, and were prepared in accordance
with GAAP applied on a consistent basis during the periods involved (except as
may be indicated in the notes thereto), subject, in the case of interim
Sirona SEC Financial Statements, to normal year-end adjustments (which
are not material in significance or amount) and the absence of notes. The
books and records of Sirona and its Subsidiaries are accurate and complete in
all material respects, have been maintained in accordance with sound business
practices and accurately present and reflect in all material respects all of
the transactions and actions therein described and the Sirona SEC Financial
Statements have been prepared, in all material respects, in accordance with
such books and records. No financial statements of any Person other than
Sirona and its Subsidiaries are required by GAAP to be included in the
consolidated financial statements of Sirona. Except as required by GAAP,
Sirona has not, between June 30, 2015 and the date of this Agreement, made or
adopted any material change in its accounting methods, practices or policies
in effect on June 30, 2015.

  



    

 | 14| 
---|---|--- 

 



    



  

(d) Sirona is in compliance in all material respects with (i) the
applicable provisions of the Sarbanes-Oxley Act of 2002 and the related rules
and regulations promulgated thereunder or under the Exchange Act (the "
_Sarbanes-Oxley Act_ ") and (ii) the applicable listing and corporate
governance rules and regulations of the NASDAQ.

  



  

(e) Sirona has made available to DENTSPLY true and complete copies
of all written comment letters from the staff of the SEC received
since October 1, 2013 relating to the Sirona SEC Documents and all written
responses of Sirona thereto other than with respect to requests for
confidential treatment or which are otherwise publicly available on the SEC's
EDGAR system. To the Knowledge of Sirona, there are no outstanding or
unresolved comments in comment letters received from the SEC staff with
respect to any Sirona SEC Documents and none of the Sirona SEC Documents
(other than confidential treatment requests) is the subject of ongoing SEC
review. There are no internal investigations with respect to which Sirona has
retained outside counsel, SEC inquiries or investigations or other
governmental inquiries or investigations, to the Knowledge of Sirona, pending
or threatened, in each case regarding any accounting practices of Sirona.

  



  

(f) Sirona has established and maintains disclosure controls and
procedures and internal control over financial reporting (as such terms
are defined in paragraphs (e) and (f), respectively, of Rule 13a-15 and
paragraph (e) of Rule 15d-15 under the Exchange Act) as required by Rules
13a-15 and 15d-15 under the Exchange Act. Sirona's disclosure controls and
procedures are designed to ensure that all information (both financial and
non-financial) required to be disclosed by Sirona in the reports that it
files or furnishes under the Exchange Act is recorded, processed, summarized
and reported within the time periods specified in the rules and forms of the
SEC, and that all such information is accumulated and communicated to Sirona's
management as appropriate to allow timely decisions regarding required
disclosure and to make the certifications required pursuant to Sections
302 and 906 of the Sarbanes-Oxley Act. Sirona's management has completed an
assessment of the effectiveness of Sirona's disclosure controls and
procedures and, to the extent required by applicable Law, presented in any
applicable Sirona SEC Document that is a report on Form 10-K or Form 10-Q, or
any amendment thereto, its conclusions about the effectiveness of the
disclosure controls and procedures as of the end of the period covered by
such report or amendment based on such evaluation. Based on
Sirona's management's most recently completed evaluation of Sirona's internal
control over financial reporting prior to the date hereof, (i) Sirona had no
significant deficiencies or material weaknesses in the design or operation of
its internal control over financial reporting that would reasonably be
expected to adversely affect Sirona's ability to record, process,
summarize and report financial information and (ii) Sirona does not have
Knowledge of any fraud, whether or not material, that involves management or
other employees who have a significant role in Sirona's internal control over
financial reporting.

  



    

 | 15| 
---|---|--- 

 



    



  

(g) Sirona and its Subsidiaries do not have any liabilities or
obligations of any nature (whether absolute or contingent, asserted or
unasserted, known or unknown, primary or secondary, direct or indirect, and
whether or not accrued or required to be reflected in Sirona\'s financial
statements in accordance with GAAP), except (i) as disclosed, reflected or
reserved against in the most recent audited balance sheet included in the
Sirona SEC Financial Statements or the notes thereto, (ii) for liabilities and
obligations incurred in the ordinary course of business since the date of the
most recent audited balance sheet included in the Sirona SEC
Financial Statements, (iii) for liabilities and obligations arising out of or
in connection with this Agreement, the Merger or the Transactions and (iv)
for liabilities and obligations that, individually or in the aggregate, have
not had, and would not reasonably be expected to have, a Sirona Material
Adverse Effect.

  



  

3.6 _Absence of Certain Changes or Events_. Since July 1, 2015 and
through the date of this Agreement, (a) Sirona and its Subsidiaries have
conducted their businesses in all material respects only in the ordinary
course and in a manner consistent with past practice and (b) there has not
been any change, event, development, condition or occurrence that,
individually or in the aggregate, has had or would reasonably be expected to
have a Sirona Material Adverse Effect. Since July 1, 2015 and through the date
of this Agreement, neither Sirona nor any of its Subsidiaries has taken any
action that would have constituted a breach of, or required DENTSPLY's
consent pursuant to, _Sections 5.1(e)_, _(m)_ , _(n)_ , _(p)_ , _(r)_ and
_(s)_  had the covenants therein applied since July 1, 2015.

  



  

3.7 _Information Supplied_. None of the information supplied or to
be supplied by Sirona for inclusion or incorporation by reference in (i)
the registration statement on Form S-4 to be filed with the SEC by DENTSPLY
in connection with the Merger (the " _Form S-4_") will, at the time the Form
S-4 is filed with the SEC, and at any time it is amended or supplemented or at
the time it becomes effective under the Securities Act, contain any untrue
statement of a material fact or omit to state any material fact required to
be stated therein or necessary to make the statements therein not misleading,
and (ii) the Joint Proxy Statement will, at the date it or any amendment or
supplement is mailed to each of the holders of DENTSPLY Common Stock and
Sirona Common Stock and at the time of each of the DENTSPLY Shareholders
Meeting and Sirona Shareholders Meeting, contain any untrue statement of a
material fact or omit to state a material fact necessary to make the
statements therein, in light of the circumstances in which they are made, not
misleading (except that no representation or warranty is made by Sirona to
such portions thereof that relate expressly to DENTSPLY or any of its
Subsidiaries, including Merger Sub, or to statements made therein based on
information supplied by or on behalf of DENTSPLY for inclusion or
incorporation by reference therein). The Form S-4 and Joint Proxy Statement
will comply as to form in all material respects with the requirements of the
Securities Act or Exchange Act, as applicable, and other applicable Law.

  



    

 | 16| 
---|---|--- 

 



    



  

3.8 _Legal Proceedings_. As of the date hereof, there are no
Proceedings pending, or to the Knowledge of Sirona, threatened against
Sirona or any of its Subsidiaries or any of their respective assets, rights
or properties or any of the officers or directors of Sirona, that would, in
each case, individually or in the aggregate, reasonably be expected to prevent
or materially delay the consummation of the Transactions. There are no
Proceedings pending, or to the Knowledge of Sirona, threatened against Sirona
or any of its Subsidiaries or any of their respective assets, rights or
properties or any of the officers or directors of Sirona, except, in each
case, for those that, individually or in the aggregate, have not had, and
would not reasonably be expected to have, a Sirona Material Adverse Effect.
Neither Sirona nor any of its Subsidiaries nor any of their respective
properties, rights or assets is or are subject to any Order, except for those
that, individually or in the aggregate, have not had, and would not reasonably
be expected to have, a Sirona Material Adverse Effect.

  



  

3.9 _Compliance with Laws_.

  



  

(a) (i) Sirona and its Subsidiaries are in compliance, and for the
past five years have been in compliance, with all Laws and Orders
applicable to Sirona or any of its Subsidiaries or any assets owned or used
by any of them (except for such past noncompliance as has been remedied and
imposes no continuing obligations or costs on Sirona or its Subsidiaries), and
(ii) neither Sirona nor any of its Subsidiaries has received any written
communication during the past five years from a Governmental Entity that
alleges that Sirona or any of its Subsidiaries is not in compliance with any
such Law or Order, except in the case of clauses (i) and (ii) where any non-
compliance, individually or in the aggregate, has not had and would not
reasonably be expected to have, a Sirona Material Adverse Effect.

  



  

(b) Sirona and each of its Subsidiaries (i) are in compliance, and
for the past five years have been in compliance, in all material
respects with the United States Foreign Corrupt Practices Act of 1977 (the "
_FCPA_ ") and any other applicable Anti-corruption Laws; (ii) during the past
five years have not been investigated, to the Knowledge of Sirona, by any
Governmental Entity with respect to, or been given notice by a Governmental
Entity or any other Person of, any actual or alleged violation by Sirona
or any of its Subsidiaries of the FCPA or any other Anti-corruption Laws and
(iii) during the past five years have had an operational and effective FCPA
and anti-corruption compliance program that includes, at a minimum, policies,
procedures and training intended to enhance awareness of and compliance by
Sirona and its Subsidiaries with the FCPA and any other applicable Anti-
corruption Laws.

  



  

(c) To the Knowledge of Sirona, none of Sirona or its Subsidiaries
has, directly or indirectly through its Representatives or any
Person authorized to act on its behalf (including any distributor, agent,
sales intermediary or other third party), offered, promised, paid, authorized
or given, money or anything of value to any Person for the purpose of: (i)
influencing any act or decision of any Government Official or Other Covered
Party; (ii) inducing any Government Official or Other Covered Party to do or
omit to do an act in violation of a lawful duty; (iii) securing any improper
advantage; or (iv) inducing any Government Official or Other Covered Party to
influence the act or decision of a government or government instrumentality,
in order to obtain or retain business, or direct business to, any person or
entity, in any way.

  



    

 | 17| 
---|---|--- 

 



    



  

(d) To the Knowledge of Sirona, during the past five years, Sirona
and its Subsidiaries have maintained complete and accurate books and records,
including records of payments to any agents, consultants, representatives,
third parties and Government Officials, in accordance with GAAP, in all
material respects. There have been no false or fictitious entries made in the
books and records of Sirona or its Subsidiaries relating to any unlawful
offer, payment, promise to pay, or authorization of the payment of any
money, or unlawful offer, gift, promise to give, or authorization of the
giving of anything of value, including any bribe, kickback or other illegal
or improper payment, and Sirona and its Subsidiaries have not established or
maintained a secret or unrecorded fund.

  



  

(e) To the Knowledge of Sirona, during the past five years, none of
Sirona or its Subsidiaries has had a customer or supplier or other business
relationship with, is a party to any Contract with, or has engaged in any
transaction with, any Person (i) that is organized or domiciled in or that is
a citizen of Cuba, Iran, North Korea, Sudan, or Syria (including any
Governmental Entity within such country) or (ii) that is the subject of any
international economic or trade sanction administered or enforced by the
Office of Foreign Assets Control of the United States Department of the
Treasury (" _OFAC_ "), the United Nations Security Council, the European
Union, Her Majesty's Treasury, the United Kingdom Export Control Organization
or other relevant sanctions authority (including but not limited to being
listed on the Specially Designated Nationals and Blocked Persons List
administered by OFAC).

  



  

3.10 _Permits_. Sirona and each of its Subsidiaries have all required
governmental permits, licenses, franchises, certificates,
registrations, approvals, exemptions, clearances, billings and authorizations
and similar rights (" _Permits_ ") necessary for the conduct of their
business and the use of their properties and assets, as presently conducted
and used, and each of the Permits is valid, subsisting and in full force and
effect, except where the failure to have or maintain such Permit, individually
or in the aggregate, has not had and would not reasonably be expected to have
a Sirona Material Adverse Effect. Except as would not reasonably be expected
to have, individually or in the aggregate, a Sirona Material Adverse Effect,
(i) the operation of the business of Sirona and its Subsidiaries as currently
conducted is not, and has not been since June 30, 2012, in violation of, nor
is Sirona or its Subsidiaries in default or violation under, any Permit
(except for such past violation or default as has been remedied and imposes
no continuing obligations or costs on Sirona or its Subsidiaries), and (ii) to
the Knowledge of Sirona, no event has occurred which, with notice or the
lapse of time or both, would constitute a default or violation of any term,
condition or provision of any Permit. There are no actions pending or, to the
Knowledge of Sirona, threatened, that seek the revocation, cancellation or
modification of any Permit, except where such revocation, cancellation or
modification, individually or in the aggregate, has not had and would not
reasonably be expected to have, a Sirona Material Adverse Effect. Since June
30, 2012, neither Sirona nor its Subsidiaries have received written notice of
any charge, claim or assertion alleging any violations of or noncompliance
with any Permit, nor to the Knowledge of Sirona, has any charge, claim or
assertion been threatened, except where such notice, charge, claim or
assertion, individually or in the aggregate, has not had and would not
reasonably be expected to have, a Sirona Material Adverse Effect.

  



    

 | 18| 
---|---|--- 

 



    



  

3.11 _Employee Benefit Plans_.

  



  

(a) _Section 3.11(a)_ of the Sirona Disclosure Schedule sets forth
a true and complete list of each "employee benefit plan" as defined in
Section 3(3) of ERISA and any other plan, policy, program, Contract, or
arrangement (whether written or oral) providing compensation or other
benefits to any current or former director, officer or employee (or to any
dependent or beneficiary thereof) of Sirona or any of its Subsidiaries, in
each case that is maintained, sponsored or contributed to by Sirona or any of
its U.S. ERISA Affiliates, or under which Sirona or any of its Subsidiaries
has any material obligation or material liability, whether actual or
contingent, including all incentive, bonus, deferred compensation, profit-
sharing, pension, retirement, vacation, holiday, sick pay, cafeteria, fringe
benefit, medical, disability, retention, severance, termination, change in
control, stock purchase, stock option, stock appreciation, phantom stock,
restricted stock or other equity-based compensation plans, policies, programs,
practices or arrangements, in each case, which (x) is not sponsored and
administered by a Governmental Entity and (y) is not required by Law to be
provided (each a " _Sirona Benefit Plan_ "). Neither Sirona, nor to the
Knowledge of Sirona, any other Person, has any express or implied commitment,
whether legally enforceable or not, to (i) modify, change or terminate
any Sirona Benefit Plan, other than with respect to a modification, change or
termination required by ERISA, the Code or the terms of such Sirona Benefit
Plan or (ii) adopt any new Sirona Benefit Plan.

  



  

(b) With respect to each Sirona Benefit Plan, Sirona has made
available to DENTSPLY a current written copy thereof (if any) and, to
the extent applicable: (i) any related trust agreement; (ii) the most recent
IRS determination letter; (iii) the most recent summary plan description and
summary of material modifications, and (iv) for the most recent plan year (A)
the Form 5500 and attached schedules and (B) audited financial statements.

  



  

(c) Each Sirona Benefit Plan has been administered in all material
respects in accordance with its terms and all applicable Laws,
including ERISA and the Code, and contributions required to be made under the
terms of any of the Sirona Benefit Plans have been timely made or, if not yet
due, have been properly reflected on the most recent consolidated balance
sheet filed or incorporated by reference in the Sirona SEC Documents.

  



  

(d) Except as has not had or would not reasonably be expected to
have, individually or in the aggregate, a Sirona Material Adverse Effect: (i)
each Sirona Benefit Plan which is intended to qualify under Section 401(a) of
the Code has either received a favorable determination letter or opinion
letter from the IRS as to its qualified status, and each trust established in
connection with any Sirona Benefit Plan which is intended to be exempt from
federal income taxation under Section 501(a) of the Code is so exempt, and to
Sirona's Knowledge no fact or event has occurred that could adversely affect
the qualified status of any such Sirona Benefit Plan or the exempt status of
any such trust, (ii) to Sirona's Knowledge there has been no prohibited
transaction (within the meaning of Section 406 of ERISA or Section 4975 of
the Code), other than a transaction that is exempt under a statutory or
administrative exemption, with respect to any Sirona Benefit Plan, and (iii)
no Proceeding has been brought, or to the Knowledge of Sirona is threatened,
against or with respect to any Sirona Benefit Plan, including any audit or
inquiry by the IRS or United States Department of Labor (other than for
routine benefits claims).

  



    

 | 19| 
---|---|--- 

 



    



  

(e) No Sirona Benefit Plan is a multiemployer plan (as defined in
Section 3(37) or Section 4001(a)(3) of ERISA) (" _Multiemployer Plan_ ") or
other plan subject to Title IV of ERISA or the minimum funding requirements of
Section 302 of ERISA or Section 412 of the Code, and during the preceding six
(6) years none of Sirona or any ERISA Affiliate thereof has maintained,
sponsored or contributed to or been required to contribute to a Multiemployer
Plan or other pension plan subject to Title IV of ERISA. No material
liability under Title IV of ERISA has been incurred by Sirona or any ERISA
Affiliate thereof that has not been satisfied in full, and no condition
exists that presents a material risk to Sirona or any ERISA Affiliate thereof
of incurring or being subject (whether primarily, jointly or secondarily) to
a material liability thereunder. None of Sirona or any of its
Subsidiaries has incurred any material withdrawal liability under Section
4201 of ERISA.

  



  

(f) No amount that could be received (whether in cash or property or
the vesting of property), as a result of the consummation of the Merger or
other Transactions, by any employee, officer or director of Sirona or any of
its Subsidiaries who is a "disqualified individual" (within the meaning of
Section 280G of the Code) could be characterized as an "excess parachute
payment" (within the meaning of Section 280G(b)(1) of the Code).

  



  

(g) Except as required by Law, no Sirona Benefit Plan provides post-
employment medical, disability or life insurance benefits to any
former director, employee or their respective dependents.

  



  

(h) Except for the adjustment and assumption of the Sirona Stock
Options and Sirona RSUs in accordance with _Section 2.6_ , neither
the execution of this Agreement nor the consummation of the Merger or other
Transactions will (i) entitle any employee or director of Sirona or any of
its Subsidiaries to a bonus, severance or change in control payment, (ii)
accelerate the time of payment or vesting or trigger any payment or funding
(through a grantor trust or otherwise) of compensation or benefits, increase
the amount payable or trigger any other material obligation pursuant to any
of the Sirona Benefit Plans or (iii) result in any breach or violation of, or
default under any Sirona Benefit Plan.

  



  

(i) Each Sirona Benefit Plan that constitutes in any part a
nonqualified deferred compensation plan within the meaning of Section 409A of
the Code has been operated and maintained in all material respects in
operational and documentary compliance with Section 409A of the Code and all
IRS guidance promulgated thereunder, to the extent such section and such
guidance have been applicable to such Sirona Benefit Plan. There is no
agreement, plan, Contract or other arrangement to which Sirona or, to the
Knowledge of Sirona, any of its Subsidiaries is a party or by which any of
them is otherwise bound to compensate any Person in respect of Taxes
pursuant to Section 409A or 4999 of the Code.

  



  

(j) Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Sirona Material Adverse
Effect, with respect to each Sirona Benefit Plan established or maintained
outside of the United States of America primarily for the benefit of
employees of Sirona or any Subsidiary thereof residing outside the United
States of America (a " _Sirona Foreign Benefit Plan_ "): (i) all employer and
employee contributions to each Sirona Foreign Benefit Plan required by law or
by the terms of any Sirona Foreign Benefit Plan have been made or, if
applicable, accrued, in accordance with normal accounting practices; (ii) the
fair market value of the assets of each funded Sirona Foreign Benefit Plan,
the liability of each insurer for any Sirona Foreign Benefit Plan funded
through insurance or the book reserve established for any Sirona Foreign
Benefit Plan, together with any accrued contributions, is sufficient to
procure or provide for the accrued benefit obligations with respect to all
current and former participants in such Sirona Foreign Benefit Plan according
to the actuarial assumptions and valuations most recently used to determine
employer contributions to such Sirona Foreign Benefit Plan, and neither the
execution of this Agreement nor the consummation of the Merger or other
Transactions will cause such assets or insurance obligations to be less than
such benefit obligations; and (iii) to the Knowledge of Sirona, each Sirona
Foreign Benefit Plan required to be registered has been registered and has
been maintained in good standing with applicable regulatory authorities.

  



    

 | 20| 
---|---|--- 

 



    



  

3.12 _Employee and Labor Matters_.

  



  

(a) Neither Sirona nor any of its Subsidiaries is a party to or
bound by any material collective bargaining agreement, material agreement
with any works council, or material labor contract, no labor union, labor
organization, works council, or group of employees of Sirona or any of its
Subsidiaries has made a pending demand for recognition or certification, and
there are no representation or certification proceedings or petitions seeking
a representation proceeding presently pending or threatened in writing to be
brought or filed with the National Labor Relations Board or any other labor
relations tribunal or authority with respect to any individuals employed by
or otherwise performing services for Sirona or any of its Subsidiaries (the "
_Sirona Business Personnel_ "), and there is no unfair labor practice
complaint or grievance or other administrative or judicial complaint, action
or investigation pending or, to the Knowledge of Sirona, threatened in
writing against Sirona or any of its Subsidiaries by the National Labor
Relations Board or any other Governmental Entity with respect to any present
or former Sirona Business Personnel which is reasonably likely to materially
interfere with the business activities of Sirona and its Subsidiaries, taken
as a whole. There is no labor strike, dispute, lockout, slowdown or stoppage
pending or, to the Knowledge of Sirona, threatened against or affecting Sirona
or any Subsidiary which would, individually or in the aggregate, reasonably
be expected to have a Sirona Material Adverse Effect.

  



  

(b) Neither Sirona nor any of its Subsidiaries are required to
provide notice to any work council or similar representative body prior to
the execution of this Agreement or the consummation of the Transactions,
except where the failure to provide such notice would not, individually or in
the aggregate, reasonably be expected to (i) result in material liability to
Sirona and its Subsidiaries, taken as a whole, or (ii) materially delay or
prevent the consummation of the Transactions.

  



  

(c) Sirona and its Subsidiaries are and for the past five years have
been in compliance with all applicable Laws respecting employment
and employment practices, including, without limitation, all Laws respecting
terms and conditions of employment, health and safety, wage payment, wages
and hours, child labor, collective bargaining, immigration and work
authorizations, employment discrimination, retaliation, civil rights,
veterans' rights, disability rights or benefits, equal opportunity, plant
closures and layoffs, affirmative action, workers' compensation, labor
relations, social welfare obligations, proper classification of employees as
exempt and non-exempt and as employees and independent contractors,
unemployment insurance and the collection and payment of withholding and/or
social security Taxes and any similar Tax, except for noncompliance as
individually or in the aggregate, has not had and would not reasonably be
expected to have, a Sirona Material Adverse Effect.

  



    

 | 21| 
---|---|--- 

 



    



  

(d) To the Knowledge of Sirona, no Sirona Business Personnel is in
any respect in violation of any term of any employment agreement,
nondisclosure agreement, common law nondisclosure obligation, fiduciary duty,
noncompetition agreement, restrictive covenant or other obligation to Sirona
or any of its Subsidiaries or to a former employer of any such employee
relating (i) to the right of any such individual to be employed by or provide
services for Sirona or its Subsidiaries or (ii) to the knowledge or use of
trade secrets or proprietary information, in each case except as,
individually or in the aggregate, has not had and would not reasonably be
expected to have, a Sirona Material Adverse Effect.

  



  

(e) Sirona and its Subsidiaries are not delinquent in payments to
any current or former Sirona Business Personnel for any services or
amounts required to be reimbursed or otherwise paid except as has not had and
would not reasonably be expected to have, individually or in the aggregate, a
Sirona Material Adverse Effect.

  



  

3.13 _Environmental Matters_. Except as, individually or in the
aggregate, has not had and would not reasonably be expected to have, a Sirona
Material Adverse Effect:

  



  

(a) Sirona and each of its Subsidiaries (i) have been within the
last five (5) years, and are, in compliance with all, and are not subject to
any liability with respect to noncompliance with any, applicable Environmental
Laws, (ii) have and hold, or have applied for, all Environmental Permits
necessary for the conduct of their business and the use of their properties
and assets, as currently conducted and used, and (iii) are in compliance with
their respective Environmental Permits.

  



  

(b) There are no Environmental Claims pending, nor to the Knowledge
of Sirona, threatened against Sirona or any of its Subsidiaries, and none of
Sirona or any of its Subsidiaries has received any notification of any
allegation of actual or potential responsibility for any Release or
threatened Release of any Hazardous Materials with respect to any location.

  



  

(c) There have been no Releases of Hazardous Materials at any
properties that are owned, operated, leased or used by Sirona or any of
its Subsidiaries, or to the Knowledge of Sirona, at properties that were
formerly owned, operated, leased or used by Sirona or any of its
Subsidiaries, that are reasonably likely to cause Sirona or any of its
Subsidiaries to incur liability pursuant to applicable Environmental Law.

  



  

(d) None of Sirona or any of its Subsidiaries (i) has entered into
or agreed to any consent decree or consent order or is otherwise subject to
any judgment, decree, or judicial or administrative Order relating to
compliance with Environmental Laws or Environmental Permits, the
investigation, sampling, monitoring, treatment, remediation, response, removal
or cleanup of Hazardous Materials, and no Proceeding is pending, or to the
Knowledge of Sirona is threatened, with respect thereto, or (ii) is an
indemnitor by contract or otherwise in connection with any claim, demand,
suit or action threatened or asserted by any third-party for any liability
under any Environmental Law or otherwise relating to any Hazardous Materials.

  



    

 | 22| 
---|---|--- 

 



    



  

3.14 _Real Property_.

  



  

(a) Sirona or its Subsidiaries, as the case may be, holds good,
valid and marketable fee title to the Sirona Owned Real Property, free
and clear of all Liens, except for Permitted Liens.

  



  

(b) Sirona or its Subsidiaries, as the case may be, has a valid and
subsisting leasehold or subleasehold interest in the Sirona Leased
Real Property free and clear of all Liens, except for Permitted Liens.

  



  

(c) The Sirona Owned Real Property and the Sirona Leased Real
Property are referred to collectively herein as the " _Sirona
Real Property_." The Sirona Real Property constitutes all real property
necessary for the conduct of the business of Sirona and its Subsidiaries,
taken as a whole, as currently conducted. Except as has not had and would not
reasonably be expected to have, individually or in the aggregate, a Sirona
Material Adverse Effect, neither Sirona nor any of its Subsidiaries has
received written notice of any Proceedings in eminent domain, condemnation or
other similar Proceedings that are pending, and to Sirona's Knowledge there
are no such Proceedings threatened, affecting any portion of the Sirona Real
Property and neither Sirona nor any of its Subsidiaries has received written
notice of the existence of any Order or of any pending Proceeding relating to
the ownership, lease, use, occupancy or operation by any Person of the Sirona
Real Property. Neither Sirona nor any of its Subsidiaries has
leased, subleased, licensed or otherwise granted any Person a material right
to use or occupy any of the Sirona Real Property or any material portion
thereof. Neither Sirona nor any of its Subsidiaries has granted any option or
other right to any third party to purchase any of the material Sirona Real
Property or any material portion thereof. Except as has not had and would not
reasonably be expected to have, individually or in the aggregate, a Sirona
Material Adverse Effect, each Sirona Real Property and all buildings and
improvements located on the Sirona Real Property are in a state of good
operating condition, subject to reasonable wear and tear.

  



  

3.15 _Tax Matters_.

  



  

(a) Except as would not, individually or in the aggregate,
reasonably be expected to have a Sirona Material Adverse Effect:

  



  

(i)  all Tax Returns that are required to be filed by or with
respect to Sirona or any of its Subsidiaries have been timely filed
(taking into account any extension of time within which to file), and all
such Tax Returns are true, complete and accurate;

  



  

(ii) Sirona and its Subsidiaries have paid all Taxes due and owing by
any of them (whether or not shown on any Tax Return), have
established adequate accruals and reserves, in accordance with GAAP, on the
financial statements included in the Sirona SEC Documents for all Taxes
payable by Sirona and its Subsidiaries for all taxable periods and portions
thereof through the date of such financial statements and have not received
written notice of any deficiencies for any Tax of Sirona or any of its
Subsidiaries from any taxing authority for which there are not adequate
reserves on the financial statements included in the Sirona SEC Documents;

  



    

 | 23| 
---|---|--- 

 



    

  



  

(iii) Sirona and its Subsidiaries have withheld and paid all Taxes
required to have been withheld and paid in connection with amounts paid
or owing to any employee, independent contractor, creditor, stockholder or
other third party; such withheld amounts were either timely paid to the
appropriate taxing authority or set aside in accounts for such purpose and
were reported to the appropriate taxing authority and to each such employee,
independent contractor, creditor, stockholder or other third party, as
required under Law;

  



  

(iv) neither Sirona nor any of its Subsidiaries is the subject of any
currently ongoing Tax audit or other proceeding with respect to Taxes nor has
any audit or other proceeding with respect to Taxes been proposed against any
of them in writing, and any deficiencies asserted or assessments made as a
result of any audit or other proceeding with respect to Taxes have been paid
in full, are being contested in good faith, or adequate accruals or reserves
for such deficiencies or assessments have been established;

  



  

(v)   no claim has ever been made in writing by a taxing authority of
a jurisdiction where Sirona or one of its Subsidiaries has not filed Tax
Returns that Sirona or such Subsidiary is or may be subject to taxation by
that jurisdiction;

  



  

(vi)   neither Sirona nor any of its Subsidiaries has waived any
statute of limitations with respect to Taxes or agreed to any extension of
time with respect to a Tax assessment or deficiency;

  



  

(vii) neither Sirona nor any of its Subsidiaries has constituted a
"distributing corporation" or a "controlled corporation" (within the meaning
of Section 355(a)(1)(A) of the Code) in a distribution of stock intended to
qualify for tax-free treatment under Section 355 of the Code (or any similar
provision of state, local, or non-U.S. Law) or otherwise as part of a plan (or
series of related transactions), within the meaning of Section 355(e) of the
Code, that includes the Merger, in the two years prior to the date of this
Agreement;

  



  

(viii) none of Sirona or any of its Subsidiaries is a party to any
written Tax allocation, sharing, indemnity, or reimbursement agreement
or arrangement (other than an agreement with Sirona or its Subsidiaries or
any customary Tax indemnification provisions in ordinary course commercial
agreement or arrangements that are not primarily related to Taxes) or has any
liability for Taxes of any Person (other than Sirona or any of its
Subsidiaries) under U.S. Treasury Regulation Section 1.1502-6 (or any similar
provision of state, local, or non-U.S. Law) or as transferee or successor;

  



  

(ix)   there are no Liens for Taxes upon any property or assets of
Sirona or any of its Subsidiaries, except for Taxes not yet due and payable;

  



    

 | 24| 
---|---|--- 

 



    



  

(x)   neither Sirona nor any of its Subsidiaries has entered into
any "listed transaction" within the meaning of U.S. Treasury Regulation
Section 1.6011-4(b)(2) (or any similar provision of state, local or non-U.S.
Law);

  



  

(xi)   Sirona has made available to DENTSPLY or its legal or
accounting representative copies of all U.S. federal and state income Tax
Returns for Sirona and each of its Subsidiaries filed for all periods
including and after the period ended December 31, 2011;

  



  

(xii) Sirona is not a United States real property holding corporation
within the meaning of Section 897(c)(2) of the Code;

  



  

(xiii)  neither Sirona nor any of its Subsidiaries (i) has filed any
extension of time within which to file any Tax Returns that have not been
filed, except in the ordinary course of business, (ii) has entered into any
agreement or other arrangement waiving or extending the statute of
limitations or the period of assessment or collection of any Taxes, (iii) has
granted any power of attorney that is in force with respect to any matters
relating to any Taxes, (iv) has applied for a ruling from a taxing authority
relating to any Taxes that has not been granted or has proposed to enter into
an agreement with a taxing authority that is pending, (v) has, since December
31, 2011, been issued any private letter rulings, technical advice memoranda
or similar agreement or rulings by any taxing authority, or (vi) will be
required to include any item of income or gain in, or be required to exclude
any item of deduction of loss from, any period ending after the Closing Date
as a result of any (A) "closing agreement" as described in Section 7121 of
the Code (or any similar provision of state, local or non-U.S. Tax Law), (B)
installment sale or open transaction made on or prior to the Closing Date,
(C) election under section 108(i) of the Code or (D) prepaid amount received
prior to the Closing Date; and

  



  

(xiv) neither Sirona nor any of its Subsidiaries has agreed to,
requested, or is required to include any adjustment under Section 481 of
the Code (or any corresponding provision of applicable state, local or
non-U.S. Tax Law) by reason of a change in accounting method or otherwise.

  



  

(b) Neither Sirona nor any of its Subsidiaries has knowledge of any
facts, agreements, plans or other circumstances or has taken or agreed to
take any action that would reasonably be expected to prevent or impede the
Merger from qualifying as a "reorganization" within the meaning of Section
368(a) of the Code.

  



  

(c) It is agreed and understood that no representation or warranty
is made by Sirona in respect of Tax matters in any Section of this Agreement
other than _Section 3.5_, _Section 3.6_ , _Section 3.7_ , _Section 3.11_ and
this _Section 3.15_.

  



    

 | 25| 
---|---|--- 

 



    



  

3.16 _Material Contracts_.

  



  

(a) All Contracts required to be filed as exhibits to the Sirona SEC
Documents have been so filed in a timely manner. _Section 3.16(a)_ of the
Sirona Disclosure Schedule sets forth a true and complete list, as of the date
hereof, of each of the following Contracts to which Sirona or any of its
Subsidiaries is a party or by which Sirona or any of its Subsidiaries or any
of their assets or businesses are bound (and any amendments, supplements and
modifications thereto):

  



  

(i) any Contract that is a "material contract" (as such term is
defined in Item 601(b)(10) of Regulation S-K of the Exchange Act);

  



  

(ii) any Contract that materially limits the ability of Sirona or any
of its affiliates (including, following the consummation of the
Transactions, the Surviving Corporation and its affiliates) to compete or
provide services in any line of business or with any Person or in
any geographic area or market segment or to engage in any type of business
(including any license, collaboration, agency or distribution agreements);

  



  

(iii) any Contract required to be disclosed pursuant to Item 404 of
Regulation S-K of the Exchange Act;

  



  

(iv) any Contract or series of related Contracts relating to
indebtedness for borrowed money (A) in excess of $10 million or (B)
that becomes due and payable as a result of the Transactions;

  



  

(v) any license, sublicense, option, development or collaboration
agreement or other Contract relating to Sirona Material Intellectual Property
reasonably expected to result in payments in excess of $10 million in any
twelve (12) month period after the Closing Date (excluding license agreements
for "shrink-wrap," "click-wrap" or other commercially available off-the-
shelf software that is not the subject of a negotiated agreement, and
excluding agreements the primary purpose of which is to purchase tangible
goods or procure services unrelated to Intellectual Property and in the
ordinary course of business);

  



  

(vi) any Contract reasonably expected to result in payments in excess
of $10 million in any twelve (12) month period after the Closing Date that
provides for any material "most favored nation" provision or equivalent
preferential pricing terms or similar obligations to which Sirona or any of
its Subsidiaries is subject;

  



  

(vii) any Contract with any of Sirona's top 20 suppliers (including
purchasing agreements and group purchasing agreements) (measured by dollar
volume of purchases of Sirona during the twelve (12) months ended June 30,
2015);

  



    

 | 26| 
---|---|--- 

 



    



  

(viii) any Contract with any of Sirona's top 20 customers (measured by
dollar volume of spending by the customer during the twelve (12) months ended
June 30, 2015);

  



  

(ix) any purchase, sale or supply contract that contains volume
requirements or commitments, exclusive or preferred purchasing
arrangements or promotional requirements reasonably expected to result in
payments in excess of $10 million in any twelve (12) month period after the
Closing Date;

  



  

(x) any lease, sublease, occupancy agreement or other Contract with
respect to the Sirona Leased Real Property reasonably expected to result in
payments in excess of $10 million in any twelve (12) month period after the
Closing Date;

  



  

(xi) any agreement that grants any right of first refusal or right of
first offer or similar right or that limits or purports to limit the ability
of Sirona or any of its Subsidiaries to own, operate, sell, transfer, pledge
or otherwise dispose of any material amount of assets or businesses (in any
case in excess of $10 million);

  



  

(xii) any acquisition or divestiture agreement (A) entered into since
June 30, 2012 with a purchase price in excess of $20 million or (B) that
contains "earn-out" provisions or other contingent payment obligations that
could reasonably be expected to exceed $10 million (including indemnification
obligations) that have not been satisfied in full;

  



  

(xiii) any agreement that by its terms limits the payment of dividends
or other distributions by Sirona or any of its Subsidiaries;

  



  

(xiv) any Contract for any joint venture, partnership or similar
arrangement, or any Contract involving a sharing of revenues, profits,
losses, costs, or liabilities by Sirona or any of its Subsidiaries with any
other Person involving a potential combined commitment or payment by Sirona
and any of its Subsidiaries in excess of $10 million annually;

  



  

(xv) any "single source" supply Contract pursuant to which goods or
materials that are material to Sirona or any of its Subsidiaries are supplied
to Sirona or such Subsidiary from an exclusive source reasonably expected to
result in payments in excess of $10 million in any twelve (12) month period
after the Closing Date;

  



  

(xvi) any Contract with any Governmental Entity reasonably expected to
result in payments in excess of $10 million in any twelve (12) month period
after the Closing Date; or

  



    

 | 27| 
---|---|--- 

 



    



  

(xvii) any other agreement which would prohibit or delay beyond the
Outside Date the consummation of Merger or any other Transaction
contemplated by this Agreement.

  



  

(b) Sirona has heretofore made available to DENTSPLY true, correct
and complete copies of the Contracts set forth in _Section 3.16(a)_.

  



  

(c) Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Sirona Material Adverse Effect, (i)
all Contracts set forth or required to be set forth in _Section 3.16(a)_ of
the Sirona Disclosure Schedule or filed or required to be filed as exhibits
to the Sirona SEC Documents (the " _Sirona Material Contracts_ ") are
valid, binding and in full force and effect and are enforceable by Sirona or
its applicable Subsidiary in accordance with their terms, except as limited
by Laws affecting the enforcement of creditors' rights generally, by general
equitable principles or by the discretion of any Governmental Entity before
which any Proceeding seeking enforcement may be brought, (ii) Sirona, or its
applicable Subsidiary, has performed all obligations required to be performed
by it under the Sirona Material Contracts, and it is not (with or without
notice or lapse of time, or both) in breach or default thereunder and, to the
Knowledge of Sirona, no other party to any Sirona Material Contract is (with
or without notice or lapse of time, or both) in breach or default
thereunder, (iii) since January 1, 2015, neither Sirona nor any of its
Subsidiaries has received written notice of any actual, alleged, possible or
potential violation of, or failure to comply with, any term or requirement of
any Sirona Material Contract, and (iv) neither Sirona nor any of its
Subsidiaries has received any written notice of the intention of any party to
cancel, terminate, change the scope of rights under or fail to renew any
Sirona Material Contract.

  



  

3.17 _Intellectual Property_.

  



  

(a) With respect to all (i) issued patents and pending patent
applications, (ii) trademark and service mark registrations and
applications, (iii) copyright registrations and applications, and (iv)
internet domain name registrations, in each case that are owned by Sirona or
any of its Subsidiaries (collectively, the " _Sirona Registered Intellectual
Property_ "), except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Sirona Material Adverse Effect, (A)
either Sirona or one of its Subsidiaries is the sole owner and possesses all
right, title and interest in and to the item, free and clear of all Liens
(other than Permitted Liens), and (B) no Proceeding is pending or, to
Knowledge of Sirona, threatened, that challenges the legality, validity,
enforceability, registration, use or ownership of the item (except for office
actions by the applicable Governmental Entities in the normal course of
prosecution efforts in connection with applications for the registration or
issuance of Intellectual Property). Each item of material Sirona Registered
Intellectual Property that is registered, filed, issued, or applied for has
been duly registered in, filed in or issued by the official governmental
registers and/or issuers (or officially recognized registers or issuers) for
such Intellectual Property and each such registration, filing, issuance and/or
application, to the Knowledge of Sirona, (x) has not been abandoned or
cancelled, (y) has been maintained effective by all requisite
filings, renewals and payments, and (z) remains in full force and effect.

  



    

 | 28| 
---|---|--- 

 



    



  

(b) Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Sirona Material Adverse
Effect, each of Sirona and its Subsidiaries owns and possesses all right,
title and interest in and to (or has the right pursuant to a valid and
enforceable license or otherwise possesses legally enforceable rights to use)
all Intellectual Property that is necessary for or used or held for use in
the conduct of the business of Sirona and its Subsidiaries in substantially
the same manner as presently conducted and currently proposed to be
conducted. Neither the execution and delivery of this Agreement by Sirona, nor
the performance of this Agreement by Sirona, will result in the loss,
forfeiture, termination, or impairment of, or give rise to a right of
any Person to limit, terminate, or consent to the continued use of, any
rights of Sirona or any of its Subsidiaries in any Intellectual Property
except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Sirona Material Adverse Effect.

  



  

(c) Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Sirona Material Adverse Effect, to
the Knowledge of Sirona, neither Sirona nor any of its Subsidiaries nor the
conduct of their businesses is infringing, misappropriating, diluting, or
otherwise violating the Intellectual Property rights of any Person. Neither
Sirona nor any of its Subsidiaries has received any written charge,
complaint, claim, demand, or notice since June 30, 2012 (or earlier, if
presently not resolved) alleging any such infringement, misappropriation,
dilution, or violation (including any claim that Sirona or any of its
Subsidiaries must license or refrain from using any Intellectual Property
rights of any Person) which alleged infringement, misappropriation, dilution,
or violation, if true, would reasonably be expected to have, individually or
in the aggregate, a Sirona Material Adverse Effect. To the Knowledge of
Sirona, no Person is infringing, misappropriating, diluting or otherwise
violating any Intellectual Property owned by Sirona or any of its
Subsidiaries except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Sirona Material Adverse Effect.
Neither Sirona nor any of its Subsidiaries has made or asserted any
charge, complaint, claim, demand or notice since June 30, 2012 (or earlier,
if presently not resolved) alleging any such infringement, misappropriation,
dilution, or violation which alleged infringement, misappropriation, dilution,
or violation, if true, would reasonably be expected to have, individually or
in the aggregate, a Sirona Material Adverse Effect.

  



  

(d) Sirona and its Subsidiaries have taken commercially reasonable
steps to maintain, police and protect the Intellectual Property that
is material to their business (" _Sirona Material Intellectual Property_ ").
Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Sirona Material Adverse Effect, all Sirona
Material Intellectual Property that derives independent economic value,
actual or potential, from not being generally known to the public or to other
persons who can obtain economic value from its disclosure or use has been
maintained in confidence in accordance with protection procedures that are in
accordance with procedures customarily used in the industry to protect rights
of like importance and, to the Knowledge of Sirona, adequate for protection.
To the Knowledge of Sirona, there has been no unauthorized disclosure of any
Sirona Material Intellectual Property. Except as has not had and would not
reasonably be expected to have, individually or in the aggregate, a Sirona
Material Adverse Effect, to the Knowledge of Sirona, all former and current
officers, directors, employees, personnel, consultants, advisors, agents, and
independent contractors of Sirona and its Subsidiaries, and each of their
predecessors, who have contributed to or participated in the conception and
development of Intellectual Property for such entities have entered into valid
and binding proprietary rights agreements with Sirona or one of its
Subsidiaries or predecessors, vesting ownership of such Intellectual
Property in Sirona or one of its Subsidiaries. No such Person has asserted,
and to the Knowledge of Sirona, no such Person has, any right, title,
interest or other claim in, or the right to receive any royalties or other
consideration with respect to, any Sirona Material Intellectual Property.

  



    

 | 29| 
---|---|--- 

 



    



  

(e) Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Sirona Material Adverse Effect, the
IT Assets of Sirona and its Subsidiaries operate in all material respects in
accordance with their documentation and functional specifications and as
required by Sirona and its Subsidiaries to operate the business of Sirona and
its Subsidiaries as presently conducted and have not, since June 30, 2012,
materially malfunctioned or failed. Sirona and its Subsidiaries have
implemented commercially reasonable measures to protect the confidentiality
and security of such IT Assets and information stored or contained therein
against any unauthorized use, access, interruption or corruption. Sirona and
its Subsidiaries have implemented commercially reasonable data backup, data
storage, system redundancy and disaster avoidance procedures with respect to
their IT Assets.

  



  

(f) To the Knowledge of Sirona, no software included in the Sirona
Material Intellectual Property, which is distributed to any third party by or
on behalf of Sirona or its Subsidiaries (other than software identified as
belonging to a third party and subject to a third party paid or public
license), or for which Sirona or its Subsidiaries may have plans to distribute
to any third party, incorporates or is comprised of or distributed with any
publicly available software, or is otherwise subject to the provisions of any
"open source" or third party license agreement that (i) requires the
distribution of source code in connection with the distribution of such
software in object code form; (ii) materially limits Sirona's or any of its
Subsidiaries' freedom to seek full compensation in connection with marketing,
licensing, and distributing such applications; or (iii) allows a customer or
requires that a customer have the right to decompile, disassemble or
otherwise reverse engineer the software by its terms and not by operation of
law.

  



  

3.18 _Healthcare Compliance Matters_.

  



  

(a) (i) Sirona and each of its Subsidiaries are in compliance and
since June 30, 2012 have been in compliance with all Health Care
Laws applicable to Sirona or any of its Subsidiaries or any assets owned or
used by any of them (except for such past noncompliance as has been remedied
and imposes no continuing obligations or costs on Sirona or its Subsidiaries),
and (ii) neither Sirona nor any of its Subsidiaries has received any written
communication since June 30, 2012 from a Governmental Entity that remains
uncured or unresolved and that alleges that Sirona or any of its Subsidiaries
is not in compliance with any Health Care Law, except in the case of clauses
(i) and (ii) where any non-compliance, individually or in the aggregate, has
not had and would not reasonably be expected to have, a Sirona Material
Adverse Effect. Neither Sirona nor, to the Knowledge of Sirona, any of
its Subsidiaries is a party to or has any ongoing reporting obligations
pursuant to or under any corporate integrity agreements, deferred prosecution
agreements, monitoring agreements, consent decrees, settlement orders, plans
of correction or similar agreements with or imposed by any Governmental
Entity. Additionally, none of Sirona, its Subsidiaries or any of its
respective employees, officers or directors has been excluded, suspended or
debarred from participation in any U.S. state or federal health care program
or, to the Knowledge of Sirona, has been convicted of any crime or is subject
to a governmental inquiry, investigation, Proceeding, or other similar
action, or has engaged in any conduct, that could reasonably be expected to
result in debarment, suspension, or exclusion.

  



    

 | 30| 
---|---|--- 

 



    



  

(b) Sirona and each of its Subsidiaries have, maintain and are
operating in material compliance with all Permits of the United States
Food and Drug Administration (" _FDA_ ") and comparable Governmental Entities
which are required for the conduct of their business as currently conducted
(collectively, the " _FDA Permits_ "), and all such FDA Permits are valid,
subsisting, and in full force and effect, except where the failure to have,
maintain or operate in material compliance with the FDA Permits has not had,
and would not reasonably be expected to have, individually or in the
aggregate, a Sirona Material Adverse Effect. Sirona and each of its
Subsidiaries have fulfilled and performed all of their material obligations
with respect to the FDA Permits, and no event has occurred which allows, or
with notice or lapse of time or both, would allow revocation or termination
thereof or results in any other material impairment of the rights of the
holder of any FDA Permit, except where the failure to so fulfill or perform,
or the occurrence of such event, would not result in a Sirona Material Adverse
Effect. Sirona and each of its Subsidiaries have operated and currently are
in compliance in all material respects with applicable Laws administered or
enforced by the FDA and comparable Governmental Entities, except where the
failure to so comply would not result in a Sirona Material Adverse
Effect. Sirona and each of its Subsidiaries have not received, since June 30,
2012, written notice of any pending or threatened Proceeding (other than FDA
audits) from the FDA, any Governmental Entity, any qui-tam relator or
applicable foreign Governmental Entity alleging that any operation or
activity of Sirona or any of its Subsidiaries is in material violation of any
applicable Health Care Law which violation would reasonably be expected to
have a material and adverse impact on Sirona and its Subsidiaries, taken as a
whole.

  



  

(c) Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Sirona Material Adverse Effect, all
applications, notifications, submissions, information, claims, reports and
statistics, and other data and conclusions derived therefrom, utilized as the
basis for or submitted in connection with any and all requests for a FDA
Permit from the FDA or other Governmental Entity relating to Sirona and each
of its Subsidiaries, their business and products, when submitted to the FDA
or other Governmental Entity were true, complete and correct as of the date
of submission and any necessary or required updates, changes, corrections or
modification to such applications, submissions, information and data have been
submitted to the FDA or other Governmental Entity.

  



  

(d) Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Sirona Material Adverse
Effect, since June 30, 2012, Sirona and each of its Subsidiaries have not had
any product or manufacturing site (whether owned by Sirona or its
Subsidiary(s), or a contract manufacturer for their products) subject to a
Governmental Entity (including FDA) shutdown or import or export prohibition,
nor received any FDA Form 483 or other Governmental Entity notice of
inspectional observations, "warning letters," "untitled letters" or requests
or requirements to make changes to the products, or similar correspondence or
notice from the FDA or other Governmental Entity alleging or asserting
noncompliance with any applicable Law, Permit or such requests or
requirements of a Governmental Entity.

  



    

 | 31| 
---|---|--- 

 



    



  

(e) Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Sirona Material Adverse Effect, (i)
since June 30, 2012, there have been no (A) recalls, field notifications,
field corrections, market withdrawals or replacements, safety alerts or other
notice of action relating to an alleged lack of safety, efficacy, or
regulatory compliance (" _Safety Notices_ ") with respect to the products of
Sirona and its Subsidiaries or (B) to the Knowledge of Sirona, complaints
with respect to such products that are currently unresolved and (ii) to the
Knowledge of Sirona, there are no facts that would be reasonably likely to
result in (A) a Safety Notice with respect to such products, (B) a change in
labeling of any such products, or (C) a termination or suspension of
marketing or testing of any such products.

  



  

(f) Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a Sirona Material Adverse Effect, (i)
the clinical, pre-clinical and other studies and tests conducted by or on
behalf of or sponsored by Sirona or its Subsidiaries or in which Sirona or
its Subsidiaries, or any of their products or product candidates have
participated were, and if still pending are, being conducted in accordance
with standard medical and scientific research procedures and all applicable
Laws, including, but not limited to, the Federal Food, Drug and Cosmetic Act
and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58
and 812 and (ii) no investigational device exemption filed by or on behalf of
Sirona or its Subsidiaries with the FDA has been terminated or suspended by
the FDA, and neither the FDA nor any applicable foreign Governmental Entity
has commenced, or, to the Knowledge of Sirona, threatened to commence, any
action to place a clinical hold order on, or otherwise terminate, delay or
suspend, any proposed or ongoing clinical investigation conducted or proposed
to be conducted by or on behalf of Sirona and its Subsidiaries.

  



  

(g) Neither Sirona nor any of its Subsidiaries is the subject of any
pending or, to the Knowledge of Sirona, threatened investigation in
respect of Sirona, its Subsidiaries or their products, by the FDA pursuant to
its "Fraud, Untrue Statements of Material Facts, Bribery, and Illegal
Gratuities" Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991)
and any amendments thereto. Since June 30, 2012, neither Sirona nor, to the
Knowledge of Sirona, any of their officers, employees or agents (within the
meaning of the applicable Law) has been convicted of any crime or engaged in
any conduct that could result in a material debarment or exclusion under (i)
21 U.S.C. Section 335a or (ii) any similar Law. As of the date hereof, no
Proceedings that would reasonably be expected to result in such a debarment
or exclusion are pending or, to the Knowledge of Sirona, threatened against
Sirona, its Subsidiaries, or any of their officers, employees or agents.

  



  

3.19 _Broker 's Fees_. Except for the financial advisors' fees set
forth in _Section 3.19_ of the Sirona Disclosure Schedule, neither Sirona
nor any of its Subsidiaries nor any of their respective officers or directors
on behalf of Sirona or such Subsidiaries has employed any financial advisor,
broker or finder or incurred any liability for any financial advisory fee,
broker's fees, commissions or finder's fees in connection with any of the
Transactions.

  



  

3.20 _Opinion of Financial Advisor_. Jefferies LLC, Sirona's financial
advisor, has delivered to the Sirona Board its opinion in writing or orally,
in which case, such opinion will be subsequently confirmed in writing, to the
effect that, as of the date thereof and based upon and subject to the factors
and assumptions set forth therein, the Exchange Ratio is fair from a financial
point of view to the holders of the shares of Sirona Common Stock.

  



    

 | 32| 
---|---|--- 

 



    



  

3.21 _Ownership of DENTSPLY Common Stock_. Neither Sirona nor any of
its affiliates or associates is, nor at any time during the last three
(3) years has Sirona or any of its affiliates or associates been, an
"interested stockholder" of DENTSPLY as defined in Section 203 of the DGCL.
Sirona and its Subsidiaries, affiliates and associates do not beneficially own
any shares of DENTSPLY Common Stock or other securities of DENTSPLY or any
options, warrants or other rights to acquire DENTSPLY Common Stock or
other securities of, or any other economic interest (through derivative
securities or otherwise) in, DENTSPLY.

  



  

3.22 _Insurance_. All insurance policies (including policies providing
casualty, liability, and workers compensation coverage, but excluding
any Sirona Benefit Plans) to which Sirona or any of its Subsidiaries is
currently a party are in full force and effect, and, to the Knowledge of
Sirona, have been issued by licensed insurers, all premiums with respect
thereto covering all periods up to and including the Closing Date have been
paid, and no notice of cancellation or termination has been received with
respect to any such policies, except for such cancellations or terminations
which would have not had and would not reasonably be expected to have,
individually or in the aggregate, a Sirona Material Adverse Effect. Except as
has not had and would not reasonably be expected to have, individually or in
the aggregate, a Sirona Material Adverse Effect, each of Sirona and its
Subsidiaries is, and since October 1, 2013 has been, insured with respect to
its assets and properties and the conduct of its business in such amounts and
against such risks as are in its reasonable judgment sufficient for
compliance with Law and as are adequate to protect its assets and properties
and the conduct of its business.

  



  

3.23 _No Other Representations or Warranties_. Except for the
representations and warranties expressly contained in this _Article
3_, neither Sirona nor any of its affiliates nor any Person acting on any of
their behalf makes any other express or any implied representations or
warranties with respect to (a) Sirona or any of its Subsidiaries, any of their
businesses, operations, assets, liabilities, condition (financial or
otherwise) or prospects or any other matter relating to Sirona or any of its
Subsidiaries or (b) the accuracy or completeness of any documentation,
forecasts or other information provided by Sirona, any affiliate of Sirona or
any Person acting on any of their behalf to DENTSPLY, Merger Sub, any
affiliate of DENTSPLY or any Person acting on any of their behalf.

  



  

ARTICLE 4 
 Representations and Warranties of DENTSPLY AND MERGER SUB

  



  

Except (a) as set forth in the DENTSPLY Disclosure Schedule (subject to
_Section 8.15_) and (b) as otherwise disclosed or identified in the
DENTSPLY SEC Documents publicly filed or furnished after December 31, 2013
and prior to the date hereof (other than (i) any forward-looking disclosures
contained in the "Forward Looking Statements" and "Risk Factors" sections of
the DENTSPLY SEC Documents and any other disclosures included therein to the
extent they are primarily predictive, cautionary or forward looking in nature
and (ii) information included in, or incorporated by reference as, exhibits
and schedules to any DENTSPLY SEC Document, and provided that the exception
provided for in this clause (b) shall be applied if, and only if, the nature
and content of the applicable disclosure in any such DENTSPLY SEC Document
publicly filed or furnished prior to the date hereof is reasonably
specific as to matters and items such that the subject matter of such
disclosure is reasonably apparent on the face of the text of such disclosure
to be applicable to the representation set forth herein), DENTSPLY and Merger
Sub hereby represent and warrant to Sirona as follows:

  



    

 | 33| 
---|---|--- 

 



    



  

4.1 _Corporate Organization_. Each of DENTSPLY and, except where the
failure to be in good standing has not had and would not reasonably
be expected to have, individually or in the aggregate, a DENTSPLY Material
Adverse Effect, its Subsidiaries, including Merger Sub, is a corporation or
other entity duly organized, validly existing and, to the extent applicable,
in good standing under the laws of the jurisdiction of its organization and
has the requisite corporate or other entity power and authority to own or
lease all of its properties and assets and to carry on its business as it is
now being conducted. Each of DENTSPLY and its Subsidiaries, including Merger
Sub, is duly licensed or qualified to do business in each jurisdiction in
which the nature of the business conducted by it or the character or location
of the properties and assets owned or leased by it makes such licensing or
qualification necessary, except where the failure to be so licensed or
qualified, has not had and would not reasonably be expected to have,
individually or in the aggregate, a DENTSPLY Material Adverse Effect. The
copies of the certificate of incorporation (the " _DENTSPLY Charter_ ") and
bylaws (the " _DENTSPLY Bylaws_ ") of DENTSPLY, as most recently filed with
the DENTSPLY SEC Documents, and the certificate of incorporation and bylaws
of Merger Sub previously provided to Sirona, are true, complete and correct
copies of such documents as in effect as of the date of this Agreement.
DENTSPLY is not in violation of any of the provisions of the DENTSPLY Charter
or the DENTSPLY Bylaws. True and complete copies of all minute books of
DENTSPLY since January 1, 2013 have been made available by DENTSPLY to
Sirona, except for such portions of the minutes subject to attorney-client
privilege or with respect to the consideration of a possible acquisition or
business combination involving DENTSPLY.

  



  

4.2 _DENTSPLY Capitalization_.

  



  

(a) The authorized capital stock of DENTSPLY consists of two hundred
million (200,000,000) shares of DENTSPLY Common Stock and two hundred fifty
thousand (250,000) shares of preferred stock, par value $1.00 per share ("
_DENTSPLY Preferred Stock_ "). As of September 11, 2015, (i) 139,813,774
shares of DENTSPLY Common Stock (other than treasury shares) were issued and
outstanding, all of which were validly issued and fully paid, nonassessable
and free of preemptive rights, (ii) 22,961,694 shares of DENTSPLY Common
Stock were held in the treasury of DENTSPLY or by its Subsidiaries, (iii)
8,752,637 shares of DENTSPLY Common Stock were issuable (and such number was
reserved for issuance) upon exercise of DENTSPLY Stock Options and DENTSPLY
RSUs outstanding as of such date and (iv) no shares of DENTSPLY Preferred
Stock were issued and outstanding. Except for DENTSPLY Stock Options
and DENTSPLY RSUs to purchase not more than 8,752,637 shares of DENTSPLY
Common Stock, there are no options, warrants or other rights, agreements,
arrangements or commitments of any character to which DENTSPLY or any of its
Subsidiaries is a party or by which DENTSPLY or any of its Subsidiaries is
bound relating to the issued or unissued capital stock or other Equity
Interests of DENTSPLY or any of its Subsidiaries, or securities convertible
into or exchangeable for such capital stock or other Equity Interests, or
obligating DENTSPLY or any of its Subsidiaries to issue or sell any shares of
its capital stock or other Equity Interests, or securities convertible into
or exchangeable for such capital stock of, or other Equity Interests in,
DENTSPLY or any of its Subsidiaries. Since September 11, 2015, DENTSPLY has
not issued any shares of its capital stock or other Equity Interests, or
securities convertible into or exchangeable for such capital stock or other
Equity Interests, other than those shares of capital stock reserved for
issuance described in this _Section 4.2(a)_. DENTSPLY has previously provided
Sirona with a true and complete list, as of the date hereof, of the prices at
which each outstanding DENTSPLY Stock Option and DENTSPLY RSU may be exercised
under the applicable DENTSPLY Stock Plan, the number of DENTSPLY Stock
Options and DENTSPLY RSUs outstanding at each such price and the
vesting schedule of the DENTSPLY Stock Options and DENTSPLY RSUs. None of the
DENTSPLY Stock Options are "incentive stock options" within the meaning of
Section 422 of the Code. All shares of DENTSPLY Common Stock subject to
issuance under the applicable DENTSPLY Stock Plan, upon issuance prior to the
Effective Time on the terms and conditions specified in the instruments
pursuant to which they are issuable, will be duly authorized, validly issued,
fully paid, nonassessable and free of preemptive rights. There are no bonds,
debentures, notes or other indebtedness of DENTSPLY having the right to vote
on any matters on which shareholders of DENTSPLY may vote. Neither DENTSPLY
nor any of its Subsidiaries is a party to any voting agreement with respect to
the voting of any Equity Interests of DENTSPLY or any of its Subsidiaries.

  



    

 | 34| 
---|---|--- 

 



    



  

(b) Except with respect to DENTSPLY RSUs, there are no outstanding
contractual obligations of DENTSPLY or any of its Subsidiaries (i)
restricting the transfer of, (ii) affecting the voting rights of, (iii)
requiring the repurchase, redemption or disposition of, or containing any
right of first refusal with respect to, (iv) requiring the registration for
sale of, or (v) granting any preemptive or antidilutive right with respect
to, any shares of DENTSPLY Common Stock or any capital stock of, or other
Equity Interests in, DENTSPLY or any of its Subsidiaries.

  



  

(c) _Section 4.2(c)_ of the DENTSPLY Disclosure Schedule sets forth
a true and complete list of all of the Subsidiaries of DENTSPLY and
the jurisdiction or organization of each such Subsidiary. Except for Merger
Sub and as set forth in _Section 4.2(c)_ of the DENTSPLY Disclosure
Schedule, none of DENTSPLY or any of its Subsidiaries holds an Equity Interest
in any other Person. Each outstanding share of capital stock of or other
Equity Interest in each Subsidiary of DENTSPLY is duly authorized, validly
issued, fully paid, nonassessable and free of preemptive rights and is owned,
beneficially and of record, by DENTSPLY or one or more of its wholly-
owned Subsidiaries free and clear of all Liens. There are no outstanding
contractual obligations of DENTSPLY or any of its Subsidiaries to provide
funds to, or make any investment (in the form of a loan, capital contribution
or otherwise) in, any Subsidiary of DENTSPLY (in excess of $5 million) or any
other Person, other than guarantees by DENTSPLY of any indebtedness or other
obligations of any wholly-owned Subsidiary of DENTSPLY.

  



    

 | 35| 
---|---|--- 

 



    



  

4.3 _Authority; Execution and Delivery; Enforceability_.

  



  

(a) Each of DENTSPLY and Merger Sub has all necessary power and
authority to execute and deliver this Agreement, to perform and comply
with each of its obligations under this Agreement and, subject to the receipt
of the DENTSPLY Shareholder Approval, to consummate the Transactions
applicable to such party. The execution and delivery by each of DENTSPLY and
Merger Sub of this Agreement, the performance and compliance by DENTSPLY and
Merger Sub with each of its obligations herein and the consummation by
DENTSPLY and Merger Sub of the Transactions have been duly authorized by all
necessary corporate action on the part of DENTSPLY and Merger Sub, subject
to the receipt of the DENTSPLY Shareholder Approval and to the adoption of
this Agreement by DENTSPLY as the sole shareholder of Merger Sub, and no
other corporate proceedings on the part of DENTSPLY and Merger Sub and no
other shareholder votes are necessary to authorize this Agreement or the
consummation by DENTSPLY and Merger Sub of the Transactions to which it is a
party. Each of DENTSPLY and Merger Sub has duly and validly executed and
delivered this Agreement and, assuming the due authorization, execution and
delivery by Sirona of this Agreement, this Agreement constitutes its legal,
valid and binding obligation, enforceable against it in accordance with its
terms, except as limited by Laws affecting the enforcement of creditors'
rights generally, by general equitable principles or by the discretion of any
Governmental Entity before which any Proceeding seeking enforcement may be
brought.

  



  

(b) The Board of Directors of DENTSPLY (the " _DENTSPLY Board_ "),
at a meeting duly called and held, unanimously adopted resolutions (i)
approving this Agreement and the consummation of the Transactions upon the
terms and subject to the conditions set forth in this Agreement, (ii)
determining that the terms of the Agreement and the Transactions are fair to,
and in the best interests of, DENTSPLY and its shareholders, (iii) directing
that the DENTSPLY Share Issuance and the Amended and Restated DENTSPLY
Charter be submitted to the shareholders of DENTSPLY for approval, and (iv)
recommending that DENTSPLY\'s shareholders approve the DENTSPLY Share
Issuance and the Amended and Restated DENTSPLY Charter (the " _DENTSPLY
Recommendation_ ").

  



  

(c) To the Knowledge of DENTSPLY, no takeover, anti-takeover,
business combination, control share acquisition or similar Law applies to the
Transactions. The only vote of holders of any class or series of DENTSPLY
Common Stock or other Equity Interests of DENTSPLY necessary to approve the
Transactions is the approval of (i) the DENTSPLY Share Issuance by a majority
of the total votes cast on such proposal by holders of the DENTSPLY Common
Stock outstanding and entitled to vote thereon and (ii) the Amended and
Restated DENTSPLY Charter by the holders of a majority of the DENTSPLY Common
Stock outstanding and entitled to vote thereon (together, the " _DENTSPLY
Shareholder Approval_ "). No other vote of the holders of DENTSPLY Common
Stock or any other Equity Interests of DENTSPLY is necessary to consummate
the Transactions.

  



    

 | 36| 
---|---|--- 

 



    



  

4.4 _No Conflicts_.

  



  

(a) The execution and delivery of this Agreement by DENTSPLY and
Merger Sub does not and will not, and the performance of this Agreement by
DENTSPLY and Merger Sub and the consummation of the Transactions will not, (i)
assuming the DENTSPLY Shareholder Approval is obtained, conflict with or
violate any provision of the DENTSPLY Charter or the DENTSPLY Bylaws or any
equivalent organizational documents of any Subsidiary of DENTSPLY, including
Merger Sub, (ii) assuming that all consents, approvals, authorizations and
permits described in _Section 4.4(b)_ have been obtained and all filings and
notifications described in _Section 4.4(b)_ have been made and any waiting
periods thereunder have terminated or expired, conflict with or violate any
Law applicable to any of DENTSPLY or any of its Subsidiaries, including
Merger Sub, or by which any property or asset of DENTSPLY or any of its
Subsidiaries, including Merger Sub, is bound or affected or (iii) require any
consent or approval under, result in any breach of or any loss or impairment
of any benefit under, constitute a change of control or default (or an event
which with notice or lapse of time or both would become a default) under or
give to others any right of termination, vesting, amendment, acceleration or
cancellation of, or result in the creation of a Lien on any property or asset
of DENTSPLY or any of its Subsidiaries, including Merger Sub, pursuant to,
any Contract or Permit, except, with respect to clauses (ii) and (iii), for
any such conflicts, violations, breaches, defaults or other occurrences which
would not, individually or in the aggregate, reasonably be expected to (A)
prevent or delay beyond the Outside Date consummation of the Merger, (B)
otherwise prevent or delay beyond the Outside Date performance by DENTSPLY of
any of its material obligations under this Agreement or (C) have a DENTSPLY
Material Adverse Effect.

  



  

(b) The execution and delivery of this Agreement by DENTSPLY and
Merger Sub does not and will not, and the consummation by DENTSPLY and Merger
Sub of the Transactions to which it is a party and compliance by DENTSPLY and
Merger Sub with any of the terms or provisions hereof or thereof will not,
require any consent, approval, authorization or permit of, or filing with or
notification to, any Governmental Entity or any other Person, except (i) under
the Exchange Act, Securities Act, any applicable blue sky Law and the rules
and regulations of the NASDAQ (ii) under the HSR Act, the EU Merger Regulation
or other applicable foreign, federal, state or supranational antitrust,
competition, fair trade or similar applicable Laws, (iii) the filing of the
Certificate of Merger as required by the DGCL and (iv) where failure to obtain
such consents, approvals, authorizations or permits, or to make such filings
or notifications to a Person other than a Governmental Entity, would not,
individually or in the aggregate, reasonably be expected to (A) prevent or
delay beyond the Outside Date consummation of the Merger or other
Transactions, (B) otherwise prevent or delay beyond the Outside Date
performance by DENTSPLY or Merger Sub of any of their respective material
obligations under this Agreement or (C) have a DENTSPLY Material Adverse
Effect.

  



  

4.5 _SEC Documents; Financial Statements; Undisclosed Liabilities_.

  



  

(a) DENTSPLY has filed or furnished all reports, schedules, forms,
statements, registration statements, prospectuses and other documents
required to be filed or furnished by DENTSPLY with the SEC under the
Securities Act or the Exchange Act since January 1, 2013 (the " _DENTSPLY SEC
Documents_ "). None of the Subsidiaries of DENTSPLY is required to make or
makes any filings with the SEC.

  



  

(b) As of its respective filing date, and, if amended, as of the
date of the last amendment prior to the date of this Agreement, each DENTSPLY
SEC Document complied in all material respects with the requirements of the
Exchange Act or the Securities Act, as the case may be, and the rules and
regulations of the SEC promulgated thereunder applicable to such DENTSPLY SEC
Document did not contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary in order
to make the statements therein, in light of the circumstances under which
they were made, not misleading.

  



    

 | 37| 
---|---|--- 

 



    



  

(c) The consolidated financial statements of DENTSPLY included in
the DENTSPLY SEC Documents (including, in each case, any notes or
schedules thereto) and all related compilations, reviews and other reports
issued by DENTSPLY's accountants with respect thereto (the " _DENTSPLY SEC
Financial Statements_ "), comply as to form in all material respects with
applicable accounting requirements and the published rules and regulations of
the SEC with respect thereto. The DENTSPLY SEC Financial Statements
fairly present, in all material respects, the financial condition and the
results of operations, cash flows and changes in shareholders' equity of
DENTSPLY (on a consolidated basis) as of the respective dates of and for the
periods referred to in the DENTSPLY SEC Financial Statements, and were
prepared in accordance with GAAP applied on a consistent basis during the
periods involved (except as may be indicated in the notes thereto), subject,
in the case of interim DENTSPLY SEC Financial Statements, to normal year-
end adjustments (which are not material in significance or amount) and the
absence of notes. The books and records of DENTSPLY and its Subsidiaries are
accurate and complete in all material respects, have been maintained in
accordance with sound business practices and accurately present and reflect
in all material respects all of the transactions and actions therein described
and the DENTSPLY SEC Financial Statements have been prepared, in all material
respects, in accordance with such books and records. No financial statements
of any Person other than DENTSPLY and its Subsidiaries are required by GAAP to
be included in the consolidated financial statements of DENTSPLY. Except as
required by GAAP, DENTSPLY has not, between June 30, 2015 and the date of this
Agreement, made or adopted any material change in its accounting methods,
practices or policies in effect on June 30, 2015.

  



  

(d) DENTSPLY is in compliance in all material respects with (i) the
applicable provisions of the Sarbanes-Oxley Act and (ii) the
applicable listing and corporate governance rules and regulations of the
NASDAQ.

  



  

(e) DENTSPLY has made available to Sirona true and complete copies
of all written comment letters from the staff of the SEC received since
January 1, 2013 relating to the DENTSPLY SEC Documents and all written
responses of DENTSPLY thereto other than with respect to requests for
confidential treatment or which are otherwise publicly available on the SEC's
EDGAR system. To the Knowledge of DENTSPLY, there are no outstanding or
unresolved comments in comment letters received from the SEC staff with
respect to any DENTSPLY SEC Documents and none of the DENTSPLY SEC Documents
(other than confidential treatment requests) is the subject of ongoing SEC
review. There are no internal investigations with respect to which DENTSPLY
has retained outside counsel, SEC inquiries or investigations or other
governmental inquiries or investigations, to the Knowledge of DENTSPLY,
pending or threatened, in each case regarding any accounting practices of
DENTSPLY.

  



    

 | 38| 
---|---|--- 

 



    



  

(f) DENTSPLY has established and maintains disclosure controls and
procedures and internal control over financial reporting (as such terms
are defined in paragraphs (e) and (f), respectively, of Rule 13a-15 and
paragraph (e) of Rule 15d-15 under the Exchange Act) as required by Rules
13a-15 and 15d-15 under the Exchange Act. DENTSPLY's disclosure controls and
procedures are designed to ensure that all information (both financial and
non-financial) required to be disclosed by DENTSPLY in the reports that it
files or furnishes under the Exchange Act is recorded, processed, summarized
and reported within the time periods specified in the rules and forms of the
SEC, and that all such information is accumulated and communicated to
DENTSPLY's management as appropriate to allow timely decisions regarding
required disclosure and to make the certifications required pursuant to
Sections 302 and 906 of the Sarbanes-Oxley Act. DENTSPLY's management has
completed an assessment of the effectiveness of DENTSPLY's disclosure
controls and procedures and, to the extent required by applicable Law,
presented in any applicable DENTSPLY SEC Document that is a report on Form
10-K or Form 10-Q, or any amendment thereto, its conclusions about the
effectiveness of the disclosure controls and procedures as of the end of the
period covered by such report or amendment based on such evaluation. Based on
DENTSPLY's management's most recently completed evaluation of DENTSPLY's
internal control over financial reporting prior to the date hereof, (i)
DENTSPLY had no significant deficiencies or material weaknesses in the design
or operation of its internal control over financial reporting that would
reasonably be expected to adversely affect DENTSPLY's ability to record,
process, summarize and report financial information and (ii) DENTSPLY does
not have Knowledge of any fraud, whether or not material, that involves
management or other employees who have a significant role in DENTSPLY's
internal control over financial reporting.

  



  

(g) DENTSPLY and its Subsidiaries do not have any liabilities or
obligations of any nature (whether absolute or contingent, asserted or
unasserted, known or unknown, primary or secondary, direct or indirect, and
whether or not accrued or required to be reflected in DENTSPLY\'s financial
statements in accordance with GAAP), except (i) as disclosed, reflected or
reserved against in the most recent audited balance sheet included in the
DENTSPLY SEC Financial Statements or the notes thereto, (ii) for liabilities
and obligations incurred in the ordinary course of business since the date of
the most recent audited balance sheet included in the DENTSPLY SEC
Financial Statements, (iii) for liabilities and obligations arising out of or
in connection with this Agreement, the Merger or the Transactions and (iv)
for liabilities and obligations that, individually or in the aggregate, have
not had, and would not reasonably be expected to have, a DENTSPLY Material
Adverse Effect.

  



  

4.6 _Absence of Certain Changes or Events_. Since July 1, 2015 and
through the date of this Agreement, (a) DENTSPLY and its Subsidiaries have
conducted their businesses in all material respects only in the ordinary
course and in a manner consistent with past practice and (b) there has not
been any change, event, development, condition or occurrence that,
individually or in the aggregate, has had or would reasonably be expected to
have a DENTSPLY Material Adverse Effect. Since July 1, 2015 through the date
of this Agreement, neither DENTSPLY nor any of its Subsidiaries has taken any
action that would have constituted a breach of, or required Sirona's consent
pursuant to, _Sections 5.2(e)_, _(m)_ , _(n)_ , _(p)_ , _(r)_ and _(s)_  had
the covenants therein applied since July 1, 2015.

  



    

 | 39| 
---|---|--- 

 



    



  

4.7 _Information Supplied_. None of the information supplied or to
be supplied by DENTSPLY or Merger Sub for inclusion or incorporation by
reference in (i) the Form S-4 will, at the time the Form S-4 is filed with
the SEC, and at any time it is amended or supplemented or at the time it
becomes effective under the Securities Act, contain any untrue statement of a
material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein not misleading, and (ii)
the Joint Proxy Statement will, at the date it or any amendment or supplement
is mailed to holders of the shares of DENTSPLY Common Stock and at the time
of the DENTSPLY Shareholders Meeting, contain any untrue statement of a
material fact or omit to state a material fact necessary to make the
statements therein, in light of the circumstances in which they are made, not
misleading (except that no representation or warranty is made by DENTSPLY or
Merger Sub to such portions thereof that relate expressly to Sirona and
its Subsidiaries or to statements made therein based on information supplied
by or on behalf of Sirona for inclusion or incorporation by reference
therein). The Joint Proxy Statement will comply as to form in all material
respects with the requirements of the Exchange Act and other applicable Law.

  



  

4.8 _Legal Proceedings_. As of the date hereof, there are no
Proceedings pending, or to the Knowledge of DENTSPLY, threatened
against DENTSPLY or any of its Subsidiaries or any of their respective
assets, rights or properties or any of the officers or directors of DENTSPLY,
that would, in each case, individually or in the aggregate, reasonably be
expected to prevent or materially delay the consummation of the Transactions.
There are no Proceedings pending, or to the Knowledge of DENTSPLY, threatened
against DENTSPLY or any of its Subsidiaries or any of their respective
assets, rights or properties or any of the officers or directors of
DENTSPLY, except, in each case, for those that, individually or in the
aggregate, have not had, and would not reasonably be expected to have, a
DENTSPLY Material Adverse Effect. Neither DENTSPLY nor any of its Subsidiaries
nor any of their respective properties, rights or assets is or are subject to
any Order, except for those that, individually or in the aggregate, have not
had, and would not reasonably be expected to have, a DENTSPLY Material
Adverse Effect.

  



  

4.9 _Compliance with Laws_.

  



  

(a) (i) DENTSPLY and its Subsidiaries are in compliance, and for the
past five years have been in compliance, with all Laws and Orders
applicable to DENTSPLY or any of its Subsidiaries or any assets owned or used
by any of them (except for such past noncompliance as has been remedied and
imposes no continuing obligations or costs on DENTSPLY or its Subsidiaries),
and (ii) neither DENTSPLY nor any of its Subsidiaries has received any
written communication during the past five years from a Governmental Entity
that alleges that DENTSPLY or any of its Subsidiaries is not in compliance
with any such Law or Order, except in the case of clauses (i) and (ii) where
any non-compliance, individually or in the aggregate, has not had and would
not reasonably be expected to have, a DENTSPLY Material Adverse Effect.

  



  

(b) DENTSPLY and each of its Subsidiaries (i) are in compliance, and
for the past five years have been in compliance, in all material
respects with the FCPA and any other applicable Anti-corruption Laws; (ii)
during the past five years have not been investigated, to the Knowledge of
DENTSPLY, by any Governmental Entity with respect to, or been given notice by
a Governmental Entity or any other Person of, any actual or alleged violation
by DENTSPLY or any of its Subsidiaries of the FCPA or any other Anti-
corruption Laws; and (iii) during the past five years have had an operational
and effective FCPA and anti-corruption compliance program that includes, at a
minimum, policies, procedures and training intended to enhance awareness of
and compliance by DENTSPLY and its Subsidiaries with the FCPA and any other
applicable Anti-corruption Laws.

  



    

 | 40| 
---|---|--- 

 



    



  

(c) To the Knowledge of DENTSPLY, none of DENTSPLY or its
Subsidiaries has directly or indirectly through its Representatives or any
Person authorized to act on its behalf (including any distributor, agent,
sales intermediary or other third party), offered, promised, paid, authorized
or given money or anything of value to any Person for the purpose of: (i)
influencing any act or decision of any Government Official or Other Covered
Party; (ii) inducing any Government Official or Other Covered Party to do or
omit to do an act in violation of a lawful duty; (iii) securing any improper
advantage; or (iv) inducing any Government Official or Other Covered Party to
influence the act or decision of a government or government instrumentality,
in order to obtain or retain business, or direct business to, any Person or
entity, in any way.

  



  

(d) To the Knowledge of DENTSPLY, during the past five years,
DENTSPLY and its Subsidiaries have maintained complete and accurate books and
records, including records of payments to any agents, consultants,
representatives, third parties and Government Officials, in accordance with
GAAP, in all material respects. There have been no false or fictitious entries
made in the books and records of DENTSPLY or its Subsidiaries relating to any
unlawful offer, payment, promise to pay, or authorization of the payment of
any money, or unlawful offer, gift, promise to give, or authorization of the
giving of anything of value, including any bribe, kickback or other illegal
or improper payment, and DENTSPLY and its Subsidiaries have not established or
maintained a secret or unrecorded fund.

  



  

(e) To the Knowledge of DENTSPLY, during the past five years, none
of DENTSPLY or its Subsidiaries has had a customer or supplier or
other business relationship with, is a party to any Contract with, or has
engaged in any transaction with, any Person (i) that is organized or
domiciled in or that is a citizen of Cuba, Iran, North Korea, Sudan, or Syria
(including any Governmental Entity within such country) or (ii) that is the
subject of any international economic or trade sanction administered or
enforced by OFAC, the United Nations Security Council, the European Union,
Her Majesty's Treasury, the United Kingdom Export Control Organization or
other relevant sanctions authority (including but not limited to being listed
on the Specially Designated Nationals and Blocked Persons List administered
by OFAC).

  



  

4.10 _Permits_. DENTSPLY and each of its Subsidiaries have all Permits
necessary for the conduct of their business and the use of their
properties and assets, as presently conducted and used, and each of the
Permits is valid, subsisting and in full force and effect, except where the
failure to have or maintain such Permit, individually or in the aggregate, has
not had and would not reasonably be expected to have, a DENTSPLY Material
Adverse Effect. Except as would not reasonably be expected to have,
individually or in the aggregate, a DENTSPLY Material Adverse Effect, (i) the
operation of the business of DENTSPLY and its Subsidiaries as currently
conducted is not, and has not been since June 30, 2012, in violation of, nor
is DENTSPLY or its Subsidiaries in default or violation under, any Permit
(except for such past violation or default as has been remedied and imposes no
continuing obligations or costs on DENTSPLY or its Subsidiaries), and (ii) to
the Knowledge of DENTSPLY, no event has occurred which, with notice or the
lapse of time or both, would constitute a default or violation of any term,
condition or provision of any Permit. There are no actions pending or, to the
Knowledge of DENTSPLY, threatened, that seek the revocation, cancellation or
modification of any Permit, except where such revocation, cancellation or
modification, individually or in the aggregate, has not had and would not
reasonably be expected to have, a DENTSPLY Material Adverse Effect. Since
June 30, 2012, neither DENTSPLY nor its Subsidiaries have received written
notice of any charge, claim or assertion alleging any violations of or
noncompliance with any Permit, nor to the Knowledge of DENTSPLY, has any
charge, claim or assertion been threatened, except where such notice, charge,
claim or assertion, individually or in the aggregate, has not had and would
not reasonably be expected to have, a DENTSPLY Material Adverse Effect.

  



    

 | 41| 
---|---|--- 

 



    



  

4.11 _Employee Benefit Plans_.

  



  

(a) _Section 4.11(a)_ of the DENTSPLY Disclosure Schedule sets
forth a true and complete list of each "employee benefit plan" as defined in
Section 3(3) of ERISA and any other plan, policy, program, Contract, or
arrangement (whether written or oral) providing compensation or other
benefits to any current or former director, officer or employee (or to any
dependent or beneficiary thereof) of DENTSPLY or any of its Subsidiaries, in
each case that is maintained, sponsored or contributed to by DENTSPLY or any
of its U.S. ERISA Affiliates, or under which DENTSPLY or any of its
Subsidiaries has any material obligation or material liability,
whether actual or contingent, including all incentive, bonus, deferred
compensation, profit-sharing, pension, retirement, vacation, holiday, sick
pay, cafeteria, material fringe benefit, medical, disability, retention,
severance, termination, change in control, stock purchase, stock option,
stock appreciation, phantom stock, restricted stock or other equity-based
compensation plans, policies, programs, practices or arrangements, in each
case, which (x) is not sponsored and administered by a Governmental Entity and
(y) is not required by Law to be provided (each a " _DENTSPLY Benefit Plan_
"). Neither DENTSPLY, nor to the Knowledge of DENTSPLY, any other Person, has
any express or implied commitment, whether legally enforceable or not, to (i)
modify, change or terminate any DENTSPLY Benefit Plan, other than with
respect to a modification, change or termination required by ERISA, the Code
or the terms of such DENTSPLY Benefit Plan or (ii) adopt any new DENTSPLY
Benefit Plan.

  



  

(b) With respect to each DENTSPLY Benefit Plan, DENTSPLY has made
available to Sirona a current written copy thereof (if any) and, to
the extent applicable: (i) any related trust agreement; (ii) the most recent
IRS determination letter; (iii) the most recent summary plan description and
summary of material modifications, and (iv) for the most recent plan year (A)
the Form 5500 and attached schedules and (B) audited financial statements.

  



  

(c) Each DENTSPLY Benefit Plan has been administered in all material
respects in accordance with its terms and all applicable Laws,
including ERISA and the Code, and contributions required to be made under the
terms of any of the DENTSPLY Benefit Plans have been timely made or, if not
yet due, have been properly reflected on the most recent consolidated balance
sheet filed or incorporated by reference in the DENTSPLY SEC Documents.

  



    

 | 42| 
---|---|--- 

 



    



  

(d) Except as has not had or would not reasonably be expected to
have, individually or in the aggregate, a DENTSPLY Material Adverse
Effect: (i) each DENTSPLY Benefit Plan which is intended to qualify under
Section 401(a) of the Code has either received a favorable determination
letter or opinion letter from the IRS as to its qualified status, and each
trust established in connection with any DENTSPLY Benefit Plan which is
intended to be exempt from federal income taxation under Section 501(a) of the
Code is so exempt, and to DENTSPLY's Knowledge no fact or event has occurred
that could adversely affect the qualified status of any such DENTSPLY Benefit
Plan or the exempt status of any such trust, (ii) to DENTSPLY's Knowledge
there has been no prohibited transaction (within the meaning of Section 406
of ERISA or Section 4975 of the Code), other than a transaction that is exempt
under a statutory or administrative exemption, with respect to any DENTSPLY
Benefit Plan, and (iii) no Proceeding has been brought, or to the Knowledge
of DENTSPLY is threatened, against or with respect to any DENTSPLY Benefit
Plan, including any audit or inquiry by the IRS or United States Department
of Labor (other than for routine benefits claims).

  



  

(e) No DENTSPLY Benefit Plan is a Multiemployer Plan or other plan
subject to Title IV of ERISA or the minimum funding requirements of Section
302 of ERISA or Section 412 of the Code, and during the preceding six (6)
years none of DENTSPLY or any ERISA Affiliate thereof has maintained,
sponsored or contributed to or been required to contribute to a Multiemployer
Plan or other pension plan subject to Title IV of ERISA. No material
liability under Title IV of ERISA has been incurred by DENTSPLY or any ERISA
Affiliate thereof that has not been satisfied in full, and no condition
exists that presents a material risk to DENTSPLY or any ERISA
Affiliate thereof of incurring or being subject (whether primarily, jointly
or secondarily) to a material liability thereunder. None of DENTSPLY or any
of its Subsidiaries has incurred any material withdrawal liability under
Section 4201 of ERISA.

  



  

(f) No amount that could be received (whether in cash or property or
the vesting of property), as a result of the consummation of the Merger and
other Transactions, by any employee, officer or director of DENTSPLY or any of
its Subsidiaries who is a "disqualified individual" (within the meaning of
Section 280G of the Code) could be characterized as an "excess parachute
payment" (within the meaning of Section 280G(b)(1) of the Code).

  



  

(g) Except as required by Law, no DENTSPLY Benefit Plan provides
post-employment medical, disability or life insurance benefits to any
former director, employee or their respective dependents.

  



  

(h) Neither the execution of this Agreement nor the consummation of
the Merger or the other Transactions will (i) entitle any employee or
director of DENTSPLY or its Subsidiaries to a bonus, severance or change in
control payment, (ii) accelerate the time of payment or vesting or trigger
any payment or funding (through a grantor trust or otherwise) of compensation
or benefits, increase the amount payable or trigger any other material
obligation pursuant to any of the DENTSPLY Benefit Plans or (iii) result in
any breach or violation of, or default under any DENTSPLY Benefit Plan.

  



  

(i) Each DENTSPLY Benefit Plan that constitutes in any part a
nonqualified deferred compensation plan within the meaning of Section 409A of
the Code has been operated and maintained in all material respects in
operational and documentary compliance with Section 409A of the Code and all
IRS guidance promulgated thereunder, to the extent such section and such
guidance have been applicable to such DENTSPLY Benefit Plan. There is no
agreement, plan, Contract or other arrangement to which DENTSPLY or, to the
Knowledge of DENTSPLY, any of its Subsidiaries is a party or by which any of
them is otherwise bound to compensate any Person in respect of Taxes
pursuant to Section 409A or 4999 of the Code.

  



    

 | 43| 
---|---|--- 

 



    



  

(j) Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a DENTSPLY Material Adverse
Effect, with respect to each DENTSPLY Benefit Plan established or maintained
outside of the United States of America primarily for the benefit of
employees of DENTSPLY or any Subsidiary thereof residing outside the United
States of America (a " _DENTSPLY Foreign Benefit Plan_ "): (i) all employer
and employee contributions to each DENTSPLY Foreign Benefit Plan required
by law or by the terms of any DENTSPLY Foreign Benefit Plan have been made
or, if applicable, accrued, in accordance with normal accounting practices;
(ii) the fair market value of the assets of each funded DENTSPLY Foreign
Benefit Plan, the liability of each insurer for any DENTSPLY Foreign Benefit
Plan funded through insurance or the book reserve established for any DENTSPLY
Foreign Benefit Plan, together with any accrued contributions, is sufficient
to procure or provide for the accrued benefit obligations with respect to all
current and former participants in such DENTSPLY Foreign Benefit Plan
according to the actuarial assumptions and valuations most recently used to
determine employer contributions to such DENTSPLY Foreign Benefit Plan, and
neither the execution of this Agreement nor the consummation of the Merger or
other Transactions will cause such assets or insurance obligations to be less
than such benefit obligations; and (iii) to the Knowledge of DENTSPLY, each
DENTSPLY Foreign Benefit Plan required to be registered has been registered
and has been maintained in good standing with applicable regulatory
authorities.

  



  

4.12 _Employee and Labor Matters_.

  



  

(a) Neither DENTSPLY nor any of its Subsidiaries is a party to or
bound by any material collective bargaining agreement, material
agreement with any works council, or material labor contract, no labor union,
labor organization, works council, or group of employees of DENTSPLY or any
of its Subsidiaries has made a pending demand for recognition or
certification, and there are no representation or certification proceedings
or petitions seeking a representation proceeding presently pending or
threatened in writing to be brought or filed with the National Labor
Relations Board or any other labor relations tribunal or authority with
respect to any individuals employed by or otherwise performing services for
DENTSPLY or any of its Subsidiaries (the " _DENTSPLY Business Personnel_ "),
and there is no unfair labor practice complaint or grievance or other
administrative or judicial complaint, action or investigation pending or, to
the Knowledge of DENTSPLY, threatened in writing against DENTSPLY or any of
its Subsidiaries by the National Labor Relations Board or any other
Governmental Entity with respect to any present or former DENTSPLY
Business Personnel which is reasonably likely to materially interfere with
the business activities of DENTSPLY and its Subsidiaries, taken as a whole.
There is no labor strike, dispute, lockout, slowdown or stoppage pending or,
to the Knowledge of DENTSPLY, threatened against or affecting DENTSPLY or any
Subsidiary would, individually or in the aggregate, reasonably be expected to
have a DENTSPLY Material Adverse Effect.

  



  

(b) Neither DENTSPLY nor any of its Subsidiaries are required to
provide notice to any work council or similar representative body prior
to the execution of this Agreement or consummation of the Transactions,
except where failure to provide such notice would not, individually or in the
aggregate, reasonably be expected to (i) result in material liability to
DENTSPLY and its Subsidiaries, taken as a whole, or (ii) materially delay or
prevent the consummation of the Transactions.

  



    

 | 44| 
---|---|--- 

 



    



  

(c) DENTSPLY and its Subsidiaries are and for the past five years
have been in compliance with all applicable Laws respecting employment
and employment practices, including, without limitation, all Laws respecting
terms and conditions of employment, health and safety, wage payment, wages
and hours, child labor, collective bargaining, immigration and work
authorizations, employment discrimination, retaliation, civil rights,
veterans' rights, disability rights or benefits, equal opportunity, plant
closures and layoffs, affirmative action, workers' compensation, labor
relations, social welfare obligations, proper classification of employees as
exempt and non-exempt and as employees and independent contractors,
unemployment insurance and the collection and payment of withholding and/or
social security Taxes and any similar Tax, except for noncompliance as
individually or in the aggregate, has not had and would not reasonably be
expected to have, a DENTSPLY Material Adverse Effect.

  



  

(d) To the Knowledge of DENTSPLY, no DENTSPLY Business Personnel is
in any respect in violation of any term of any employment
agreement, nondisclosure agreement, common law nondisclosure obligation,
fiduciary duty, noncompetition agreement, restrictive covenant or other
obligation to DENTSPLY or any of its Subsidiaries or to a former employer of
any such employee relating (i) to the right of any such individual to be
employed by or provide services for DENTSPLY or its Subsidiaries or (ii) to
the knowledge or use of trade secrets or proprietary information, in each
case except as, individually or in the aggregate, has not had and would not
reasonably be expected to have a DENTSPLY Material Adverse Effect.

  



  

(e) DENTSPLY and its Subsidiaries are not delinquent in payments to
any current or former DENTSPLY Business Personnel for any services or
amounts required to be reimbursed or otherwise paid except as has not had and
would not reasonably be expected to have, individually or in the aggregate, a
DENTSPLY Material Adverse Effect.

  



  

4.13 _Environmental Matters_. Except as, individually or in the
aggregate, has not had and would not reasonably be expected to have, a
DENTSPLY Material Adverse Effect:

  



  

(a) DENTSPLY and each of its Subsidiaries (i) have been within the
last five (5) years, and are, in compliance with all, and are not subject to
any liability with respect to noncompliance with any, applicable Environmental
Laws, (ii) have and hold, or have applied for, all Environmental Permits
necessary for the conduct of their business and the use of their properties
and assets, as currently conducted and used, and (iii) are in compliance with
their respective Environmental Permits.

  



  

(b) There are no Environmental Claims pending, nor to the Knowledge
of DENTSPLY, threatened against DENTSPLY or any of its Subsidiaries, and none
of DENTSPLY or any of its Subsidiaries has received any notification of any
allegation of actual or potential responsibility for any Release or
threatened Release of any Hazardous Materials with respect to any location.

  



    

 | 45| 
---|---|--- 

 



    



  

(c) There have been no Releases of Hazardous Materials at any
properties that are owned, operated, leased or used by DENTSPLY or any of
its Subsidiaries, or to the Knowledge of DENTSPLY, at properties that were
formerly owned, operated, leased or used by DENTSPLY or any of its
Subsidiaries, that are reasonably likely to cause DENTSPLY or any of its
Subsidiaries to incur liability pursuant to applicable Environmental Law.

  



  

(d) None of DENTSPLY or any of its Subsidiaries (i) has entered into
or agreed to any consent decree or consent order or is otherwise subject to
any judgment, decree, or judicial or administrative Order relating to
compliance with Environmental Laws or Environmental Permits, the
investigation, sampling, monitoring, treatment, remediation, response, removal
or cleanup of Hazardous Materials, and no Proceeding is pending, or to the
Knowledge of DENTSPLY is threatened, with respect thereto, or (ii) is an
indemnitor by contract or otherwise in connection with any claim, demand,
suit or action threatened or asserted by any third-party for any liability
under any Environmental Law or otherwise relating to any Hazardous
Materials 

  



  

4.14 _Real Property_.

  



  

(a) DENTSPLY or its Subsidiaries, as the case may be, holds good,
valid, legal and marketable fee title to the DENTSPLY Owned Real
Property, free and clear of all Liens, except for Permitted Liens.

  



  

(b) DENTSPLY or its Subsidiaries, as the case may be, has a valid
and subsisting leasehold or subleasehold interest in the DENTSPLY Leased
Real Property free and clear of all Liens, except for Permitted Liens.

  



  

(c) The DENTSPLY Owned Real Property and the DENTSPLY Leased Real
Property are referred to collectively herein as the " _DENTSPLY Real
Property_." The DENTSPLY Real Property constitutes all real property necessary
for the conduct of the business of DENTSPLY and its Subsidiaries, taken as a
whole, as currently conducted. Except as has not had and would not reasonably
be expected to have, individually or in the aggregate, a DENTSPLY Material
Adverse Effect, neither DENTSPLY nor any of its Subsidiaries has received
written notice of any Proceedings in eminent domain, condemnation or other
similar Proceedings that are pending, and to DENTSPLY's Knowledge there are
no such Proceedings threatened, affecting any portion of the DENTSPLY Real
Property and neither DENTSPLY nor any of its Subsidiaries has received
written notice of the existence of any Order or of any pending Proceeding
relating to the ownership, lease, use, occupancy or operation by any Person
of the DENTSPLY Real Property. Neither DENTSPLY nor any of its Subsidiaries
has leased, subleased, licensed or otherwise granted any Person a material
right to use or occupy any of the material DENTSPLY Real Property or any
material portion thereof. Neither DENTSPLY nor any of its Subsidiaries has
granted any option or other right to any third party to purchase any of the
material DENTSPLY Real Property or any material portion thereof. Except
as has not had and would not reasonably be expected to have, individually or
in the aggregate, a DENTSPLY Material Adverse Effect, each DENTSPLY Real
Property and all buildings and improvements located on the DENTSPLY Real
Property are in a state of good operating condition, subject to reasonable
wear and tear.

  



    

 | 46| 
---|---|--- 

 



    



  

4.15 _Tax Matters_.

  



  

(a) Except as would not, individually or in the aggregate, reasonably
be expected to have a DENTSPLY Material Adverse Effect:

  



  

(i) all Tax Returns that are required to be filed by or with respect
to DENTSPLY or any of its Subsidiaries have been timely filed (taking into
account any extension of time within which to file), and all such Tax Returns
are true, complete and accurate;

  



  

(ii) DENTSPLY and its Subsidiaries have paid all Taxes due and owing
by any of them (whether or not shown on any Tax Return), have
established adequate accruals and reserves, in accordance with GAAP, on the
financial statements included in the DENTSPLY SEC Documents for all Taxes
payable by DENTSPLY and its Subsidiaries for all taxable periods and portions
thereof through the date of such financial statements and have not received
written notice of any deficiencies for any Tax of DENTSPLY or any of its
Subsidiaries from any taxing authority for which there are not adequate
reserves on the financial statements included in the DENTSPLY SEC Documents;

  



  

(iii) DENTSPLY and its Subsidiaries have withheld and paid all Taxes
required to have been withheld and paid in connection with amounts paid
or owing to any employee, independent contractor, creditor, stockholder or
other third party; such withheld amounts were either timely paid to the
appropriate taxing authority or set aside in accounts for such purpose and
were reported to the appropriate taxing authority and to each such employee,
independent contractor, creditor, stockholder or other third party, as
required under Law;

  



  

(iv) neither DENTSPLY nor any of its Subsidiaries is the subject of any
currently ongoing Tax audit or other proceeding with respect to Taxes nor has
any audit or other proceeding with respect to Taxes been proposed against any
of them in writing, and any deficiencies asserted or assessments made as a
result of any audit or other proceeding with respect to Taxes have been paid
in full, are being contested in good faith, or adequate accruals or reserves
for such deficiencies or assessments have been established;

  



  

(v) no claim has ever been made in writing by a taxing authority of a
jurisdiction where the DENTSPLY or one of its Subsidiaries has not filed Tax
Returns that DENTSPLY or such Subsidiary is or may be subject to taxation by
that jurisdiction;

  



  

(vi) neither DENTSPLY nor any of its Subsidiaries has waived any
statute of limitations with respect to Taxes or agreed to any extension of
time with respect to a Tax assessment or deficiency;

  



    

 | 47| 
---|---|--- 

 



    



  

(vii) neither DENTSPLY nor any of its Subsidiaries has constituted a
"distributing corporation" or a "controlled corporation" (within the meaning
of Section 355(a)(1)(A) of the Code) in a distribution of stock intended to
qualify for tax-free treatment under Section 355 of the Code (or any similar
provision of state, local, or non-U.S. Law) or otherwise as part of a plan (or
series of related transactions), within the meaning of Section 355(e) of the
Code, that includes the Merger, in the two years prior to the date of this
Agreement;

  



  

(viii) none of DENTSPLY or any of its Subsidiaries is a party to any
written Tax allocation, sharing, indemnity, or reimbursement agreement or
arrangement (other than an agreement with DENTSPLY or its Subsidiaries or any
customary Tax indemnification provisions in ordinary course commercial
agreements or arrangements that are not primarily related to Taxes) or has any
liability for Taxes of any Person (other than DENTSPLY or any of its
Subsidiaries) under U.S. Treasury Regulation Section 1.1502-6 (or any similar
provision of state, local, or non-U.S. Law) or as transferee or successor;

  



  

(ix) there are no Liens for Taxes upon any property or assets of
DENTSPLY or any of its Subsidiaries, except for Taxes not yet due and
payable;

  



  

(x) neither DENTSPLY nor any of its Subsidiaries has entered into any
"listed transaction" within the meaning of U.S. Treasury Regulation Section
1.6011-4(b)(2) (or any similar provision of state, local or non-U.S. Law);

  



  

(xi) DENTSPLY has made available to Sirona or its legal or accounting
representative copies of all U.S. federal and state income Tax Returns for
DENTSPLY and each of its Subsidiaries filed for all periods including and
after the period ended December 31, 2011;

  



  

(xii) DENTSPLY is not a United States real property holding
corporation within the meaning of Section 897(c)(2) of the Code;

  



  

(xiii) neither DENTSPLY nor any of its Subsidiaries (i) has filed any
extension of time within which to file any Tax Returns that have not
been filed, except in the ordinary course of business, (ii) has entered into
any agreement or other arrangement waiving or extending the statute of
limitations or the period of assessment or collection of any Taxes, (iii) has
granted any power of attorney that is in force with respect to any matters
relating to any Taxes, (iv) has applied for a ruling from a taxing authority
relating to any Taxes that has not been granted or has proposed to enter into
an agreement with a taxing authority that is pending, (v) has, since December
31, 2011, been issued any private letter rulings, technical advice memoranda
or similar agreement or rulings by any taxing authority, or (vi) will be
required to include any item of income or gain in, or be required to exclude
any item of deduction of loss from, any period ending after the Closing Date
as a result of any (A) "closing agreement" as described in Section 7121 of
the Code (or any similar provision of state, local or non-U.S. Tax Law), (B)
installment sale or open transaction made on or prior to the Closing Date,
(C) election under section 108(i) of the Code or (D) prepaid amount
received prior to the Closing Date; and

  



    

 | 48| 
---|---|--- 

 



    



  

(xiv) neither DENTSPLY nor any of its Subsidiaries has agreed to,
requested, or is required to include any adjustment under Section 481 of
the Code (or any corresponding provision of applicable state, local or
non-U.S. Tax Law) by reason of a change in accounting method or otherwise.

  



  

(b) Neither DENTSPLY nor any of its Subsidiaries has knowledge of any
facts, agreements, plans or other circumstances or has taken or agreed to
take any action that would reasonably be expected to prevent or impede the
Merger from qualifying as a "reorganization" within the meaning of Section
368(a) of the Code.

  



  

(c) It is agreed and understood that no representation or warranty is
made by DENTSPLY in respect of Tax matters in any Section of this Agreement
other than _Section 4.5_, _Section 4.6_ , _Section 4.7_ , _Section 4.11_ and
this _Section 4.15_.

  



  

4.16 _Material Contracts_.

  



  

(a) All Contracts required to be filed as exhibits to the DENTSPLY
SEC Documents have been so filed in a timely manner. _Section 4.16(a)_ of
the DENTSPLY Disclosure Schedule sets forth a true and complete list, as of
the date hereof, of each of the following Contracts to which DENTSPLY or any
of its Subsidiaries is a party or by which DENTSPLY or any of its Subsidiaries
or any of their assets or businesses are bound (and any amendments,
supplements and modifications thereto):

  



  

(i) any Contract that is a "material contract" (as such term is
defined in Item 601(b)(10) of Regulation S-K of the Exchange Act);

  



  

(ii) any Contract that materially limits the ability of DENTSPLY or
any of its affiliates (including, following the consummation of
the Transactions, the Surviving Corporation and its affiliates) to compete or
provide services in any line of business or with any Person or in any
geographic area or market segment or to engage in any type of business
(including any license, collaboration, agency or distribution agreements);

  



  

(iii) any Contract required to be disclosed pursuant to Item 404 of
Regulation S-K of the Exchange Act;

  



  

(iv) any Contract or series of related Contracts relating to
indebtedness for borrowed money (A) in excess of $10 million or (B)
that becomes due and payable as a result of the Transactions;

  



    

 | 49| 
---|---|--- 

 



    



  

(v) any license, sublicense, option, development or collaboration
agreement or other Contract relating to DENTSPLY Material
Intellectual Property reasonably expected to result in payments in excess of
$10 million in any twelve (12) month period after the Closing Date (excluding
license agreements for "shrink-wrap," "click-wrap" or other commercially
available off-the-shelf software that is not the subject of a negotiated
agreement, and excluding agreements the primary purpose of which is to
purchase tangible goods or procure services unrelated to Intellectual
Property and in the ordinary course of business);

  



  

(vi) any Contract reasonably expected to result in payments in excess
of $10 million in any twelve (12) month period after the Closing Date that
provides for any material "most favored nation" provision or equivalent
preferential pricing terms or similar obligations to which DENTSPLY or any of
its Subsidiaries is subject;

  



  

(vii) any distribution Contract with any of DENTSPLY's top three
distributors (measured by dollar volume of spending by the distributor during
the twelve (12) months ended June 30, 2015);

  



  

(viii) any purchase, sale or supply contract that contains volume
requirements or commitments, exclusive or preferred purchasing
arrangements or promotional requirements reasonably expected to result in
payments in excess of $10 million in any twelve (12) month period after the
Closing Date;

  



  

(ix) any lease, sublease, occupancy agreement or other Contract with
respect to the DENTSPLY Leased Real Property reasonably expected to result in
payments in excess of $10 million in any twelve (12) month period after the
Closing Date;

  



  

(x) any agreement that grants any right of first refusal or right of
first offer or similar right or that limits or purports to limit the ability
of DENTSPLY or any of its Subsidiaries to own, operate, sell, transfer, pledge
or otherwise dispose of any material amount of assets or businesses (in any
case in excess of $10 million);

  



  

(xi) any acquisition or divestiture agreement (A) entered into since
June 30, 2012 with a purchase price in excess of $20 million or (B) that
contains "earn-out" provisions or other contingent payment obligations that
could reasonably be expected to exceed $10 million (including indemnification
obligations) that have not been satisfied in full;

  



  

(xii) any agreement that by its terms limits the payment of dividends
or other distributions by DENTSPLY or any of its Subsidiaries;

  



  

(xiii) any Contract for any joint venture, partnership or similar
arrangement, or any Contract involving a sharing of revenues, profits,
losses, costs, or liabilities by DENTSPLY or any of its Subsidiaries with any
other Person involving a potential combined commitment or payment by DENTSPLY
and any of its Subsidiaries in excess of $10 million annually;

  



    

 | 50| 
---|---|--- 

 



    



  

(xiv) any "single source" supply contract pursuant to which goods or
materials that are material to DENTSPLY or any of its Subsidiaries are
supplied to DENTSPLY or such Subsidiary from an exclusive source reasonably
expected to result in payments in excess of $10 million in any twelve (12)
month period after the Closing Date;

  



  

(xv) any Contract with a Governmental Entity reasonably expected to
result in payments in excess of $10 million in any twelve (12) month period
after the Closing Date; or

  



  

(xvi) any other agreement which would prohibit or delay beyond the
Outside Date the consummation of Merger or any other Transaction
contemplated by this Agreement.

  



  

(b) DENTSPLY has heretofore made available to Sirona true, correct
and complete copies of the Contracts set forth in _Section 4.16(a)_.

  



  

(c) Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a DENTSPLY Material Adverse
Effect, (i) all Contracts set forth or required to be set forth in _Section
4.16(a)_ of the DENTSPLY Disclosure Schedule or filed or required to be filed
as exhibits to the DENTSPLY SEC Documents (the " _DENTSPLY Material Contracts_
") are valid, binding and in full force and effect and are enforceable by
DENTSPLY or its applicable Subsidiary in accordance with their terms, except
as limited by Laws affecting the enforcement of creditors' rights generally,
by general equitable principles or by the discretion of any Governmental
Entity before which any Proceeding seeking enforcement may be brought, (ii)
DENTSPLY, or its applicable Subsidiary, has performed all obligations
required to be performed by it under the DENTSPLY Material Contracts, and it
is not (with or without notice or lapse of time, or both) in breach or default
thereunder and, to the Knowledge of DENTSPLY, no other party to any DENTSPLY
Material Contract is (with or without notice or lapse of time, or both) in
breach or default thereunder, (iii) since January 1, 2015, neither DENTSPLY
nor any of its Subsidiaries has received written notice of any actual,
alleged, possible or potential violation of, or failure to comply with, any
term or requirement of any DENTSPLY Material Contract, and (iv) neither
DENTSPLY nor any of its Subsidiaries has received any written notice of the
intention of any party to cancel, terminate, materially change the scope of
rights under or fail to renew any DENTSPLY Material Contract.

  



  

4.17 _Intellectual Property_.

  



  

(a) With respect to all (i) issued patents and pending patent
applications, (ii) trademark and service mark registrations and
applications, (iii) copyright registrations and applications, and (iv)
internet domain name registrations, in each case that are owned by
DENTSPLY or any of its Subsidiaries (collectively, the " _DENTSPLY Registered
Intellectual Property_ "), except as has not had and would not reasonably be
expected to have, individually or in the aggregate, a DENTSPLY Material
Adverse Effect, (A) either DENTSPLY or one of its Subsidiaries is the sole
owner and possesses all right, title and interest in and to the item, free
and clear of all Liens (other than Permitted Liens), and (B) no Proceeding is
pending or, to Knowledge of DENTSPLY, threatened, that challenges the
legality, validity, enforceability, registration, use or ownership of the item
(except for office actions by the applicable Governmental Entities in the
normal course of prosecution efforts in connection with applications for the
registration or issuance of Intellectual Property). Each item of material
DENTSPLY Registered Intellectual Property that is registered, filed, issued,
or applied for has been duly registered in, filed in or issued by the official
governmental registers and/or issuers (or officially recognized registers or
issuers) for such Intellectual Property and each such registration, filing,
issuance and/or application, to the Knowledge of DENTSPLY, (x) has not been
abandoned or cancelled, (y) has been maintained effective by all
requisite filings, renewals and payments, and (z) remains in full force and
effect.

  



    

 | 51| 
---|---|--- 

 



    



  

(b) Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a DENTSPLY Material Adverse
Effect, each of DENTSPLY and its Subsidiaries owns and possesses all right,
title and interest in and to (or has the right pursuant to a valid and
enforceable license or otherwise possesses legally enforceable rights to use)
all Intellectual Property that is necessary for or used or held for use in
the conduct of the business of DENTSPLY and its Subsidiaries in substantially
the same manner as presently conducted and currently proposed to be
conducted. Neither the execution and delivery of this Agreement by DENTSPLY,
nor the performance of this Agreement by DENTSPLY, will result in the loss,
forfeiture, termination, or impairment of, or give rise to a right of any
Person to limit, terminate, or consent to the continued use of, any rights of
DENTSPLY or any of its Subsidiaries in any Intellectual Property except as
has not had and would not reasonably be expected to have, individually or in
the aggregate, a DENTSPLY Material Adverse Effect.

  



  

(c) Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a DENTSPLY Material Adverse
Effect, to the Knowledge of DENTSPLY, neither DENTSPLY nor any of its
Subsidiaries nor the conduct of their businesses is infringing,
misappropriating, diluting, or otherwise violating the Intellectual Property
rights of any Person. Neither DENTSPLY nor any of its Subsidiaries
has received any written charge, complaint, claim, demand, or notice since
June 30, 2012 (or earlier, if presently not resolved) alleging any such
infringement, misappropriation, dilution, or violation (including any claim
that DENTSPLY or any of its Subsidiaries must license or refrain from using
any Intellectual Property rights of any Person) which alleged infringement,
misappropriation, dilution, or violation, if true, would reasonably be
expected to have, individually or in the aggregate, a DENTSPLY Material
Adverse Effect. To the Knowledge of DENTSPLY, no Person is infringing,
misappropriating, diluting or otherwise violating any Intellectual Property
owned by DENTSPLY or any of its Subsidiaries except as has not had and would
not reasonably be expected to have, individually or in the aggregate, a
DENTSPLY Material Adverse Effect. Neither DENTSPLY nor any of its Subsidiaries
has made or asserted any charge, complaint, claim, demand or notice since
June 30, 2012 (or earlier, if presently not resolved) alleging any
such infringement, misappropriation, dilution, or violation which alleged
infringement, misappropriation, dilution, or violation, if true, would
reasonably be expected to have, individually or in the aggregate, a DENTSPLY
Material Adverse Effect.

  



    

 | 52| 
---|---|--- 

 



    



  

(d) DENTSPLY and its Subsidiaries have taken commercially reasonable
steps to maintain, police and protect the Intellectual Property that
is material to their business (" _DENTSPLY Material Intellectual Property_
"). Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a DENTSPLY Material Adverse Effect, all
DENTSPLY Material Intellectual Property that derives independent economic
value, actual or potential, from not being generally known to the public or to
other persons who can obtain economic value from its disclosure or use has
been maintained in confidence in accordance with protection procedures that
are in accordance with procedures customarily used in the industry to protect
rights of like importance and, to the Knowledge of DENTSPLY, adequate for
protection. To the Knowledge of DENTSPLY, there has been no unauthorized
disclosure of any DENTSPLY Material Intellectual Property. Except as has not
had and would not reasonably be expected to have, individually or in the
aggregate, a DENTSPLY Material Adverse Effect, to the Knowledge of DENTSPLY,
all former and current officers, directors, employees, personnel,
consultants, advisors, agents, and independent contractors of DENTSPLY and its
Subsidiaries, and each of their predecessors, who have contributed to or
participated in the conception and development of Intellectual Property for
such entities have entered into valid and binding proprietary rights
agreements with DENTSPLY or one of its Subsidiaries or predecessors, vesting
ownership of such Intellectual Property in DENTSPLY or one of its
Subsidiaries. No such Person has asserted, and to the Knowledge of DENTSPLY,
no such Person has, any right, title, interest or other claim in, or the right
to receive any royalties or other consideration with respect to, any DENTSPLY
Material Intellectual Property.

  



  

(e) Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a DENTSPLY Material Adverse
Effect, the IT Assets of DENTSPLY and its Subsidiaries operate in all
material respects in accordance with their documentation and
functional specifications and as required by DENTSPLY and its Subsidiaries to
operate the business of DENTSPLY and its Subsidiaries as presently conducted
and have not, since June 30, 2012, materially malfunctioned or failed.
DENTSPLY and its Subsidiaries have implemented commercially reasonable
measures to protect the confidentiality and security of such IT Assets and
information stored or contained therein against any unauthorized use, access,
interruption or corruption. DENTSPLY and its Subsidiaries have implemented
commercially reasonable data backup, data storage, system redundancy and
disaster avoidance procedures with respect to their IT Assets.

  



  

(f) To the Knowledge of DENTSPLY, no software included in the
DENTSPLY Material Intellectual Property, which is distributed to any
third party by or on behalf of DENTSPLY or its Subsidiaries (other than
software identified as belonging to a third party and subject to a third
party paid or public license), or for which DENTSPLY or its Subsidiaries may
have plans to distribute to any third party, incorporates or is comprised of
or distributed with any publicly available software, or is otherwise subject
to the provisions of any "open source" or third party license agreement that
(i) requires the distribution of source code in connection with the
distribution of such software in object code form; (ii) materially limits
DENTSPLY's or any of its Subsidiaries' freedom to seek full compensation in
connection with marketing, licensing, and distributing such applications; or
(iii) allows a customer or requires that a customer have the right to
decompile, disassemble or otherwise reverse engineer the software by
its terms and not by operation of law.

  



    

 | 53| 
---|---|--- 

 



    



  

4.18 _Healthcare Compliance Matters_.

  



  

(a) (i) DENTSPLY and each of its Subsidiaries are in compliance and
since June 30, 2012 have been in compliance with all Health Care
Laws applicable to DENTSPLY or any of its Subsidiaries or any assets owned or
used by any of them (except for such past noncompliance as has been remedied
and imposes no continuing obligations or costs on DENTSPLY or its
Subsidiaries), and (ii) neither DENTSPLY nor any of its Subsidiaries has
received any written communication since June 30, 2012 from a Governmental
Entity that remains uncured or unresolved and that alleges that DENTSPLY or
any of its Subsidiaries is not in compliance with any Health Care Law, except
in the case of clauses (i) and (ii) where any non-compliance, individually or
in the aggregate, has not had and would not reasonably be expected to have, a
DENTSPLY Material Adverse Effect. Neither DENTSPLY nor, to the Knowledge of
DENTSPLY, any of its Subsidiaries is a party to or has any ongoing reporting
obligations pursuant to or under any corporate integrity agreements, deferred
prosecution agreements, monitoring agreements, consent decrees, settlement
orders, plans of correction or similar agreements with or imposed by any
Governmental Entity. Additionally, none of DENTSPLY, its Subsidiaries or any
of its respective employees, officers or directors has been excluded,
suspended or debarred from participation in any U.S. state or federal health
care program or, to the Knowledge of DENTSPLY, has been convicted of any
crime or is subject to a governmental inquiry, investigation, Proceeding, or
other similar action, or has engaged in any conduct, that could reasonably be
expected to result in debarment, suspension, or exclusion.

  



  

(b) DENTSPLY and each of its Subsidiaries have, maintain and are
operating in material compliance with all FDA Permits, and all such FDA
Permits are valid, subsisting, and in full force and effect, except where the
failure to have, maintain or operate in material compliance with the FDA
Permits has not had, and would not reasonably be expected to have,
individually or in the aggregate, a DENTSPLY Material Adverse Effect.
DENTSPLY and each of its Subsidiaries have fulfilled and performed all of
their material obligations with respect to the FDA Permits, and no event has
occurred which allows, or with notice or lapse of time or both, would allow
revocation or termination thereof or results in any other material impairment
of the rights of the holder of any FDA Permit, except where the failure to so
fulfill or perform, or the occurrence of such event, would not result in a
DENTSPLY Material Adverse Effect. DENTSPLY and each of its Subsidiaries have
operated and currently are in compliance in all material respects with
applicable Laws administered or enforced by the FDA and comparable
Governmental Entities, except where the failure to so comply would not result
in a DENTSPLY Material Adverse Effect. DENTSPLY and each of its Subsidiaries
have not received, since June 30, 2012, written notice of any pending or
threatened Proceeding (other than FDA audits) from the FDA, any Governmental
Entity, any qui-tam relator or applicable foreign Governmental Entity
alleging that any operation or activity of DENTSPLY or any of its Subsidiaries
is in material violation of any applicable Health Care Law which violation
would reasonably be expected to have a material and adverse impact on DENTSPLY
and its Subsidiaries, taken as a whole.

  



    

 | 54| 
---|---|--- 

 



    



  

(c) Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a DENTSPLY Material Adverse
Effect, all applications, notifications, submissions, information, claims,
reports and statistics, and other data and conclusions derived therefrom,
utilized as the basis for or submitted in connection with any and all requests
for a FDA Permit from the FDA or other Governmental Entity relating to
DENTSPLY and each of its Subsidiaries, their business and products, when
submitted to the FDA or other Governmental Entity were true, complete and
correct as of the date of submission and any necessary or required updates,
changes, corrections or modification to such applications, submissions,
information and data have been submitted to the FDA or other
Governmental Entity.

  



  

(d) Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a DENTSPLY Material Adverse
Effect, since June 30, 2012, DENTSPLY and each of its Subsidiaries have not
had any product or manufacturing site (whether owned by DENTSPLY or its
Subsidiary(s), or a contract manufacturer for their products) subject to a
Governmental Entity (including FDA) shutdown or import or export prohibition,
nor received any FDA Form 483 or other Governmental Entity notice of
inspectional observations, "warning letters," "untitled letters" or requests
or requirements to make changes to the products, or similar correspondence or
notice from the FDA or other Governmental Entity alleging or asserting
noncompliance with any applicable Law, Permit or such requests or
requirements of a Governmental Entity.

  



  

(e) Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a DENTSPLY Material Adverse
Effect, (i) since June 30, 2012, there have been no (A) Safety Notices with
respect to the products of DENTSPLY and its Subsidiaries or (B) to the
Knowledge of DENTSPLY, complaints with respect to such products that are
currently unresolved and (ii) to the Knowledge of DENTSPLY, there are no
facts that would be reasonably likely to result in (A) a Safety Notice with
respect to such products, (B) a change in labeling of any such products, or
(C) a termination or suspension of marketing or testing of any such products.

  



  

(f) Except as has not had and would not reasonably be expected to
have, individually or in the aggregate, a DENTSPLY Material Adverse
Effect, (i) the clinical, pre-clinical and other studies and tests conducted
by or on behalf of or sponsored by DENTSPLY or its Subsidiaries or in which
DENTSPLY or its Subsidiaries, or any of their products or product candidates
have participated were, and if still pending are, being conducted in
accordance with standard medical and scientific research procedures and all
applicable Laws, including, but not limited to, the Federal Food, Drug and
Cosmetic Act and its applicable implementing regulations at 21 C.F.R. Parts
50, 54, 56, 58 and 812 and (ii) no investigational device exemption filed by
or on behalf of DENTSPLY or its Subsidiaries with the FDA has been terminated
or suspended by the FDA, and neither the FDA nor any applicable foreign
Governmental Entity has commenced, or, to the Knowledge of DENTSPLY,
threatened to commence, any action to place a clinical hold order on, or
otherwise terminate, delay or suspend, any proposed or ongoing clinical
investigation conducted or proposed to be conducted by or on behalf of
DENTSPLY and its Subsidiaries.

  



    

 | 55| 
---|---|--- 

 



    



  

(g) Neither DENTSPLY nor any of its Subsidiaries is the subject of
any pending or, to the Knowledge of DENTSPLY, threatened investigation
in respect of DENTSPLY, its Subsidiaries or their products, by the FDA
pursuant to its "Fraud, Untrue Statements of Material Facts, Bribery, and
Illegal Gratuities" Final Policy set forth in 56 Fed. Reg. 46191 (September
10, 1991) and any amendments thereto. Since June 30, 2012, neither DENTSPLY
nor, to the Knowledge of DENTSPLY, any of their officers, employees or agents
(within the meaning of the applicable Law) has been convicted of any crime or
engaged in any conduct that could result in a material debarment or exclusion
under (i) 21 U.S.C. Section 335a or (ii) any similar Law. As of the date
hereof, no Proceedings that would reasonably be expected to result in such a
debarment or exclusion are pending or, to the Knowledge of DENTSPLY,
threatened against DENTSPLY, its Subsidiaries, or any of their officers,
employees or agents.

  



  

4.19 _Broker 's Fees_. Except for the financial advisors' fees set
forth in _Section 4.19_ of the DENTSPLY Disclosure Schedule, neither
DENTSPLY nor any of its Subsidiaries nor any of their respective officers or
directors on behalf of DENTSPLY or such Subsidiaries has employed any
financial advisor, broker or finder or incurred any liability for any
financial advisory, broker's fees, commissions or finder's fees in connection
with any of the Transactions.

  



  

4.20 _Opinion of Financial Advisor_. Moelis and Company LLC, DENTSPLY's
financial advisor, has delivered to the DENTSPLY Board its opinion in writing
or orally, in which case, such opinion will be subsequently confirmed in
writing, to the effect that, as of the date thereof and based upon and
subject to the factors and assumptions set forth therein, the Exchange Ratio
is fair from a financial point of view to DENTSPLY.

  



  

4.21 _Ownership of Sirona Common Stock_. Neither DENTSPLY nor any of
its affiliates or associates is, nor at any time during the last three (3)
years has DENTSPLY or any of its affiliates or associates been, an "interested
stockholder" of Sirona as defined in Section 203 of the DGCL. DENTSPLY and
its Subsidiaries, affiliates and associates do not beneficially own any shares
of Sirona Common Stock or other securities of Sirona or any options, warrants
or other rights to acquire Sirona Common Stock or other securities of, or any
other economic interest (through derivative securities or otherwise) in,
Sirona.

  



  

4.22 _Insurance_. All insurance policies (including policies
providing casualty, liability and workers compensation coverage, but excluding
any DENTSPLY Benefit Plan) to which DENTSPLY or any of its Subsidiaries is
currently a party are in full force and effect, and, to the Knowledge of
DENTSPLY, have been issued by licensed insurers, all premiums with respect
thereto covering all periods up to and including the Closing Date have been
paid, and no notice of cancellation or termination has been received with
respect to any such policies, except for such cancellations or terminations
which would have not had and would not reasonably be expected to have,
individually or in the aggregate, a DENTSPLY Material Adverse Effect. Except
as has not had and would not reasonably be expected to have, individually or
in the aggregate, a DENTSPLY Material Adverse Effect, each of DENTSPLY and its
Subsidiaries is, and since December 31, 2013 has been, insured with respect
to its assets and properties and the conduct of its business in such amounts
and against such risks as are in its reasonable judgment sufficient for
compliance with Law and as are adequate to protect its assets and properties
and the conduct of its business.

  



    

 | 56| 
---|---|--- 

 



    



  

4.23 _Merger Sub_. Since its date of incorporation, Merger Sub has
not carried on any business or conducted any operations other than
the execution of this Agreement, the performance of its obligations hereunder
and matters ancillary thereto. The authorized capital stock of Merger Sub
consists of one thousand (1,000) shares of common stock, par value $0.01 per
share, all of which have been validly issued, are fully paid and
nonassessable and are owned directly or indirectly by DENTSPLY free and clear
of any Liens.

  



  

4.24 _No Other Representations or Warranties_. Except for the
representations and warranties expressly contained in this _Article
4_, neither DENTSPLY nor any of its affiliates nor any Person acting on any
of their behalf makes any other express or any implied representations or
warranties with respect to (a) DENTSPLY or any of its Subsidiaries, any of
their businesses, operations, assets, liabilities, condition (financial or
otherwise) or prospects or any other matter relating to DENTSPLY or any of its
Subsidiaries or (b) the accuracy or completeness of any documentation,
forecasts or other information provided by DENTSPLY, any affiliate of
DENTSPLY or any Person acting on any of their behalf to Sirona, any affiliate
of Sirona or any Person acting on any of their behalf.

  



  

ARTICLE 5 
 Covenants

  



  

5.1 _Conduct of Business by Sirona Pending the Effective Time_.
Sirona agrees that, between the date of this Agreement and the
Effective Time, except as set forth in _Section 5.1_ of the Sirona
Disclosure Schedule or as otherwise expressly contemplated by any other
provision of this Agreement, unless DENTSPLY shall otherwise consent in
writing (such consent not to be unreasonably withheld, conditioned or
delayed), Sirona will, and will cause each of its Subsidiaries to, (i) conduct
its operations only in the ordinary course of business consistent with past
practice, (ii) use its commercially reasonable efforts to keep available the
services of the current officers, employees and consultants of Sirona and each
of its Subsidiaries and to preserve the goodwill and current relationships of
Sirona and each of its Subsidiaries with customers, suppliers and other
Persons with which Sirona or any of its Subsidiaries has business relations,
and (iii) use its commercially reasonable efforts to preserve intact its
business organization and comply with all applicable Law. Without limiting
the foregoing, and as an extension thereof, except as set forth in _Section
5.1_ of the Sirona Disclosure Schedule or as otherwise expressly contemplated
by any other provision of this Agreement, Sirona shall not, and shall not
permit any of its Subsidiaries to, between the date of this Agreement and the
Effective Time, directly or indirectly, take any of the following actions
without the prior written consent of DENTSPLY (such consent not to be
unreasonably withheld, conditioned or delayed):

  



  

(a) amend or otherwise change its certificate of incorporation or
bylaws or equivalent organizational documents;

  



  

(b) issue, sell, pledge, dispose of, grant, transfer or encumber, or
authorize the issuance, sale, pledge, disposition, grant, transfer,
or encumbrance of, any shares of capital stock of, or other Equity Interests
in, Sirona or any of its Subsidiaries of any class, or securities convertible
into, or exchangeable or exercisable for, any shares of such capital stock or
other Equity Interests, or any options, warrants or other rights of any kind
to acquire any shares of such capital stock or other Equity Interests or
such convertible or exchangeable securities, or any other ownership interest
(including any such interest represented by Contract right), or any "phantom"
stock, "phantom" stock rights, stock appreciation rights or stock based
performance rights, of Sirona or any of its Subsidiaries, other than (i) the
issuance of Sirona Common Stock upon the exercise of Sirona Stock
Options, Sirona RSUs or Sirona Performance Units outstanding as of the date
hereof in accordance with their terms or (ii) the issuance of any Sirona
Stock Options, Sirona RSUs or Sirona Performance Units pursuant to the terms
of any employment agreement outstanding as of the date hereof in accordance
with its terms;

  



    

 | 57| 
---|---|--- 

 



    



  

(c) sell, pledge, dispose of, transfer, lease, license, guarantee or
encumber any property or assets of Sirona or any of its Subsidiaries with
value in excess of $10 million, except pursuant to existing Contracts or the
sale or purchase of goods in the ordinary course of business consistent with
past practice;

  



  

(d) (i) sell, assign, pledge, grant or acquire, agree to grant to or
acquire from any Person, or otherwise encumber, transfer, license, abandon,
place in the public domain, permit to lapse, disclose or agree to disclose or
otherwise dispose of any material Sirona Registered Intellectual Property or
any Sirona Material Intellectual Property, except pursuant to the terms of
existing Contracts or the licensing of any such Intellectual Property in the
ordinary course of business consistent with past practice or (ii)
compromise, settle or agree to settle, or consent to judgment in, any one or
more actions or institute any action concerning any Sirona
Material Intellectual Property except in the ordinary course of business
consistent with past practice;

  



  

(e) declare, set aside, make or pay any dividend or other
distribution (whether payable in cash, shares, property or a combination
thereof) with respect to any of its capital stock or other Equity Interests
(other than dividends paid by a wholly-owned Subsidiary of Sirona to Sirona
or another wholly-owned Subsidiary of Sirona) or enter into any agreement with
respect to the voting or registration of its capital stock or other Equity
Interests;

  



  

(f) reclassify, combine, split, subdivide or amend the terms of, or
redeem, purchase or otherwise acquire, directly or indirectly, any of its
capital stock or other Equity Interests;

  



  

(g) merge or consolidate Sirona or any of its Subsidiaries with any
Person or adopt a plan of complete or partial liquidation or
resolutions providing for a complete or partial liquidation, dissolution,
restructuring, recapitalization or other reorganization of Sirona or any of
its Subsidiaries, other than internal reorganizations in the ordinary course
of business that would not have a material and adverse impact on Sirona and
its Subsidiaries or the Transaction;

  



  

(h) acquire (including by merger, consolidation, or acquisition of
shares or assets) any interest in any Person or any assets thereof in
each case with value in excess of $10 million, other than in the ordinary
course of business consistent with past practice or pursuant to the Contracts
set forth on _Section 5.1(h)_ of the Sirona Disclosure Schedule;

  



    

 | 58| 
---|---|--- 

 



    



  

(i) repurchase, repay, refinance or incur any indebtedness for
borrowed money, except as required by the terms of any such indebtedness as of
the date hereof, or issue any debt securities or assume, guarantee or
endorse, or otherwise as an accommodation become responsible for (whether
directly, contingently or otherwise), the obligations of any Person (other
than a wholly-owned Subsidiary of Sirona) for borrowed money, except for
borrowings under Sirona's existing credit facilities or issuances of
commercial paper for working capital and general corporate purposes in the
ordinary course of business consistent with past practice;

  



  

(j) make any loans, advances or capital contributions to, or
investments in, any other Person (other than any wholly-owned Subsidiary
of Sirona) in excess of $10 million in the aggregate;

  



  

(k) terminate, cancel, renew, or request or agree to any material
change in or waiver under any Sirona Material Contract, or enter into or
amend any Contract that, if existing on the date hereof, would be a Sirona
Material Contract, in each case other than in the ordinary course of business
consistent with past practice;

  



  

(l) make or authorize any capital expenditure in excess of Sirona's
capital expenditure budget as disclosed to DENTSPLY prior to the date hereof,
other than capital expenditures that are not, in the aggregate, in excess of
$10 million;

  



  

(m) except in the ordinary course of business consistent with past
practice or to the extent required by (i) applicable Law, (ii) the
existing terms of any Sirona Benefit Plan disclosed in _Section 3.11(a)_ of
the Sirona Disclosure Schedule or (iii) contractual commitments or corporate
policies with respect to severance or termination pay in existence on the date
of this Agreement disclosed in _Section 3.11(a)_ of the Sirona Disclosure
Schedule: (A) increase the compensation or benefits payable or to
become payable to directors, officers or employees of Sirona or its
Subsidiaries; (B) grant any rights to severance or termination pay or bonus
payments to, or enter into any employment or severance agreement with, any
director, officer or employee of Sirona or its Subsidiaries, or establish,
adopt, enter into or amend any collective bargaining agreement or other
Contract with any labor union or labor organization, Sirona Benefit Plan or
similar plan, agreement, trust, fund, policy or arrangement for the
benefit of any director, officer or employee of Sirona or its Subsidiaries,
except to the extent required by the terms of a collective bargaining
agreement in existence on the date of this Agreement or in the ordinary course
of business consistent with past practice; (C) take any action to amend or
waive any performance or vesting criteria or accelerate vesting,
exercisability or funding under any Sirona Benefit Plan; or (D) terminate the
employment of any officer of Sirona other than for cause;

  



  

(n) forgive any loans to directors, officers or employees of Sirona
or its Subsidiaries;

  



  

(o) waive, release, pay, discharge or satisfy any claims,
liabilities or obligations (absolute, accrued, contingent or otherwise) with
value in excess of $10 million, except in the ordinary course of business
consistent with past practice and in accordance with their terms;

  



  

(p) make any change in accounting policies, practices, principles,
methods or procedures, other than as required by GAAP or by a
Governmental Entity;

  



    

 | 59| 
---|---|--- 

 



    



  

(q) waive, release, assign, settle or compromise any claims or
rights with value in excess of $10 million held by Sirona or any of its
Subsidiaries;

  



  

(r) compromise, settle or agree to settle any Proceeding or
investigation (including any Proceeding or investigation relating to this
Agreement or the Transactions) other than compromises, settlements or
agreements in the ordinary course of business consistent with past practice
that involve only the payment of monetary damages not in excess of $10 million
individually or $50 million in the aggregate, in any case without the
imposition of equitable relief on, or the admission of wrongdoing by, Sirona
or any of its Subsidiaries;

  



  

(s) except as required by applicable Law, make, change or revoke any
material Tax election, change any Tax accounting period for purposes of a
material Tax or material method of Tax accounting, file any material amended
Tax Return, settle or compromise any audit or proceeding relating to a
material amount of Taxes, agree to an extension or waiver of the statute of
limitations with respect to a material amount of Taxes, enter into any
"closing agreement" within the meaning of Section 7121 of the Code (or
any similar provision of state, local, or non-U.S. Law) with respect to any
material Tax, surrender any right to claim a material Tax refund, or
undertake any transaction with any non-U.S. Subsidiary of Sirona that would
reasonably be expected to have any significant U.S. federal income tax
consequences to Sirona or its Subsidiaries (clause (p), clause (t) and this
clause (s) being the sole provisions of this _Section 5.1_ governing Tax
matters);

  



  

(t) take any action that would, or fail to take any action, the
failure of which would, reasonably be expected to prevent the Merger
from qualifying as a reorganization within the meaning of Section 368(a) of
the Code;

  



  

(u) write up, write down or write off the book value of any assets,
in the aggregate, in excess of $10 million, except for depreciation
and amortization in accordance with GAAP consistently applied;

  



  

(v) convene any annual or special meeting (or any adjournment
thereof) of the shareholders of Sirona, other than the Sirona Shareholders
Meeting and the 2016 annual meeting of shareholders (only if such 2016 annual
meeting is not otherwise combined with the Sirona Shareholders Meeting);

  



  

(w) fail to use reasonable efforts to maintain existing material
insurance policies or comparable replacement policies to the extent
available for a reasonable cost; or

  



  

(x) authorize or enter into any Contract to do any of the foregoing
or otherwise make any commitment to do any of the foregoing.

  



    

 | 60| 
---|---|--- 

 



    



  

5.2 _Conduct of Business by DENTSPLY Pending the Effective Time_.
DENTSPLY agrees that, between the date of this Agreement and the
Effective Time, except as set forth in _Section 5.2_ of the DENTSPLY
Disclosure Schedule or as otherwise expressly contemplated by any other
provision of this Agreement, unless Sirona shall otherwise consent in writing
(such consent not to be unreasonably withheld, conditioned or delayed),
DENTSPLY will, and will cause each of its Subsidiaries to, (i) conduct its
operations only in the ordinary course of business consistent with past
practice, (ii) use its commercially reasonable efforts to keep available the
services of the current officers, employees and consultants of DENTSPLY and
each of its Subsidiaries and to preserve the goodwill and current
relationships of DENTSPLY and each of its Subsidiaries with customers,
suppliers and other Persons with which DENTSPLY or any of its Subsidiaries
has business relations, (iii) use its commercially reasonable efforts to
preserve intact its business organization and comply with all applicable
Laws. Without limiting the foregoing, and as an extension thereof, except as
set forth in _Section 5.2_ of the DENTSPLY Disclosure Schedule or as
otherwise expressly contemplated by any other provision of this Agreement,
DENTSPLY shall not, and shall not permit any of its Subsidiaries to, between
the date of this Agreement and the Effective Time, directly or indirectly,
take any of the following actions without the prior written consent of Sirona
(such consent not to be unreasonably withheld, conditioned or delayed):

  



  

(a) amend or otherwise change its certificate of incorporation or
bylaws or equivalent organizational documents;

  



  

(b) issue, sell, pledge, dispose of, grant, transfer or encumber, or
authorize the issuance, sale, pledge, disposition, grant, transfer,
or encumbrance of, any shares of capital stock of, or other Equity Interests
in, DENTSPLY or any of its Subsidiaries of any class, or securities
convertible into, or exchangeable or exercisable for, any shares of such
capital stock or other Equity Interests, or any options, warrants or other
rights of any kind to acquire any shares of such capital stock or other Equity
Interests or such convertible or exchangeable securities, or any other
ownership interest (including any such interest represented by Contract
right), or any "phantom" stock, "phantom" stock rights, stock appreciation
rights or stock based performance rights, of DENTSPLY or any of its
Subsidiaries, other than (i) the issuance of DENTSPLY Common Stock upon the
exercise of DENTSPLY Stock Options or DENTSPLY RSUs outstanding as of the
date hereof in accordance with their terms, (ii) the issuance of any DENTSPLY
Stock Options or DENTSPLY RSUs pursuant to the terms of any employment
agreement outstanding as of the date hereof in accordance with its terms or
(iii) in connection with the assumption and conversion of Sirona Stock Options
and Sirona RSUs in accordance with the terms of this Agreement;

  



  

(c) sell, pledge, dispose of, transfer, lease, license, guarantee or
encumber any property or assets of DENTSPLY or any of its Subsidiaries with
value in excess of $10 million, except pursuant to existing Contracts or the
sale or purchase of goods in the ordinary course of business consistent with
past practice;

  



  

(d) (i) sell, assign, pledge, grant or acquire, agree to grant to or
acquire from any Person, or otherwise encumber, transfer, license, abandon,
place in the public domain, permit to lapse, disclose or agree to disclose or
otherwise dispose of any material DENTSPLY Registered Intellectual Property
or any DENTSPLY Material Intellectual Property, except pursuant to the terms
of existing Contracts or the licensing of any such Intellectual Property in
the ordinary course of business consistent with past practice or (ii)
compromise, settle or agree to settle, or consent to judgment in, any one or
more actions or institute any action concerning any DENTSPLY
Material Intellectual Property except in the ordinary course of business
consistent with past practice;

  



    

 | 61| 
---|---|--- 

 



    



  

(e) declare, set aside, make or pay any dividend or other
distribution (whether payable in cash, shares, property or a combination
thereof) with respect to any of its capital stock or other Equity Interests
(other than (i) quarterly cash dividends in an amount not to exceed $0.0725
per share declared and paid by DENTSPLY in the ordinary course of business
consistent with current practice and (ii) dividends paid by a wholly-owned
Subsidiary of DENTSPLY to DENTSPLY or another wholly-owned Subsidiary of
DENTSPLY) or enter into any agreement with respect to the voting or
registration of its capital stock or other Equity Interests;

  



  

(f) reclassify, combine, split, subdivide or amend the terms of, or
redeem, purchase or otherwise acquire, directly or indirectly, any of its
capital stock or other Equity Interests;

  



  

(g) merge or consolidate DENTSPLY or any of its Subsidiaries with
any Person or adopt a plan of complete or partial liquidation or
resolutions providing for a complete or partial liquidation, dissolution,
restructuring, recapitalization or other reorganization of DENTSPLY or any of
its Subsidiaries, other than internal reorganizations in the ordinary course
of business that would not have a material and adverse impact on DENTSPLY and
its Subsidiaries or the Transaction;

  



  

(h) acquire (including by merger, consolidation, or acquisition of
stock or assets) any interest in any Person or any assets thereof in
each case with value in excess of $10 million, other than in the ordinary
course of business consistent with past practice or pursuant to the Contracts
set forth on _Section 5.2(h)_ of the DENTSPLY Disclosure Schedule;

  



  

(i) repurchase, repay, refinance or incur any indebtedness for
borrowed money, except as required by the terms of any indebtedness as of the
date hereof, or issue any debt securities or assume, guarantee or endorse, or
otherwise as an accommodation become responsible for (whether directly,
contingently or otherwise), the obligations of any Person (other than a
wholly-owned Subsidiary of DENTSPLY) for borrowed money, except for
borrowings under DENTSPLY's existing credit facilities or issuances of
commercial paper for working capital and general corporate purposes in the
ordinary course of business consistent with past practice;

  



  

(j) make any loans, advances or capital contributions to, or
investments in, any other Person (other than any wholly-owned Subsidiary
of DENTSPLY) in excess of $10 million in the aggregate;

  



  

(k) terminate, cancel, renew, or request or agree to any material
change in or waiver under any DENTSPLY Material Contract, or enter into or
amend any Contract that, if existing on the date hereof, would be a DENTSPLY
Material Contract, in each case other than in the ordinary course of business
consistent with past practice;

  



    

 | 62| 
---|---|--- 

 



    



  

(l) make or authorize any capital expenditure in excess of
DENTSPLY's capital expenditure budget as disclosed to Sirona prior to
the date hereof, other than capital expenditures that are not, in the
aggregate, in excess of $10 million;

  



  

(m) except in the ordinary course of business consistent with past
practice or to the extent required by (i) applicable Law, (ii) the
existing terms of any DENTSPLY Benefit Plan disclosed in _Section 4.11(a)_ of
the DENTSPLY Disclosure Schedule or (iii) contractual commitments or
corporate policies with respect to severance or termination pay in existence
on the date of this Agreement disclosed in _Section 4.11(a)_ of the DENTSPLY
Disclosure Schedule: (A) increase the compensation or benefits payable or to
become payable to directors, officers or employees of DENTSPLY or its
Subsidiaries; (B) grant any rights to severance or termination pay or bonus
payments to, or enter into any employment or severance agreement with, any
director, officer or employee of DENTSPLY or its Subsidiaries, or establish,
adopt, enter into or amend any collective bargaining agreement or other
Contract with any labor union or labor organization, DENTSPLY Benefit Plan or
similar plan, agreement, trust, fund, policy or arrangement for the
benefit of any director, officer or employee of DENTSPLY or its Subsidiaries,
except to the extent required by the terms of a collective bargaining
agreement in existence on the date of this Agreement or in the ordinary course
of business consistent with practice; (C) take any action to amend or waive
any performance or vesting criteria or accelerate vesting, exercisability or
funding under any DENTSPLY Benefit Plan; or (D) terminate the employment of
any officer of DENTSPLY other than for cause;

  



  

(n) forgive any loans to directors, officers or employees of
DENTSPLY or its Subsidiaries;

  



  

(o) waive, release, pay, discharge or satisfy any claims,
liabilities or obligations (absolute, accrued, contingent or otherwise) with
value in excess of $10 million, except in the ordinary course of business
consistent with past practice and in accordance with their terms;

  



  

(p) make any change in accounting policies, practices, principles,
methods or procedures, other than as required by GAAP or by a
Governmental Entity;

  



  

(q) waive, release, assign, settle or compromise any claims or
rights with value in excess of $10 million held by DENTSPLY or any of its
Subsidiaries;

  



  

(r) compromise, settle or agree to settle any Proceeding or
investigation (including any Proceeding or investigation relating to this
Agreement or the Transactions) other than compromises, settlements or
agreements in the ordinary course of business consistent with past practice
that involve only the payment of monetary damages not in excess of $10 million
individually or $50 million in the aggregate, in any case without the
imposition of equitable relief on, or the admission of wrongdoing by, DENTSPLY
or any of its Subsidiaries;

  



    

 | 63| 
---|---|--- 

 



    



  

(s) except as required by applicable Law, make, change or revoke any
material Tax election, change any Tax accounting period for purposes of a
material Tax or material method of Tax accounting, file any material amended
Tax Return, settle or compromise any audit or proceeding relating to a
material amount of Taxes, agree to an extension or waiver of the statute of
limitations with respect to a material amount of Taxes, enter into any
"closing agreement" within the meaning of Section 7121 of the Code (or
any similar provision of state, local, or non-U.S. Law) with respect to any
material Tax, or surrender any right to claim a material Tax refund, or
undertake any transaction with any non-U.S. Subsidiary of DENTSPLY that would
reasonably be expected to have any significant U.S. federal income tax
consequences to DENTSPLY or its Subsidiaries (clause (p), clause (t) and this
clause (s) being the sole provisions of this _Section 5.2_ governing Tax
matters);

  



  

(t) take any action that would, or fail to take any action, the
failure of which would, reasonably be expected to prevent the Merger
from qualifying as a reorganization within the meaning of Section 368(a) of
the Code;

  



  

(u) write up, write down or write off the book value of any assets,
in the aggregate, in excess of $10 million, except for depreciation
and amortization in accordance with GAAP consistently applied;

  



  

(v) convene any annual or special meeting (or any adjournment
thereof) of the shareholders of DENTSPLY, other than the DENTSPLY
Shareholders Meeting and the 2016 annual meeting of shareholders (only if
such 2016 annual meeting is not otherwise combined with the
DENTSPLY Shareholders Meeting);

  



  

(w) fail to use reasonable efforts to maintain existing material
insurance policies or comparable replacement policies to the extent
available for a reasonable cost; or

  



  

(x) authorize or enter into any Contract to do any of the foregoing
or otherwise make any commitment to do any of the foregoing.

  



    

 | 64| 
---|---|--- 

 



    



  

5.3 _Preparation of the Form S-4 and the Joint Proxy Statement;
Shareholders Meetings_.

  



  

(a) As promptly as practicable after the execution of this
Agreement, (i) DENTSPLY and Sirona shall jointly prepare and cause to be
filed with the SEC, the Joint Proxy Statement to be sent to the shareholders
of DENTSPLY and the shareholders of Sirona, as applicable, relating to the
DENTSPLY Shareholders Meeting and the Sirona Shareholders Meeting and (ii)
DENTSPLY and Sirona shall prepare and DENTSPLY shall file with the SEC the
Form S-4, in which the Joint Proxy Statement will be included as a
prospectus, in connection with the registration under the Securities Act of
the shares of DENTSPLY Common Stock to be issued in the Merger. Each of
DENTSPLY and Sirona shall use its reasonable best efforts to have the Form S-4
declared effective as promptly as practicable after such filing (including by
responding to comments of the SEC) and, prior to the effective date of the
Form S-4, each of DENTSPLY and Sirona shall take all action reasonably
required (other than qualifying to do business in any jurisdiction in which it
is not now so qualified or filing a general consent to service of process in
any such jurisdiction) to be taken under any applicable securities Laws in
connection with the issuance of Sirona Common Stock. Each of DENTSPLY and
Sirona shall furnish all information as may be reasonably requested by the
other party in connection with any such action and the preparation, filing and
distribution of the Form S-4 and the Joint Proxy Statement. As promptly as
practicable after the Form S-4 shall have become effective, each of
DENTSPLY and Sirona shall use its reasonable best efforts to cause the Joint
Proxy Statement to be mailed to its respective shareholders. No filing of, or
amendment or supplement to, the Form S-4 will be made by DENTSPLY, and no
filing of, or amendment or supplement to, the Joint Proxy Statement will be
made by DENTSPLY or Sirona, in each case without providing the other party
with a reasonable opportunity to review and comment thereon. If at any time
prior to the Effective Time any information relating to DENTSPLY or
Sirona, or any of their respective affiliates, directors or officers, should
be discovered by DENTSPLY or Sirona which should be set forth in an amendment
or supplement to either the Form S-4 or the Joint Proxy Statement, so that
either such document would not include any misstatement of a material fact or
omit to state any material fact necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading, the
party that discovers such information shall promptly notify the other party
and an appropriate amendment or supplement describing such information shall
be promptly filed with the SEC and, to the extent required by Law,
disseminated to the shareholders of DENTSPLY and the shareholders of Sirona.
Each party shall notify the other party promptly of the time when the Form
S-4 has become effective, and of the issuance of any stop order or suspension
of the qualification of the shares of DENTSPLY Common Stock issuable in
connection with the Merger for offering or sale in any jurisdiction. In
addition, each party agrees to provide the other party and their respective
counsel with copies of any written comments, and shall inform the other party
of any oral comments, that such party or its counsel may receive from time to
time from the SEC or its staff with respect to the Form S-4 or the Joint
Proxy Statement promptly after receipt of such comments, and any written or
oral responses thereto. Each party and their respective counsel shall be
given a reasonable opportunity to review any such written responses and each
party shall give due consideration to the additions, deletions or changes
suggested thereto by the other party and their respective counsel.

  



  

(b) _Sirona Shareholders Meeting_.

  



  

(i) Sirona shall, promptly following the date on which the Form S-4
has been filed with the SEC and the parties otherwise mutually determine to
be appropriate, establish a record date for, and, as soon as practicable
following the effectiveness of the Form S-4, duly call and give notice of and
convene and hold a meeting of its shareholders (the " _Sirona Shareholders
Meeting_ ") for the purpose of seeking the Sirona Shareholder Approval;
_provided_ , _however_ , that Sirona may postpone or adjourn the Sirona
Shareholders Meeting (A) with the prior written consent of DENTSPLY; (B) if a
quorum has not been established; (C) to allow reasonable additional time for
the filing and mailing of any supplemental or amended disclosure which the
Sirona Board has determined in good faith after consultation with outside
counsel is necessary under applicable Law and for such supplemental or amended
disclosure to be disseminated and reviewed by Sirona's shareholders prior to
the Sirona Shareholders Meeting; (D) to allow reasonable additional time to
solicit additional proxies, if and to the extent the requisite Sirona
Shareholder Approval would not otherwise be obtained; or (E) if required by
Law; _provided_ , _however_ , that in the case of clauses (B), (C), (D) and
(E), the Sirona Shareholders Meeting shall not be postponed or adjourned for
more than ten (10) Business Days in the aggregate from the originally
scheduled date of the Sirona Shareholders Meeting without the prior written
consent of DENTSPLY. Sirona shall, upon the reasonable request of DENTSPLY,
advise DENTSPLY at least on a daily basis on each of the last seven (7)
Business Days prior to the date of the Sirona Shareholders Meeting as to the
aggregate tally of proxies received by Sirona with respect to the
Sirona Shareholder Approval.

  



    

 | 65| 
---|---|--- 

 



    



  

(ii) Sirona shall, through the Sirona Board, make the Sirona
Recommendation and include such Sirona Recommendation in the Joint Proxy
Statement (subject to _Section 5.4_ ) and use its reasonable best efforts to
(A) solicit from its shareholders proxies in favor of the adoption of this
Agreement and the Transactions, including the Merger and (B) take all other
action necessary or advisable to secure the Sirona Shareholder Approval.
Except as expressly permitted in _Section 5.4(b)_ and _Section 5.4(d)_
, neither the Sirona Board nor any committee thereof shall (x) withhold,
withdraw, modify or qualify, or propose publicly to withhold, withdraw,
modify or qualify, in a manner adverse to DENTSPLY, the approval,
determination of advisability, or recommendation by the Sirona Board of, this
Agreement, the Merger and the other Transactions, (y) make, or permit any
director or executive officer to make, any public statement in connection
with the Sirona Shareholders Meeting by or on behalf of the Sirona Board
or such committee that would reasonably be expected to have the same effect
or (z) approve, determine to be advisable, or recommend, or propose publicly
to approve, determine to be advisable, or recommend, any Competing Proposal
(the actions specified in the foregoing clauses (x), (y) and (z) being
referred to as a " _Sirona Adverse Recommendation Change_ ").

  



  

(iii) Notwithstanding any Sirona Adverse Recommendation Change,
unless this Agreement is terminated in accordance with its terms, the
obligations of the parties hereunder shall continue in full force and effect.
Without limiting the generality of the foregoing, unless this Agreement is
terminated in accordance with its terms, this Agreement and the Merger shall
be submitted to the shareholders of Sirona for approval at the Sirona
Shareholders Meeting whether or not (x) the Sirona Board shall have effected a
Sirona Adverse Recommendation Change or (y) any Competing Proposal shall have
been publicly proposed or announced or otherwise submitted to Sirona or any
of its Representatives.

  



    

 | 66| 
---|---|--- 

 



    



  

(c) _DENTSPLY Shareholders Meeting_.

  



  

(i) DENTSPLY shall, as soon as practicable following the date on
which the Form S-4 has been filed with the SEC and the parties otherwise
mutually determine to be appropriate, establish a record date for, and, as
soon as practicable following the effectiveness of the Form S-4, duly call
and give notice of and convene and hold a meeting of its shareholders (the "
_DENTSPLY Shareholders Meeting_ ") for the purpose of seeking the DENTSPLY
Shareholder Approval; _provided_ , _however_ , that DENTSPLY may postpone or
adjourn the DENTSPLY Shareholders Meeting (A) with the prior written consent
of Sirona; (B) if a quorum has not been established; (C) to allow reasonable
additional time for the filing and mailing of any supplemental or amended
disclosure which the DENTSPLY Board has determined in good faith after
consultation with outside counsel is necessary under applicable Law and for
such supplemental or amended disclosure to be disseminated and reviewed by
DENTSPLY's shareholders prior to the DENTSPLY Shareholders Meeting; (D) to
allow reasonable additional time to solicit additional proxies, if and to the
extent the requisite DENTSPLY Shareholder Approval would not otherwise be
obtained; or (E) if required by Law; _provided_ , _however_ , that in the case
of clauses (B), (C), (D) and (E), the DENTSPLY Shareholders Meeting shall not
be postponed or adjourned for more than ten (10) Business Days in the
aggregate from the originally scheduled date of the DENTSPLY Shareholders
Meeting without the prior written consent of Sirona. DENTSPLY shall, upon the
reasonable request of Sirona, advise Sirona at least on a daily basis on each
of the last seven (7) Business Days prior to the date of the DENTSPLY
Shareholders Meeting as to the aggregate tally of proxies received by
DENTSPLY with respect to the DENTSPLY Shareholder Approval.

  



  

(ii) DENTSPLY shall, through the DENTSPLY Board, make the DENTSPLY
Recommendation and include such DENTSPLY Recommendation in the Joint
Proxy Statement (subject to _Section 5.4_ ) and use its reasonable best
efforts to (A) solicit from its shareholders proxies in favor of the approval
of the DENTSPLY Share Issuance and the Amended and Restated Charter and (B)
take all other action necessary or advisable to secure the DENTSPLY
Shareholder Approval. Except as expressly permitted in _Section 5.4(b)_ and
_Section 5.4(d)_ , neither the DENTSPLY Board nor any committee thereof shall
(x) withhold, withdraw, modify or qualify, or propose publicly to withhold,
withdraw, modify or qualify, in a manner adverse to Sirona, the approval,
determination of advisability, or recommendation by the DENTSPLY Board of,
the DENTSPLY Share Issuance and the Amended and Restated DENTSPLY Charter, (y)
make, or permit any director or executive officer to make, any public
statement in connection with the DENTSPLY Shareholders Meeting by or on
behalf of the DENTSPLY Board or such committee that would reasonably be
expected to have the same effect or (z) approve, determine to be advisable,
or recommend, or propose publicly to approve, determine to be advisable, or
recommend, any Competing Proposal (the actions specified in the foregoing
clauses (x), (y) and (z) being referred to as a " _DENTSPLY
Adverse Recommendation Change_ ").

  



  

(iii) Notwithstanding any DENTSPLY Adverse Recommendation Change,
unless this Agreement is terminated in accordance with its terms, the
obligations of the parties hereunder shall continue in full force and effect.
Without limiting the generality of the foregoing, unless this Agreement is
terminated in accordance with its terms, the DENTSPLY Share Issuance and the
Amended and Restated DENTSPLY Charter shall be submitted to the shareholders
of DENTSPLY for approval at the DENTSPLY Shareholders Meeting whether or not
(x) the DENTSPLY Board shall have effected a DENTSPLY Adverse Recommendation
Change or (y) any Competing Proposal shall have been publicly proposed
or announced or otherwise submitted to DENTSPLY or any of its
Representatives.

  



    

 | 67| 
---|---|--- 

 



    



  

(d) Sirona and DENTSPLY will use their respective reasonable best
efforts to hold the Sirona Shareholders Meeting and the DENTSPLY
Shareholders Meeting on the same date.

  



  

5.4 _No Solicitation of Transactions_.

  



  

(a) Each of Sirona and DENTSPLY shall immediately cease, and shall
cause its respective Subsidiaries and Representatives to immediately cease,
any discussions or negotiations with any Person that may be ongoing with
respect to a Competing Proposal, or any proposal that could reasonably be
expected to lead to a Competing Proposal, and shall request to have returned
promptly to Sirona or DENTSPLY, as applicable, any confidential information
that has been provided in any such discussions or negotiations. From the date
hereof until the earlier of the Effective Time or the date of termination of
this Agreement in accordance with _Article 7_, each of Sirona and DENTSPLY
shall not, and shall cause its respective Subsidiaries and Representatives not
to, directly or indirectly, (i) solicit, initiate or knowingly encourage or
induce (including by way of furnishing information which has not been
previously publicly disseminated), or take any other action designed to
facilitate, any inquiries or the making of any proposal which constitutes, or
could reasonably be expected to lead to, any Competing Proposal, or (ii)
engage in any discussions or negotiations regarding any Competing Proposal;
_provided_ , _however_ , that (x) such party may ascertain facts from the
Person making an unsolicited Competing Proposal for the sole purpose of the
Sirona Board or the DENTSPLY Board, as applicable, informing itself about the
terms of such Competing Proposal and the Person that made it and (y) if, prior
to obtaining the Sirona Shareholder Approval (in the case of Sirona) or the
DENTSPLY Shareholder Approval (in the case of DENTSPLY) and following the
receipt of a bona fide written Competing Proposal made after the date hereof
that the Sirona Board or DENTSPLY Board, as applicable, determines in good
faith (after receiving advice of its financial advisor and of its outside
legal counsel) is or could reasonably be expected to lead to a Superior
Proposal and that was not, directly or indirectly, solicited, initiated or
knowingly encouraged in violation of this _Section 5.4_ , the Sirona Board or
the DENTSPLY Board, as applicable, determines in good faith, after
consultation with outside legal counsel, that a failure to take action with
respect to such Competing Proposal, as applicable, would be inconsistent with
its fiduciary duties to Sirona's shareholders or DENTSPLY's shareholders, as
applicable, under applicable Law, Sirona or DENTSPLY may, in response to such
Competing Proposal, as applicable, and subject to compliance with _Section
5.4(c)_, (A) furnish information with respect to Sirona or DENTSPLY, as
applicable, to the Person making such Competing Proposal pursuant to an
Acceptable Confidentiality Agreement, and (B) engage in discussions
or negotiations with such Person regarding such Competing Proposal. Except as
expressly permitted by this _Section _ _5.4_ , each of DENTSPLY and Sirona
shall not, and shall cause their respective Subsidiaries and Representatives
not to, from and after the date of this Agreement until the earlier of the
Effective Time or the date, if any, on which this Agreement is terminated
pursuant to _Article_ _7_ , directly or indirectly (1) approve, endorse,
recommend or enter into, or publicly propose to approve, endorse, recommend
or enter into, any letter of intent, memorandum of understanding, agreement
in principle, acquisition agreement, merger agreement or similar definitive
agreement (other than an Acceptable Confidentiality Agreement) with respect
to any Competing Proposal; (2) take any action to make the provisions of any
takeover statute inapplicable to any transactions contemplated by a Competing
Proposal; or (3) terminate, amend, release, modify or knowingly fail to
enforce any provision of, or grant any permission, waiver or request under,
any standstill, confidentiality or similar agreement entered into by the
applicable party in respect of or in contemplation of a Competing Proposal
(other than to the extent the DENTSPLY Board or the Sirona Board, as
applicable, determines in good faith after consultation with its outside legal
counsel, that failure to take any of such actions under clause (3) would be
inconsistent with its fiduciary duties under applicable Law), or (4)
propose to do any of the foregoing. For the avoidance of doubt, nothing in
this _Section_ _5.4(a)_ shall relieve any party from its obligations under
_Section 5.6_.

  



    

 | 68| 
---|---|--- 

 



    



  

(b) Notwithstanding any other provision of this Agreement, including
_Section 5.3_ but subject to compliance with this _Section 5.4_, prior to
receipt of the Sirona Shareholder Approval, the Sirona Board may, or, prior to
receipt of the DENTSPLY Shareholder Approval, the DENTSPLY Board may, in
response to any bona fide written Competing Proposal that was not, directly or
indirectly, solicited, initiated or knowingly encouraged in violation of this
_Section 5.4_ , effect a Sirona Adverse Recommendation Change or a
DENTSPLY Adverse Recommendation Change, as applicable, if and only if (i) the
Sirona Board or the DENTSPLY Board, as applicable, concludes in good faith,
after consultation with Sirona's or DENTSPLY's outside financial advisors and
outside legal counsel, that such Competing Proposal constitutes a Superior
Proposal and (ii) the DENTSPLY Board or the Sirona Board, as applicable,
provides the other party five (5) Business Days prior written notice of its
intention to take such action (a " _Competing Proposal Notice_ "), which
notice shall include the information with respect to such Competing Proposal
that is specified in _Section 5.4(c)_, as well as a copy of such Competing
Proposal (it being agreed that neither the delivery of such notice by a party
nor any public announcement thereof that such party determines it is required
to make under applicable Law shall constitute a Sirona Adverse
Recommendation Change or a DENTSPLY Adverse Recommendation Change, as
applicable, unless and until such party shall have failed at or prior to the
end of the period referred to in clause (iii) below (and, upon the occurrence
of such failure, such notice and such public announcement shall constitute a
Sirona Adverse Recommendation Change or a DENTSPLY Adverse Recommendation
Change, as applicable) to publicly announce that it (A) is recommending the
Transactions and (B) has determined that such other Competing
Proposal (taking into account (x) any modifications or adjustments made to
the Transactions agreed to by the other party in writing and (y) any
modifications or adjustments made to such other Competing Proposal) is not a
Superior Proposal and has publicly rejected such Competing Proposal); (iii)
during the five (5) Business Days following such written notice (the "
_Negotiation Period_ "), if requested by the other party, the Board of
Directors effecting the recommendation change and its Representatives have
negotiated in good faith with the other party regarding any revisions to the
terms of the Transactions proposed by the other party in response to such
Competing Proposal; and (iv) at the end of the five (5) Business Day period
described in the foregoing clause (iii), the Sirona Board or DENTSPLY Board,
as applicable, concludes in good faith, after consultation with Sirona's or
DENTSPLY's outside legal counsel and financial advisors (and taking into
account any adjustment or modification of the terms of this Agreement to
which the other party has agreed in writing to make to the terms of the
Transactions), that the Competing Proposal continues to be a Superior
Proposal and, after consultation with Sirona's or DENTSPLY's outside legal
counsel, that the failure to make a Sirona Adverse Recommendation Change or
DENTSPLY Adverse Recommendation Change, as applicable, would be inconsistent
with the exercise by the Sirona Board or DENTSPLY Board of its fiduciary
duties to the shareholders of Sirona or shareholders of DENTSPLY under
applicable Law. Any material amendment or modification to any Competing
Proposal shall require a new Competing Proposal Notice and the Negotiation
Period shall be extended by an additional three (3) Business Days from the
date of receipt of such new Competing Proposal Notice.

  



    

 | 69| 
---|---|--- 

 



    



  

(c) In addition to the obligations of DENTSPLY and Sirona set forth
in _Section 5.4(a)_ and _Section 5.4(b)_, DENTSPLY or Sirona shall
promptly, and in any event no later than 24 hours, after it receives (i) any
Competing Proposal or indication by any Person that is considering making a
Competing Proposal, (ii) any request for non-public information relating to
DENTSPLY or Sirona or their respective Subsidiaries other than requests for
information in the ordinary course of business consistent with past practice
and unrelated to a Competing Proposal or (iii) any inquiry or request for
discussions or negotiations regarding any Competing Proposal, notify the
other party orally and in writing of any of the foregoing occurrences, the
identity of the person making such request, inquiry or Competing Proposal and
a copy of such request, inquiry or Competing Proposal (or where no such copy
is available, a reasonably detailed description of such request, inquiry or
Competing Proposal), including any modifications thereto. Each party shall
keep the other party reasonably informed (orally and in writing) on a current
basis (and in any event at the other party's request and otherwise no later
than 24 hours after the occurrence of any material changes,
developments, discussions or negotiations) of the status of any request,
inquiry or Competing Proposal (including the terms and conditions thereof and
of any modification thereto), and any material developments, discussions and
negotiations, including furnishing copies of any written inquiries, material
correspondence and draft documentation, and written summaries of any material
oral inquiries or discussions. Without limiting the foregoing, each party
shall promptly (and in any event within 24 hours) notify the other party
orally and in writing if it determines to begin providing information or to
engage in discussions or negotiations concerning a Competing
Proposal pursuant to _Section 5.4_. Each of DENTSPLY and Sirona agrees that,
subject to applicable restrictions under applicable Law, it shall, prior to
or concurrent with the time it is provided to any third parties, provide to
the other party any non-public information concerning DENTSPLY or Sirona and
their respective Subsidiaries that DENTSPLY or Sirona provided to any third
party in connection with any Competing Proposal which was not previously
provided to the other party.

  



  

(d) Notwithstanding anything in this _Section 5.4_ to the contrary,
at any time prior to obtaining the DENTSPLY Shareholder Approval or the
Sirona Shareholder Approval, the DENTSPLY Board or the Sirona Board may make
a DENTSPLY Adverse Recommendation Change or a Sirona Adverse Recommendation
Change, as applicable, if (i) such board determines that an Intervening Event
has occurred and is continuing and (ii) such board determines in good faith
(after consultation with outside counsel) that the failure to make a DENTSPLY
Adverse Recommendation Change or a Sirona Adverse Recommendation Change, as
applicable, in response to such Intervening Event would be inconsistent with
its fiduciary duties to the applicable party's shareholders under applicable
Law; _provided_ that (x) the DENTSPLY Board or the Sirona Board has given the
other party at least five (5) Business Days prior written notice of
its intention to take such action and specifying in reasonable detail the
circumstances related to such determination and (y) prior to effecting a
DENTSPLY Adverse Recommendation Change or a Sirona Adverse Recommendation
Change, the applicable party has negotiated, and has caused its
Representatives to negotiate, in good faith with the other party during such
notice period to the extent such other party wishes to negotiate, to enable
such party to revise the terms of this Agreement, such that the failure to
make a DENTSPLY Adverse Recommendation Change or a Sirona Adverse
Recommendation Change, as applicable, would not be inconsistent with its
fiduciary duties to shareholders under applicable Law.

  



    

 | 70| 
---|---|--- 

 



    



  

(e) Nothing contained in this Agreement shall prohibit the DENTSPLY
Board or the Sirona Board from (i) taking and disclosing to
their shareholders, as applicable, a position contemplated by Rule 14e-2(a)
promulgated under the Exchange Act or making a statement contemplated by Item
1012(a) of Regulation M-A or Rule 14d-9 promulgated under the Exchange Act,
(ii) making any disclosure to their shareholders, as applicable, if the
Sirona Board or DENTSPLY Board determines in good faith, after consultation
with its outside counsel, that the failure to make such disclosure would be
inconsistent with its duties to shareholders under, or would violate,
applicable Law; or (iii) making accurate disclosure to their shareholders, as
applicable, of factual information regarding the business, financial
condition or results of operations of DENTSPLY or Sirona or the fact that a
Competing Proposal has been made, the identity of the party making such
proposal or the material terms of such proposal (and such disclosure
shall not be deemed to be a DENTSPLY Adverse Recommendation Change or a
Sirona Adverse Recommendation Change, as applicable), so long as (A) any such
disclosure includes the DENTSPLY Recommendation or the Sirona Recommendation,
as applicable, without any modification or qualification thereof and
continues the prior recommendation of the DENTSPLY Board or Sirona Board, as
the case may be, and (B) does not contain either an express DENTSPLY Adverse
Recommendation Change (without giving effect to clause (y) of the definition
thereof) or an express Sirona Adverse Recommendation Change (without giving
effect to clause (y) of the definition thereof), as applicable, or any other
statements by or on behalf of the Board of Directors of such party which would
reasonably be expected to have the same effect as a DENTSPLY Adverse
Recommendation Change or a Sirona Adverse Recommendation Change, as
applicable.

  



  

(f) Any failure of DENTSPLY's or Sirona's respective Subsidiaries or
its and their respective Representatives to fully comply with this _Section
5.4_ (as if such Subsidiaries or Representatives were directly subject to this
_Section 5.4_ ) shall be deemed a breach of this _Section 5.4_ by DENTSPLY or
Sirona, as applicable.

  



  

(g) For purposes of this Agreement:

  



  

(i) " _Competing Proposal_ " shall mean, other than the
Transactions, any proposal or offer from a third party relating to (A) a
merger, reorganization, sale of assets, share exchange, consolidation,
business combination, recapitalization, dissolution, liquidation, joint
venture or similar transaction involving DENTSPLY or Sirona, or any of their
respective Subsidiaries; (B) the acquisition (whether by merger,
consolidation, equity investment, joint venture or otherwise) by any Person of
twenty percent (20%) or more of the consolidated assets of DENTSPLY or
Sirona, and their respective Subsidiaries, as determined on a book-value or
fair-market-value basis; (C) the purchase or acquisition, in any manner,
directly or indirectly, by any Person of twenty percent (20%) or more of the
issued and outstanding shares of the DENTSPLY Common Stock or the Sirona
Common Stock or any other Equity Interests in DENTSPLY or Sirona, (D) any
purchase, acquisition, tender offer or exchange offer that, if consummated,
would result in any Person beneficially owning twenty percent (20%) or more
of the shares of DENTSPLY Common Stock or Sirona Common Stock or any other
Equity Interests of DENTSPLY, Sirona or any of their respective Subsidiaries
or (E) any combination of the foregoing.

  



    

 | 71| 
---|---|--- 

 



    



  

(ii) " _Intervening Event_ " means any material event, development or
change in circumstances that first occurs, arises or becomes known
to DENTSPLY or Sirona or its respective board after the date of this
Agreement, to the extent that such event, development or change in
circumstances was not reasonably foreseeable as of the date of this Agreement
(or if known or reasonably foreseeable, the probability of magnitude of
consequences of which were not known or reasonably foreseeable) provided,
however, that in no event shall the following events, developments or changes
in circumstances constitute an Intervening Event: (1) the receipt, existence
or terms of a Competing Proposal or any matter relating thereto or
consequence thereof; (2) any change in the price, or change in
trading volume, of DENTSPLY Common Stock or Sirona Common Stock ( _provided_
, _however_ , that the exception to this clause (2) shall not apply to the
underlying causes giving rise to or contributing to such change or prevent any
of such underlying causes from being taken into account in determining
whether an Intervening Event has occurred) (3) meeting or exceeding
internal or analysts' expectations, projections or results of operations (
_provided_ , _however_ , that the exception to this clause (3) shall not
apply to the underlying causes giving rise to or contributing to such
circumstances or prevent any of such underlying causes from being taken into
account in determining whether an Intervening Event has occurred); and (4) any
action taken by either party pursuant to and in compliance with the
affirmative covenants set forth in _Section 5.6_ , and the consequences of
any such action.

  



  

(iii)  " _Superior Proposal_ " means a bona fide written Competing
Proposal (except the references therein to "20%" shall be replaced by "80%")
made by a third party which was not solicited by DENTSPLY or Sirona or any of
their respective Representatives and which, in the good faith judgment of the
DENTSPLY Board or the Sirona Board, as applicable, and after
consultation with its outside financial and legal advisors, taking into
account the various legal, financial and regulatory aspects of the
Competing Proposal, including the financing terms thereof, and the third
party making such Competing Proposal (A) if accepted, is reasonably likely to
be consummated, (B) if consummated, would result in a transaction that is more
favorable to DENTSPLY's shareholders or Sirona's shareholders, as applicable,
from a financial point of view, than the Merger and the other Transactions
contemplated hereby (after giving effect to all adjustments or modifications
to the terms thereof which may be agreed in writing to be made by the other
party (including pursuant to _Section 5.4(b)_)) and (C) if a cash transaction
(in whole or in part), financing for which is then fully committed or
reasonably determined to be available.

  



    

 | 72| 
---|---|--- 

 



    



  

5.5 _Access to Information; Confidentiality_.

  



  

(a) Upon reasonable notice, each of DENTSPLY and Sirona shall (and
shall cause their respective Subsidiaries and Representatives to) afford to
the other party and its Representatives reasonable access during normal
business hours, during the period prior to the Effective Time, to all its
properties, books, Contracts and records and its officers, employees and
Representatives and, during such period, each of DENTSPLY and Sirona shall
(and shall cause its Subsidiaries and Representatives to) furnish promptly to
the other party (i) a copy of each report, schedule, registration statement
and other document filed, published, announced or received by it during such
period pursuant to the requirements of applicable securities Laws (other than
reports or documents which such party is not permitted to disclose under
applicable Law) and (ii) consistent with its obligations under applicable Law,
all other information concerning its business, properties and personnel as
the other party may reasonably request; _provided_ , _however_ , none of
DENTSPLY or Sirona or any of their respective Subsidiaries or Representatives
shall be required to provide access to or disclose information where such
information or access would, in the reasonable judgment of such party, (x)
breach any agreement with any third party, (y) constitute a waiver of the
attorney-client or other privilege held by such party or (z)
otherwise violate any applicable Law. In the event any of the restrictions in
clauses (x) through (z) of the foregoing sentence shall apply, the parties
shall advise the other party of the subject matter of any such information
that cannot be disclosed and shall use their reasonable best efforts to make
appropriate alternate disclosure arrangements, including adopting additional
specific procedures to protect the confidentiality of sensitive material and
to ensure compliance with applicable Laws. Any such information
provided pursuant to this _Section 5.5_ shall be held in confidence to the
extent required by, and in accordance with, the provisions of that certain
Confidentiality Agreement, dated June 10, 2015 (the " _Confidentiality
Agreement_ "), between DENTSPLY and Sirona, which Confidentiality Agreement
shall remain in full force and effect.

  



  

(b) No investigation by any of the parties or their respective
Representatives or information provided, made available or delivered
pursuant to this Agreement shall affect the representations, warranties,
covenants or agreements of any other party set forth herein.

  



  

5.6 _Appropriate Action_.

  



  

(a) Sirona, Merger Sub and DENTSPLY shall use their reasonable best
efforts to take or cause to be taken all appropriate action, and to do, or
cause to be done, all things necessary to consummate and make effective the
transactions contemplated under this Agreement, including using their
reasonable best efforts to obtain, or cause to be obtained, all waivers,
permits, consents, approvals, authorizations, qualifications and orders of
all Governmental Entities and parties to Contracts with Sirona, DENTSPLY or
any of their respective Subsidiaries that may be or become necessary for the
performance of obligations pursuant to this Agreement and the consummation of
the transactions contemplated hereby. The parties shall cooperate and assist
one another in good faith (i) in connection with all actions to be taken
pursuant to this _Section 5.6(a)_ , including the preparation and making of
the filings referred to herein and, if requested, amending or furnishing
additional information thereunder, and (ii) in seeking, as promptly as
reasonably practicable, to obtain all such waivers, permits, consents,
approvals, authorizations, qualifications and orders. Upon the terms and
subject to the conditions set forth in this Agreement, each party agrees to
make any filings required to be made pursuant to the HSR Act, the EU Merger
Regulation or other applicable foreign, federal, state or supranational
antitrust, competition, fair trade or similar applicable Laws with respect to
the Transactions as promptly as reasonably practicable and to supply as
promptly as reasonably practicable to the appropriate Governmental Entities
any additional information and documentary material that may be requested by
such Governmental Entities pursuant to the HSR Act, the EU Merger Regulation
or such other applicable foreign, federal, state or supranational antitrust,
competition, fair trade or similar Laws. All such antitrust filings to be made
shall be made in substantial compliance with the requirements of the HSR Act,
the EU Merger Regulation and such other applicable foreign, federal, state or
supranational antitrust, competition, fair trade or similar Laws, as
applicable.

  



    

 | 73| 
---|---|--- 

 



    



  

(b) In furtherance, and without limiting the generality, of the
foregoing, the parties shall use their reasonable best efforts to
(i) cooperate with and assist each other in good faith to (A) determine, as
promptly as reasonably practicable, which filings are required to be made
pursuant to the HSR Act, the EU Merger Regulation or other applicable foreign,
federal, state or supranational antitrust, competition, fair trade or similar
Laws with respect to the Transactions, (B) provide or cause to be provided as
promptly as reasonably practicable to the other party all necessary
information and assistance as any Governmental Entity may from time to time
require of such party in connection with obtaining the relevant waivers,
permits, consents, approvals, authorizations, qualifications, Orders or
expiration of waiting periods in relation to such filings or in connection
with any other review or investigation of the Transactions by a Governmental
Entity pursuant to the HSR Act, the EU Merger Regulation or other applicable
foreign, federal, state or supranational antitrust, competition, fair trade
or similar Laws and (C) provide or cause to be provided as promptly
as reasonably practicable all assistance and cooperation to allow the other
party to prepare and submit any such filings or submissions required to be
submitted under the HSR Act, the EU Merger Regulation or other applicable
foreign, federal, state or supranational antitrust, competition, fair trade
or similar Laws, including providing to the other party any information that
the other party may from time to time require for the purpose of any filing
with, notification to, application with, or request for further
information made by, any Governmental Entity in respect of any such filing
and (ii) (A) cooperate with and assist each other in good faith to devise and
implement a joint strategy for making such filings, including the timing
thereof, and for obtaining any related antitrust, competition, fair trade or
similar clearances, (B) consult in advance with the other party and in good
faith take the other party\'s views into account regarding the overall
strategic direction of obtaining such antitrust, competition, fair trade or
similar clearances and (C) consult with the other party prior to taking any
material substantive position in any written submissions or, to the extent
practicable, in any discussions with Governmental Entities with respect to
such antitrust, competition, fair trade or similar clearances, including any
position as to a Divestiture. To the extent permitted by applicable Law, each
party shall permit the other party to review and discuss in advance, and
shall consider in good faith the views of the other party in connection with,
any analyses, presentations, memoranda, briefs, written arguments, opinions,
written proposals or other materials to be submitted to the Governmental
Entities. To the extent permitted by applicable Law, each party shall keep the
other apprised of the material content and status of any material
communications with, and material communications from, any Governmental
Entity with respect to the Transactions, including promptly notifying the
other party of any material communication it receives from any Governmental
Entity relating to any review or investigation of the Transactions under the
HSR Act, the EU Merger Regulation or other applicable foreign, federal, state
or supranational antitrust, competition, fair trade or similar Laws. To the
extent permitted by applicable Law, the parties shall, and shall use their
reasonable best efforts to cause their respective affiliates to use
their reasonable best efforts to, provide each other with copies of all
material correspondence, filings or communications between them or any of
their respective Representatives, on the one hand, and any Governmental Entity
or members of its staff, on the other hand, with respect to this Agreement
and the Transactions; _provided_ , _however_ , that materials may be redacted
(1) to remove references concerning the valuation of DENTSPLY and its
Subsidiaries or Sirona and its Subsidiaries, as applicable; (2) as necessary
to comply with any Contract or Laws; and (3) as necessary to address
reasonable attorney-client or other privilege or confidentiality concerns.

  



    

 | 74| 
---|---|--- 

 



    



  

(c) Subject to the penultimate sentence of this _Section 5.6(c)_ ,
Sirona and DENTSPLY shall, and shall cause each of their
respective Subsidiaries to, take any and all steps necessary to obtain
approval of the consummation of the Transactions by any antitrust
or competition Governmental Entity, including taking all steps necessary to
avoid or eliminate each and every legal impediment under any applicable
state, federal, foreign or supranational antitrust, competition, fair trade or
similar Law that may be asserted by any antitrust or competition Governmental
Entity so as to enable the parties hereto to close the Transactions as
promptly as reasonably practicable, and in any event prior to the Outside
Date, including proposing, negotiating, accepting, committing to and
effecting, by consent decree, hold separate orders, or otherwise, the sale,
divestiture or disposition of their Subsidiaries, assets, properties or
businesses, the entrance into, or the amendment, modification or termination
of, any Contracts or other arrangements, and other remedies in order to
obtain such approvals and to avoid the entry of, or to effect the dissolution
of, any injunction, temporary restraining order or other Law in any suit or
other action, arbitration, or litigation, which could otherwise have
the effect of delaying beyond the Outside Date or preventing the consummation
of any of the Transactions. In addition, Sirona and DENTSPLY shall, and shall
cause each of their respective Subsidiaries to, defend through litigation on
the merits so as to enable the parties to close the Transactions as promptly
as reasonably practicable (and in any event prior to the Outside Date) any
claim asserted in court or an administrative or other tribunal by any
antitrust or competition Governmental Entity under applicable
antitrust, competition, fair trade or similar Law in order to avoid entry of,
or to have vacated or terminated, any decree, order or judgment (whether
temporary, preliminary or permanent) or other Law that could prevent or delay
beyond the Outside Date the Closing from occurring; _provided_ , _however_ ,
that, for the avoidance of doubt, such litigation shall in no way limit the
obligations of the parties to comply with their obligations under the terms
of this _Section 5.6_. Sirona and DENTSPLY shall jointly direct and control
any such litigation with counsel of their own choosing. Notwithstanding the
foregoing or any other provision of this Agreement, neither Sirona nor
DENTSPLY nor any of their respective Subsidiaries and affiliates shall be
required to agree to any sale, transfer, license, separate holding,
divestiture or other disposition of, or to any prohibition of or any
limitation on the acquisition, ownership, operation, effective control or
exercise of full rights of ownership, or other modification of rights
in respect of, any material assets or businesses, or otherwise modify any
material business practice or contractual relationship (each, a "
_Divestiture_ "). In the event of any conflict between subsections (a), (b) or
(c) of this _Section 5.6_ , the provisions of this _Section 5.6(c)_ shall,
with respect to the matters addressed in this _Section 5.6(c)_ ,
supersede the provisions of subsection (a) and (b) of this _Section 5.6_.

  



    

 | 75| 
---|---|--- 

 



    



  

(d) Each party shall, and shall cause its respective Subsidiaries
to, respond as promptly as reasonably practicable to any inquiries
or requests for information and documentary material received from any
Governmental Entity in connection with any antitrust or competition matters
related to this Agreement and the transactions contemplated hereby.

  



  

5.7 _Certain Notices_. Each party shall give prompt notice to the
other parties if any of the following occur after the date of this
Agreement: (a) receipt of any notice or other communication in writing from
any Person alleging that the consent or approval of such Person is or may be
required in connection with the Transactions; (b) receipt of any notice or
other communication from any Governmental Entity or the NASDAQ (or any other
securities market) in connection with the Transactions; or (c) such
party becoming aware of the occurrence of an event that could prevent or
delay beyond the Outside Date the consummation of the Transactions or that
would reasonably be expected to result in any of the conditions to the Merger
set forth in _Article 6_ not being satisfied; _provided_ , _however_ , that
the delivery of any notice pursuant to this _Section 5.7_ shall not cure any
breach of any representation, warranty, covenant or agreement contained in
this Agreement or otherwise limit or affect the remedies available hereunder
to the party receiving such notice. Sirona and DENTSPLY shall promptly
provide, to the extent not publicly available, the other party with copies of
all filings made by such party with any Governmental Entity in connection
with the Transactions.

  



  

5.8 _Public Announcements_. Each party agrees that no public
release or announcement concerning the Transactions shall be issued by
any party without the prior written consent of DENTSPLY and Sirona (which
consent shall not be unreasonably withheld, conditioned or delayed), except
to the extent such release or announcement may be required by applicable Law
or the rules or regulations of any applicable securities exchange or
regulatory or governmental body to which the relevant party is subject, in
which case the party required to make the release or announcement shall use
its reasonable best efforts to allow each other party reasonable time
to comment on such release or announcement in advance of such issuance.
DENTSPLY and Sirona agree that the press release announcing the execution and
delivery of this Agreement shall be a joint release in the form heretofore
agreed by the parties. In addition, subject to the right of the DENTSPLY
Board to make a DENTSPLY Adverse Recommendation Change or the Sirona Board to
make a Sirona Adverse Recommendation Change, in each case in accordance with
and subject to the terms and conditions of _Section 5.4_, DENTSPLY and
Sirona agree to cause their respective directors and officers to refrain from
taking any position in any public statement that is (a) contrary to the
positions previously taken by Sirona and DENTSPLY with respect to this
Agreement and the Transactions, including the Merger, or (b) reasonably
likely to have a material adverse impact on the ability of the parties hereto
to consummate the Transactions.

  



    

 | 76| 
---|---|--- 

 



    



  

5.9 _Indemnification_.

  



  

(a) From and after the Effective Time, DENTSPLY shall, and shall
cause the Surviving Corporation to, indemnify, defend and hold harmless, and
shall advance expenses as incurred, to the fullest extent permitted under (i)
applicable Law, (ii) DENTSPLY's and Sirona's organizational documents in
effect as of the date of this Agreement and (iii) any Contract of DENTSPLY,
Sirona or any of their respective Subsidiaries in effect as of the date of
this Agreement, each present and former director and officer of DENTSPLY,
Sirona and any of their respective Subsidiaries (in each case, when acting in
such capacity) (each, an " _Indemnitee_ " and, collectively, the "
_Indemnitees_ ") against any costs or expenses (including reasonable
attorneys' fees), judgments, settlements, fines, losses, claims, damages or
liabilities incurred in connection with any Proceeding or
investigation, whether civil, criminal, administrative or investigative,
arising out of or pertaining to matters existing or occurring at or prior to
the Effective Time, including in connection with this Agreement or the
Transactions.

  



  

(b) DENTSPLY agrees that all rights to exculpation, indemnification
or advancement of expenses arising from, relating to, or otherwise in
respect of, acts or omissions occurring prior to the Effective Time
(including in connection with this Agreement or the Transactions)
now existing in favor of an Indemnitee as provided in its certificate of
incorporation, bylaws or other organizational documents shall survive the
Merger and shall continue in full force and effect in accordance with their
terms. For a period of no less than six (6) years from the Effective Time,
DENTSPLY shall cause the Surviving Corporation to, and the Surviving
Corporation shall, maintain in effect the exculpation, indemnification and
advancement of expenses provisions of the organizational documents of
DENTSPLY, Sirona or any of their respective Subsidiaries in effect as of the
date of this Agreement, and shall not amend, repeal or otherwise modify any
such provisions in any manner that would adversely affect the rights
thereunder of any individuals who immediately before the Effective Time were
current or former directors or officers of DENTSPLY, Sirona or any of their
respective Subsidiaries; _provided_ ,  _however_ , that all rights to
exculpation, indemnification and advancement of expenses in respect of any
Proceeding pending or asserted or any claim made within such period shall
continue until the final disposition of such Proceeding.

  



  

(c) For six (6) years from and after the Effective Time, DENTSPLY
shall maintain for the benefit of the Indemnitees, a DandO insurance policy
that provides coverage for events occurring prior to the Closing Date (the "
_D andO Insurance_") that is substantially equivalent to and in any event not
less favorable in the aggregate than the existing policy of Sirona, or,
if substantially equivalent insurance coverage is unavailable, the best
available coverage; _provided_ , _however_ , that DENTSPLY shall not be
required to pay an annual premium for the DandO Insurance in excess of 250% of
the last annual premium paid by Sirona prior to the date of this Agreement
(it being understood and agreed that, in the event that the requisite
coverage is not available for an annual premium less than or equal to 250% of
such last annual premium, DENTSPLY shall nevertheless be obligated to provide
such coverage as may be obtained for 250% of such last annual premium). The
provisions of the immediately preceding sentence shall be deemed to have been
satisfied if prepaid "tail" policies have been obtained prior to the
Effective Time, which policies provide such directors and officers with
coverage for an aggregate period of six (6) years with respect to claims
arising from facts or events that occurred on or before the Effective Time,
including in respect of the Transactions.

  



    

 | 77| 
---|---|--- 

 



    



  

(d) In the event that either DENTSPLY or the Surviving Corporation
or any of its successors or assigns (i) consolidates with or merges into any
other person and is not the continuing or surviving corporation or entity of
such consolidation or merger or (ii) transfers or conveys all or
substantially all of its properties and assets to any person, then, and in
each case, DENTSPLY shall, and shall cause the Surviving Corporation to,
cause proper provision to be made so that such successor or assign shall
expressly assume the obligations set forth in this _Section 5.9_.

  



  

(e) The provisions of this _Section 5.9_ are (i) intended to be for
the benefit of, and shall be enforceable by, each Indemnitee, his or her
heirs and his or her representatives and (ii) in addition to, and not in
substitution for, any other rights to indemnification or contribution that
any such individual may have under DENTSPLY's, Sirona's or any of their
respective Subsidiaries' organizational documents in effect as of the date of
this Agreement or in any Contract of DENTSPLY, Sirona or any of their
respective Subsidiaries in effect as of the date of this Agreement. The
obligations of DENTSPLY and the Surviving Corporation under this _Section
5.9_ shall not be terminated or modified in such a manner as to adversely
affect the rights of any Indemnitee to whom this _Section 5.9_ applies
unless (x) such termination or modification is required by applicable Law or
(y) the affected Indemnitee shall have consented in writing to such
termination or modification (it being expressly agreed that the Indemnitees
to whom this _Section 5.9_ applies shall be third party beneficiaries of this
_Section 5.9_).

  



  

(f) Nothing in this Agreement is intended to, shall be construed to
or shall release, waive or impair any rights to directors' and
officers' insurance claims under any policy that is or has been in existence
with respect to DENTSPLY, Sirona or any of their respective Subsidiaries for
any of their respective directors or officers, it being understood and agreed
that the indemnification provided for in this _Section 5.9_ is not prior to
or in substitution for any such claims under such policies.

  



  

5.10 _Financing Matters_. Between the date hereof and the Closing
Date, each of Sirona and DENTSPLY shall, and shall cause its Subsidiaries to,
use reasonable best efforts (a) to obtain all necessary waivers, consents,
amendments or approvals with respect to their respective Contracts relating
to indebtedness for borrowed money, to the extent that the consummation of the
transactions contemplated by this Agreement would result in a breach of or
default (with or without notice or lapse of time, or both) under, or give
rise to any notification or consent requirement or any right of termination,
cancellation or acceleration of any obligation, or to loss of a material
benefit under, such Contracts relating to indebtedness for borrowed money, (b)
to refinance, renew or replace the indebtedness under such Contracts on terms
mutually agreeable to Sirona and DENTSPLY, _provided_ that the
transactions contemplated by this Agreement would not result in a breach of
or default (with or without notice or lapse of time, or both) under, or give
rise to any notification or consent requirement or any right of termination,
cancellation or acceleration of any obligation, or to loss of a material
benefit under, any Contract under which such indebtedness is refinanced,
renewed or replaced or (c) to the extent that the waivers, consents,
amendments or approvals contemplated by clause (a) are not obtained and such
indebtedness is not refinanced, renewed or replaced as contemplated by clause
(b), to ensure that sufficient cash is available for the prompt payment in
full of any indebtedness under any such Contract and termination of any such
Contract, in each case at or prior to the Closing Date. In addition, between
the date hereof and the Closing Date, each of Sirona and DENTSPLY shall, and
shall cause its Subsidiaries to, use reasonable best efforts to cooperate to
develop an optimal global financing structure for DENTSPLY and
its Subsidiaries from and after the Closing, and to reasonably cooperate in
connection with the arrangement of such financing.

  



    

 | 78| 
---|---|--- 

 



    



  

5.11 _Stock Exchange Listing_. DENTSPLY and Sirona shall use their
reasonable best efforts to cause the shares of DENTSPLY Common Stock to be
issued in connection with the Merger (including shares of DENTSPLY Common
Stock to be reserved upon exercise of DENTSPLY Stock Options or vesting of
DENTSPLY RSUs) to be listed on the NASDAQ (or such other stock exchange as may
be mutually agreed upon by DENTSPLY and Sirona), subject to official notice
of issuance, prior to the Effective Time.

  



  

5.12 _Section 16 Matters_. Prior to the Effective Time, DENTSPLY and
Sirona shall take all such steps as may be required to cause any
dispositions of Sirona Common Stock (including derivative securities with
respect to Sirona Common Stock) or acquisitions of DENTSPLY Common Stock
(including derivative securities with respect to DENTSPLY Common Stock)
resulting from the Transactions by each individual who is subject to the
reporting requirements of Section 16(a) of the Exchange Act with respect to
DENTSPLY or Sirona, to be exempt under Rule 16b-3 promulgated under the
Exchange Act.

  



  

5.13 _Shareholder Litigation_. Each of DENTSPLY and Sirona shall
provide the other party the opportunity to participate in the defense of
any litigation brought by shareholders of DENTSPLY or shareholders of Sirona
or in the name of DENTSPLY or Sirona against DENTSPLY or Sirona, as
applicable, and/or their respective directors relating to the Transactions
contemplated by this Agreement, including the Merger; _provided_ , _however_
, that no party shall compromise, settle, come to an arrangement regarding or
agree to compromise, settle or come to an arrangement regarding any
litigation arising or resulting from the Transactions contemplated by this
Agreement, or consent to the same, without the prior written consent of the
other party (not be unreasonably withheld, conditioned or delayed).

  



  

5.14 _Tax Matters_.

  



  

(a) Notwithstanding anything herein to the contrary, none of Sirona,
DENTSPLY or Merger Sub shall take, or omit to take, any action that would,
or could reasonably be expected to, prevent or impede the Merger from
qualifying as a "reorganization" within the meaning of Section 368(a) of the
Code. Both prior to and following the Effective Time, Sirona and DENTSPLY
shall use their reasonable best efforts, and shall cause their respective
Subsidiaries to use their reasonable best efforts, to take or cause to be
taken any action necessary for the Merger to qualify as a "reorganization"
within the meaning of Section 368(a) of the Code (the " _Intended Tax
Treatment_ "), including (i) reasonably refraining from any action that such
party knows, or is reasonably expected to know, is reasonably likely to
prevent the Intended Tax Treatment and (ii) using its reasonable best efforts
to obtain the opinions referred to in _Sections 7.02(d)_ and _7.03(d)_ , and
any tax opinions required to be filed with the SEC in connection with the
filing of the Form S-4, including by executing customary letters of
representation. This Agreement is intended to constitute, and the parties
hereto hereby adopt this Agreement as, a "plan of reorganization" within the
meaning of Treasury Regulation Section 1.368-2(g) and 1.368-3(a). Each of
DENTSPLY and Sirona shall report the Merger as a "reorganization" within the
meaning of Section 368(a) of the Code and shall not take any position
inconsistent with such treatment unless otherwise required pursuant to a
"determination" within the meaning of Section 1313(a) of the Code.

  



    

 | 79| 
---|---|--- 

 



    



  

(b) As soon as reasonably practicable after the date of this
Agreement, DENTSPLY shall deliver to Sirona a copy of the proposed form
of the DENTSPLY Tax Opinion together with all letters or certificates that
form the basis therefor (collectively, the " _DENTSPLY Tax Opinion Materials_
"). Sirona shall be entitled to a reasonable amount of time to provide
DENTSPLY with written comments on the DENTSPLY Tax Opinion Materials.
DENTSPLY shall furnish Sirona with a copy of the final DENTSPLY Tax Opinion
Materials.

  



  

(c) As soon as reasonably practicable after the date of this
Agreement, Sirona shall deliver to DENTSPLY a copy of the proposed form
of the Sirona Tax Opinion together with all letters or certificates that form
the basis therefor (collectively, the " _Sirona Tax Opinion Materials_ ").
DENTSPLY shall be entitled to a reasonable amount of time to provide Sirona
with written comments on the Sirona Tax Opinion Materials. Sirona shall
furnish DENTSPLY with a copy of the final Sirona Tax Opinion Materials.

  



  

(d) If following the date of this Agreement and prior to five (5)
Business Days before the reasonably anticipated Closing Date DENTSPLY and
Sirona determine that the conditions set forth in _Section 6.2(d)_ and
_Section 6.3(d)_ cannot be satisfied and have not been waived, the parties
hereto may mutually determine to alter the structure of the business
combination between DENTSPLY and Sirona contemplated by this Agreement, by
consummating a second-step merger of the Surviving Corporation with and into a
Delaware limited liability company wholly-owned by DENTSPLY that is
disregarded as an entity separate from its owner for U.S. federal income tax
purposes in accordance with Delaware Law immediately following the Merger
(such second-step merger, the " _Second Merger_ ");  _provided_ , _however_ ,
that (i) such wholly-owned disregarded limited liability company shall become
a party to, and shall become bound by, the terms of this Agreement and (ii)
any action taken pursuant to this _Section 5.14(d)_ shall not (unless
consented to in writing by Sirona and DENTSPLY prior to the Closing) (x) alter
or change the Merger Consideration or any other terms set forth in _Article
1_ or _Article 2_ or (y) otherwise cause any closing condition set forth in
_Article 6_ not to be capable of being satisfied (unless duly waived by the
party entitled to the benefits thereof). If the Second Merger occurs,
references to the Merger in the fifth Recital, _Section 1.8_, _Section
3.15(b)_,  _Section 4.15(b)_, _Section 5.1(t)_, _Section 5.2(t)_, _Section
5.14_, _Section 6.2(d)_ and _Section 6.3(d)_ shall be deemed to be
references to the Merger and the Second Merger, taken together as one
integrated transaction for U.S. federal income tax purposes.

  



  

5.15 _Employee Matters_.

  



  

(a) At and following the Effective Time, DENTSPLY will and will
cause its Subsidiaries (including the Surviving Corporation and its
Subsidiaries) to honor all obligations under the Sirona Benefit Plans,
DENTSPLY Benefit Plans and applicable collective bargaining
agreements, agreements with a works council and labor contracts in accordance
with their terms as in effect immediately before the Effective Time;
_provided_ , that nothing in this _Section 5.15(a)_ is intended to prevent
DENTSPLY from causing them to be enforced in accordance with their terms,
including any reserved right to amend, modify, suspend, revoke or terminate
them.

  



    

 | 80| 
---|---|--- 

 



    



  

(b) At the Effective Time, it shall be the intent of Sirona and
DENTSPLY that, subject to obligations under applicable Law and
applicable collective bargaining agreements, agreements with a works council
and labor contracts, (i) any reductions in the employee work force of
DENTSPLY and its Subsidiaries (including the Surviving Corporation and its
Subsidiaries) shall be made on a fair and equitable basis in light of the
circumstances and the objectives to be achieved, giving consideration to
previous work history, job experience and qualifications, without regard to
whether employment prior to the Effective Time was with Sirona and its
Subsidiaries or DENTSPLY and its Subsidiaries, and any employee whose
employment is terminated or job is eliminated by DENTSPLY or its Subsidiaries
(including the Surviving Corporation and its Subsidiaries) after the
Effective Time shall be entitled to participate on a fair and equitable basis
in the job opportunity and employment placement programs offered by DENTSPLY
and its Subsidiaries (including the Surviving Corporation and its
Subsidiaries) for which the employee is eligible and (ii) employees shall be
entitled to participate in all job training, career development and
educational programs of DENTSPLY and its Subsidiaries (including the Surviving
Corporation and its Subsidiaries) for which they are eligible, and shall be
entitled to fair and equitable consideration in connection with any job
opportunities with DENTSPLY and its Subsidiaries (including the Surviving
Corporation and its Subsidiaries), in each case without regard to whether
employment prior to the Effective Time was with Sirona and its Subsidiaries or
DENTSPLY and its Subsidiaries.

  



  

(c) Subject to their obligations under applicable Law and applicable
collective bargaining agreements, agreements with a works council and labor
contracts, DENTSPLY will and will cause its Subsidiaries (including the
Surviving Corporation and its Subsidiaries) to give credit under each of
their respective employee benefit plans, programs and arrangements to
employees for all service prior to the Effective Time with Sirona or DENTSPLY
or their respective Subsidiaries, as applicable, or any predecessor employer
(to the extent that such credit was given by Sirona or DENTSPLY or any of
their respective Subsidiaries, as applicable) for all purposes for which such
service was taken into account or recognized by Sirona or DENTSPLY or their
respective Subsidiaries, as applicable, but not to the extent crediting such
service would result in duplication of benefits.

  



  

(d) Without limiting the generality of _Section 8.9_ , this _Section
5.15_ shall be binding upon and inure solely to the benefit of the parties to
this Agreement, and nothing in this _Section 5.15_ , express or implied, shall
confer upon any other Person any rights or remedies of any nature whatsoever
under or by reason of this _Section 5.15_. Nothing in this Agreement,
express or implied, is or shall be construed to establish, amend or modify
any Sirona Benefit Plan, DENTSPLY Benefit Plan or other employee or director
compensation or benefit plan. The parties to this Agreement acknowledge and
agree that the terms set forth in this  _Section 5.15_ shall not create any
right in any employee of Sirona, DENTSPLY, the Surviving Corporation or their
respective Subsidiaries or any other Person to any continued employment with
Sirona, DENTSPLY, the Surviving Corporation or their respective Subsidiaries
or any right to compensation or benefits of any nature or kind whatsoever.

  



    

 | 81| 
---|---|--- 

 



    



  

5.16 _Cooperation_. Each of DENTSPLY and Sirona will, and will cause
each of its respective Subsidiaries and Representatives to, use its
reasonable best efforts, subject to applicable Laws, to cooperate with the
other party in connection with planning the integration of the business
operations of DENTSPLY and Sirona and their respective Subsidiaries.

  



  

ARTICLE 6

  

Conditions to Consummation of the Merger

  



  

6.1 _Conditions to Obligations of Each Party Under This Agreement_.
The obligations of DENTSPLY, Sirona, and Merger Sub to consummate the
Merger are subject to the satisfaction or waiver (to the extent permitted by
applicable Law), at or prior to the Closing, of the following conditions:

  



  

(a) _Shareholder Approvals_. Sirona shall have obtained the Sirona
Shareholder Approval, and DENTSPLY shall have obtained the DENTSPLY
Shareholder Approval.

  



  

(b) _NASDAQ Listing_. The shares of DENTSPLY Common Stock issuable
to the shareholders of Sirona pursuant to this Agreement shall have
been approved for listing on the NASDAQ, subject to official notice of
issuance.

  



  

(c) _Statutes and Injunctions_. No Law or Order shall have been
promulgated, entered, enforced, enacted or issued or shall be deemed to
be applicable to the Merger by any Governmental Entity (whether temporary,
preliminary or permanent) which prohibits, restrains or makes illegal the
consummation of the Merger and shall continue in effect.

  



  

(d) _Form S-4_. The Form S-4 shall have become effective under the
Securities Act and shall not be the subject of any stop order.

  



  

(e) _HSR Act; EU Merger Regulation; Other Competition Authority
Approvals_. (i) Any applicable waiting period, together with any
extensions thereof, under the HSR Act shall have expired or been terminated;
(ii) the approval of the European Commission of the Transactions shall have
been obtained pursuant to the EU Merger Regulation (or the approval by those
national competition authorities in the European Union that have jurisdiction
as a result of a referral of the Transactions under the EU Merger Regulation);
(iii) the other antitrust, competition, investment, trade regulation or
similar approvals set forth in _Section 6.1(e)_ of the DENTSPLY Disclosure
Schedule and _Section 6.1(e)_ of the Sirona Disclosure Schedule shall have
been obtained and shall be in effect and, if applicable, the waiting period,
together with any extensions thereof, or mandated filings thereunder shall
have expired, been terminated or been made, as applicable and (iv) any other
antitrust, competition, investment, trade regulation or similar approvals
that are required under Law to have been obtained prior to Closing shall have
been obtained.

  



    

 | 82| 
---|---|--- 

 



    



  

6.2 _Conditions to Obligations of DENTSPLY and Merger Sub Under This
Agreement_. The obligations of DENTSPLY and Merger Sub to consummate
the Merger are subject to the satisfaction or waiver (to the extent permitted
by applicable Law), at or prior to the Closing, of the following conditions:

  



  

(a) The representations and warranties of Sirona set forth in this
Agreement (except those representations and warranties set forth in the
proviso below) shall be true and correct in all respects (without giving
effect to any materiality or Sirona Material Adverse Effect qualifiers
therein), as of the date of this Agreement and as of the Closing Date as
though made on and as of such date (or, in the case of representations and
warranties that address matters only as of a particular date, as of such
date), except to the extent that any failures of such representations and
warranties to be so true and correct, individually or in the aggregate,
have not had and would not reasonably be expected to have a Sirona Material
Adverse Effect; _provided_ , that (i) the representations and warranties set
forth in _Section 3.1_ (Corporation Organization), _Section 3.2_ (Sirona
Capitalization), _Section 3.3_ (Authority; Execution and Delivery;
Enforceability), _Section 3.19_ (Broker's Fees) and _Section 3.20_
(Opinion of Financial Advisor) shall be true and correct in all material
respects as of the date of this Agreement and as of the Closing Date as
though made on and of such date (or, in the case of representations and
warranties that address matters only as of a particular date, as of such
date) and (ii) the representation and warranty set forth in clause (b) of the
first sentence of _Section 3.6_  shall be true and correct in all respects as
of the date of this Agreement and as of the Closing Date as though made on and
of such date. DENTSPLY shall have received a certificate validly executed and
signed on behalf of Sirona by an executive officer of Sirona certifying that
this condition has been satisfied.

  



  

(b) Sirona shall have performed or complied with all of the material
covenants and agreements required by this Agreement to be performed
or complied with by it in all material respects and DENTSPLY shall have
received a certificate validly executed and signed on behalf of Sirona by an
executive officer of Sirona certifying that this condition has been satisfied.

  



  

(c) No change, event, development, condition, occurrence or effect
shall have occurred, arisen or become known since the date of this Agreement
that has had, or would reasonably be expected to have, individually or in the
aggregate, a Sirona Material Adverse Effect.

  



  

(d) DENTSPLY shall have (i) received a written tax opinion from
Skadden, Arps, Slate, Meagher and Flom, LLP, counsel to DENTSPLY, dated as of
the Closing Date, in form and substance reasonably satisfactory to DENTSPLY
and based on the facts, representations, assumptions and exclusions set forth
or described in such opinion, to the effect that the Merger will qualify as a
"reorganization" within the meaning of Section 368(a) of the Code (the "
_DENTSPLY Tax Opinion_ ") and (ii) a copy of the Sirona Tax Opinion. Such
counsel shall be entitled to rely upon customary representation letters from
each of Sirona and DENTSPLY (or any other relevant parties), in each case, in
form and substance reasonably satisfactory to such counsel. Each such
representation letter shall be dated as of the date of such opinion.

  



    

 | 83| 
---|---|--- 

 



    



  

6.3 _Conditions to Obligations of Sirona Under This Agreement_. The
obligation of Sirona to consummate the Merger is subject to the
satisfaction or waiver (to the extent permitted by applicable Law), at or
prior to the Closing, of the following conditions:

  



  

(a) The representations and warranties of DENTSPLY and Merger Sub
set forth in this Agreement (except those representations and warranties set
forth in the proviso below) shall be true and correct in all respects (without
giving effect to any materiality or DENTSPLY Material Adverse Effect
qualifiers therein), as of the date of this Agreement and as of the Closing
Date as though made on and as of such date (or, in the case of
representations and warranties that address matters only as of a particular
date, as of such date), except to the extent that any failures of such
representations and warranties to be so true and correct, individually or in
the aggregate, have not had, and would not reasonably be expected to have, a
DENTSPLY Material Adverse Effect; _provided_ , that (i) the representations
and warranties set forth in in _Section 4.1_ (Corporate Organization),
_Section 4.2_ (DENTSPLY Capitalization), _Section 4.3_ (Authority; Execution
and Delivery; Enforceability), _Section 4.19_ (Broker's Fees),  _Section
4.20_ (Opinion of Financial Advisor) and _Section 4.23_ (Merger Sub) shall be
true and correct in all material respects as of the date of this Agreement
and as of the Closing Date as though made on and as of such date (or, in the
case of representations and warranties that address matters only as of a
particular date, as of such date) and (ii) the representation and warranty
set forth in clause (b) of the first sentence of _Section 4.6_ shall be true
and correct in all respects as of the date of this Agreement and as of the
Closing Date as though made on and of such date. Sirona shall have received a
certificate validly executed and signed on behalf of DENTSPLY by an executive
officer of DENTSPLY certifying that this condition has been satisfied.

  



  

(b) DENTSPLY and Merger Sub shall have performed or complied with,
as applicable, all of the material covenants and agreements required by
this Agreement to be performed or complied with by it in all material
respects and Sirona shall have received a certificate validly executed and
signed on behalf of DENTSPLY by an executive officer of DENTSPLY certifying
that this condition has been satisfied.

  



  

(c) No change, event, development, condition, occurrence or effect
shall have occurred, arisen or become known since the date of this Agreement
that has had, or would reasonably be expected to have, individually or in the
aggregate, a DENTSPLY Material Adverse Effect.

  



  

(d) Sirona shall have received (i) a written tax opinion from Latham
and Watkins LLP, counsel to Sirona, dated as of the Closing Date, in form and
substance reasonably satisfactory to Sirona and based on the facts,
representations, assumptions and exclusions set forth or described in such
opinion, to the effect that the Merger will qualify as a "reorganization"
within the meaning of Section 368(a) of the Code (the " _Sirona Tax Opinion_
") and (ii) a copy of the DENTSPLY Tax Opinion. Such counsel shall be
entitled to rely upon customary representation letters from each of Sirona and
DENTSPLY (or any other relevant parties), in each case, in form and substance
reasonably satisfactory to such counsel. Each such representation letter shall
be dated as of the date of such opinion.

  



    

 | 84| 
---|---|--- 

 



    



  

ARTICLE 7 
 Termination, Amendment and Waiver

  



  

7.1 _Termination_. This Agreement may be terminated, and the Merger
contemplated hereby may be abandoned by action taken or authorized by the
Board of Directors of the terminating party or parties, whether before or
after the DENTSPLY Shareholder Approval or the Sirona Shareholder Approval:

  



  

(a) By mutual written consent of DENTSPLY and Sirona;

  



  

(b) By either DENTSPLY or Sirona:

  



  

(i) if any Law or final and non-appealable Order shall have been
promulgated, entered, enforced, enacted or issued or shall be deemed to be
applicable to the Merger by any Governmental Entity of competent jurisdiction
which permanently prohibits, restrains or makes illegal the consummation of
the Merger; _provided_ , that the right to terminate the Agreement pursuant to
this _Section 7.1(b)(i)_ shall not be available to any party whose failure to
perform any of its obligations under this Agreement is the primary cause of,
or resulted in, the enactment or issuance of any such Law or Order;

  



  

(ii) if the Transactions shall not have been consummated by the six (6)
month anniversary of the date of this Agreement whether such date is before
or after the date of the DENTSPLY Shareholder Approval and the Sirona
Shareholder Approval; _provided_ , that in the event that, as of the six (6)
month anniversary of the date of this Agreement, all conditions to Closing set
forth in _Article 6_ have been satisfied or waived (other than such
conditions that by their terms are satisfied at the Closing) other than
the conditions set forth in _Section 6.1(e)_ or _Section 6.1(c)_ (solely
with respect to the matters addressed in _Section 6.1(e)_), the termination
date may be extended from time to time by either DENTSPLY or Sirona for up to
an aggregate extension of nine (9) months (such date, including any such
permitted extensions thereof, the " _Outside Date_ ") and _provided_ , 
_further_ , that the right to terminate the Agreement pursuant to this
_Section 7.1(b)(ii)_ shall not be available to any party whose failure to
perform any of its obligations under this Agreement is the primary cause of,
or resulted in, the failure of the Transactions to be consummated by such
time;

  



  

(iii) if the DENTSPLY Shareholder Approval shall not have been obtained upon
a vote taken thereon at the DENTSPLY Shareholders Meeting duly convened
therefor or at any adjournment or postponement thereof; _provided_ that the
right to terminate this Agreement pursuant to this _Section 7.1(b)(iii)_
shall not be available to DENTSPLY if DENTSPLY's failure to perform any of
its obligations under this Agreement is the primary cause of, or resulted in,
the failure to obtain the DENTSPLY Shareholder Approval; or

  



    

 | 85| 
---|---|--- 

 



    



  

(iv) if the Sirona Shareholder Approval shall not have been obtained upon a
vote taken thereon at the Sirona Shareholders Meeting duly convened therefor
or at any adjournment or postponement thereof; _provided_ that the right to
terminate this Agreement pursuant to this _Section 7.1(b)(iv)_ shall not be
available to Sirona if Sirona's failure to perform any of its
obligations under this Agreement is the primary cause of, or resulted in, the
failure to obtain the Sirona Shareholder Approval;

  



  

(c) By Sirona:

  



  

(i) if DENTSPLY shall have breached or failed to perform any of its
representations, warranties or covenants contained in this Agreement, which
breach or failure to perform (A) is incapable of being cured by DENTSPLY prior
to the Outside Date or otherwise is not cured by the earlier of (x) twenty
(20) Business Days following written notice to DENTSPLY by Sirona of such
breach or (y) the Business Day prior to the Outside Date and (B) would result
in a failure of any condition set forth in _Section 6.3(a)_ or  _Section
6.3(b)_;

  



  

(ii) if DENTSPLY shall have breached in any material respect any of its
obligations under _Section 5.4_ ; or

  



  

(iii) if the DENTSPLY Board has effected a DENTSPLY Adverse Recommendation
Change; or

  



  

(d) By DENTSPLY:

  



  

(i) if Sirona shall have breached or failed to perform any of its
representations, warranties or covenants contained in this Agreement, which
breach or failure to perform (A) is incapable of being cured by Sirona prior
to the Outside Date or otherwise is not cured by the earlier of (x) twenty
(20) Business Days following written notice to Sirona by DENTSPLY of such
breach or (y) the Business Day prior to the Outside Date and (B) would result
in a failure of any condition set forth in _Section 6.2(a)_ or  _Section
6.2(b)_;

  



  

(ii) if Sirona shall have breached in any material respect any of its
obligations under _Section 5.4_ ; or

  



  

(iii) if the Sirona Board has effected a Sirona Adverse Recommendation
Change.

  



  

7.2 _Effect of Termination_. In the event of the valid termination
of this Agreement by either DENTSPLY or Sirona as provided in _Section
7.1_, written notice thereof shall forthwith be given by the terminating
party to the other party specifying the provision hereof pursuant to which
such termination is made. In the event of the valid termination of this
Agreement pursuant to _Section 7.1_, this Agreement shall be terminated and
this Agreement shall forthwith become void and have no effect, without any
liability or obligation on the part of DENTSPLY, Sirona or Merger Sub, other
than this _Section 7.2_, _Section 7.3_ and _Article 8_, which provisions
shall survive such termination; _provided_ , that nothing herein shall relieve
any party for any liability for Willful Breach or fraud. No termination of
this Agreement shall affect the obligations of the parties contained in the
Confidentiality Agreement, all of which obligations shall survive the
termination of this Agreement in accordance with their terms.

  



    

 | 86| 
---|---|--- 

 



    



  

7.3 _Termination Fee; Expenses_.

  



  

(a) Except as otherwise provided in this _Section 7.3_ and except
for (i) the expenses in connection with printing and mailing the Joint Proxy
Statement and the Form S-4 required in connection with the actions specified
in _Section 5.3_, (ii) all SEC filing fees relating to the Transactions and
(iii) the fees in connection with the approvals required under _Section
6.1(e)_  related to the Transactions (each of which fees and expenses shall
be borne, in each case, equally by DENTSPLY and Sirona), all fees and
expenses incurred by the parties shall be borne solely by the party that has
incurred such fees and expenses.

  



  

(b) DENTSPLY shall pay to Sirona $280 million (the " _DENTSPLY
Termination Fee_ ") if this Agreement is terminated as follows:

  



  

(i) if this Agreement is terminated pursuant to _Section 7.1(c)(ii)_ , or
_Section 7.1(c)(iii)_ , then DENTSPLY shall pay the entire DENTSPLY
Termination Fee (to the extent not previously paid) on the second Business Day
following such termination; and

  



  

(ii) (x) if this Agreement is terminated (A) pursuant to _Section
7.1(b)(iii)_, (B) pursuant to _Section 7.1(c)(i)_ or (C) pursuant to _Section
7.1(b)(ii)_ without a vote of the shareholders of DENTSPLY contemplated by
this Agreement at the DENTSPLY Shareholders Meeting having occurred, and in
any such case a Competing Proposal shall have been publicly announced
or otherwise communicated to the DENTSPLY Board at any time after the date of
this Agreement and prior to the date of the taking of the vote of the
shareholders of DENTSPLY contemplated by this Agreement at the DENTSPLY
Shareholders Meeting, in the case of clause (A), or the date of termination,
in the case of clauses (B) and (C), and (y) if within twelve (12) months after
the date of such termination, a transaction in respect of a Competing
Proposal is consummated or DENTSPLY enters into a definitive agreement
in respect of a Competing Proposal, then DENTSPLY shall pay the DENTSPLY
Termination Fee (less any Expenses previously paid to Sirona pursuant to
_Section 7.3(c)_ ) on the second Business Day following the earlier of the
date DENTSPLY enters into a definitive agreement in respect of or consummates
such transaction; _provided_ , that, solely for purposes of this _Section
7.3(b)(ii)_, the term "Competing Proposal" shall have the meaning ascribed
thereto in _Section 5.4(g)(i)_ , except that all references to 20% shall be
changed to 50%.

  



  

Any DENTSPLY Termination Fee due under this _Section 7.3(b)_ shall be paid by
wire transfer of immediately available funds.

  



  

(c) DENTSPLY shall pay to Sirona its Expenses in an amount not to
exceed $15 million, if this Agreement is terminated (i) pursuant to
_Section 7.1(b)(iii)_ (except if, prior to such termination, the Sirona
Shareholder Approval was not obtained upon a vote taken thereon at the Sirona
Shareholders Meeting duly convened therefor or at any adjournment or
postponement thereof) or (ii) pursuant to _Section 7.1(c)(i)_. Any Expenses
of Sirona due under this _Section 7.3(c)_ shall be paid by wire transfer of
immediately available funds no later than two Business Days after DENTSPLY's
receipt from Sirona of an itemized statement identifying such Expenses.

  



    

 | 87| 
---|---|--- 

 



    



  

(d) Sirona shall pay to DENTSPLY $205 million (the " _Sirona
Termination Fee_ ") if this Agreement is terminated as follows:

  



  

(i) if this Agreement is terminated pursuant to _Section 7.1(d)(ii)_ or
_Section 7.1(d)(iii)_ , then Sirona shall pay the entire Sirona Termination
Fee (to the extent not previously paid) on the second Business Day following
such termination; and

  



  

(ii) (x) if this Agreement is terminated (A) pursuant to _Section
7.1(b)(iv)_, (B) pursuant to _Section 7.1(d)(i)_ or (C) pursuant to _Section
7.1(b)(ii)_ without a vote of the shareholders of Sirona contemplated by this
Agreement at the Sirona Shareholders Meeting having occurred, and in any such
case a Competing Proposal shall have been publicly announced or
otherwise communicated to the Sirona Board at any time after the date of this
Agreement and prior to the date of the taking of the vote of the shareholders
of Sirona contemplated by this Agreement at the Sirona Shareholders Meeting,
in the case of clause (A), or the date of termination, in the case of clauses
(B) or (C), and (y) if within twelve (12) months after the date of such
termination, a transaction in respect of a Competing Proposal is consummated
or DENTSPLY enters into a definitive agreement in respect of a Competing
Proposal, then Sirona shall pay the Sirona Termination Fee (less any Expenses
previously paid to DENTSPLY pursuant to _Section 7.3(e)_ ) on the second
Business Day following the earlier of the date Sirona enters into a
definitive agreement in respect of or consummates such transaction; _provided_
, that, solely for purposes of this _Section 7.3(d)(ii)_, the term
"Competing Proposal" shall have the meaning ascribed thereto in _Section
5.4(g)(i)_, except that all references to 20% shall be changed to 50%.

  



  

Any Sirona Termination Fee due under this _Section 7.3(d)_ shall be paid by
wire transfer of immediately available funds.

  



  

(e) Sirona shall pay to DENTSPLY its Expenses in an amount not to
exceed $15 million if this Agreement is terminated (i) pursuant to
_Section 7.1(b)(iv)_ (except if, prior to such termination, the DENTSPLY
Shareholder Approval was not obtained upon a vote taken thereon at the
DENTSPLY Shareholders Meeting duly convened therefor or at any adjournment or
postponement thereof) or (ii) pursuant to  _Section 7.1(d)(i)_. Any Expenses
of DENTSPLY due under this _Section 7.3(e)_ shall be paid by wire transfer of
immediately available funds no later than two Business Days after Sirona's
receipt from DENTSPLY of an itemized statement identifying such Expenses.

  



    

 | 88| 
---|---|--- 

 



    



  

(f) The parties each agree that the agreements contained in this
_Section 7.3_ are an integral part of the Transactions, and that, without
these agreements, the parties would not enter into this Agreement.
Accordingly, if a party fails to pay any amounts due under this _Section
7.3_ and, in order to obtain such payment, Sirona or DENTSPLY, as the case may
be, commences a suit that results in a judgment against such party for such
amounts, such party shall pay interest on such amounts from the date payment
of such amounts were due to the date of actual payment at the rate equal to
the prime rate published in the Wall Street Journal for the relevant period,
together with the costs and expenses of the other party (including reasonable
legal fees and expenses) in connection with such suit. Notwithstanding
anything to the contrary in this Agreement, in the event that the DENTSPLY
Termination Fee or the Sirona Termination Fee is payable and actually paid to
DENTSPLY or Sirona in accordance with this _Section 7.3_, payment of such
DENTSPLY Termination Fee or Sirona Termination Fee, as applicable, shall be
the sole and exclusive remedy of the non-terminating party and its affiliates
against any other party or such other party's shareholders, directors,
officers, affiliates and other Representatives, for any loss or damage based
upon, arising out of or relating to this Agreement or the
negotiation, execution or performance hereof or the Transactions contemplated
hereby, except in the case of Willful Breach or fraud. Solely for purposes of
establishing the basis for the amount thereof, and without in any way
increasing the amount of the DENTSPLY Termination Fee or the Sirona
Termination Fee, expanding the circumstances in which the DENTSPLY Termination
Fee or the Sirona Termination Fee, as applicable, is to be paid or
restricting or modifying the other rights of any party hereunder, in the event
of the valid termination of this Agreement under circumstances in which the
DENTSPLY Termination Fee or the Sirona Termination Fee is payable pursuant to
this _Section 7.3_, it is agreed that each of the DENTSPLY Termination Fee
and the Sirona Termination Fee is liquidated damages, and not a penalty, and
the payment thereof in such circumstances is supported by due and sufficient
consideration;  _provided_ , that no payment of a DENTSPLY Termination Fee or
a Sirona Termination Fee shall be considered in lieu of, or a replacement or
substitution for, damages incurred in the event of any Willful Breach or
fraud.

  



  

7.4 _Amendment or Supplement_. This Agreement may be amended,
modified or supplemented by the parties by action taken or authorized by
their respective Boards of Directors at any time prior to the Effective Time,
whether before or after the DENTSPLY Shareholder Approval or the Sirona
Shareholder Approval has been obtained; _provided_ , that after the DENTSPLY
Shareholder Approval or the Sirona Shareholder Approval has been obtained, no
amendment shall be made that pursuant to applicable Law requires further
approval or adoption by the shareholders of DENTSPLY or shareholders of
Sirona without such further approval or adoption. This Agreement may not be
amended, modified or supplemented in any manner, whether by course of conduct
or otherwise, except by an instrument in writing specifically designated as
an amendment hereto, signed on behalf of each of the parties in interest at
the time of the amendment.

  



    

 | 89| 
---|---|--- 

 



    



  

7.5 _Extension of Time; Waiver_. At any time prior to the Effective
Time, the parties may, by action taken or authorized by their
respective Boards of Directors, to the extent permitted by applicable Law,
(a) extend the time for the performance of any of the obligations or acts of
the other parties, (b) waive any inaccuracies in the representations and
warranties of the other parties set forth in this Agreement or any document
delivered pursuant hereto, or (c) waive compliance with any of the agreements
or conditions of the other parties contained herein; _provided_ , that after
the DENTSPLY Shareholder Approval or the Sirona Shareholder Approval has been
obtained, no waiver may be made that pursuant to applicable Law requires
further approval or adoption by the shareholders of DENTSPLY or shareholders
of Sirona, as applicable, without such further approval or adoption. Any
agreement on the part of a party to any such waiver shall be valid only if
set forth in a written instrument executed and delivered by a duly authorized
officer on behalf of such party. No failure or delay of any party in
exercising any right or remedy hereunder shall operate as a waiver thereof,
nor shall any single or partial exercise of any such right or power, or any
abandonment or discontinuance of steps to enforce such right or power, or any
course of conduct, preclude any other or further exercise thereof or the
exercise of any other right or power. The rights and remedies of the parties
hereunder are cumulative and are not exclusive of any rights or remedies
which they would otherwise have hereunder.

  



  

ARTICLE 8 
 General Provisions

  



  

8.1 _Non-Survival of Representations and Warranties_. None of the
representations, warranties, covenants or agreements in this Agreement or
in any instrument delivered pursuant to this Agreement shall survive the
Effective Time, other than those covenants or agreements of the parties which
by their terms apply, or are to be performed in whole or in part, after the
Effective Time.

  



  

8.2 _Notices_. Any notices or other communications required or
permitted under, or otherwise given in connection with, this Agreement shall
be in writing and shall be deemed to have been duly given (a) when delivered
or sent if delivered in person or sent by facsimile transmission (provided
confirmation of facsimile transmission is obtained), (b) on the fifth Business
Day after dispatch by registered or certified mail, (c) on the next Business
Day if transmitted by national overnight courier or (d) on the date delivered
if sent by email (provided confirmation of email receipt is obtained), in
each case as follows:

  



  

If to Sirona, addressed to it at:

  



  

Sirona Dental Systems, Inc.

  

30-30 47th Avenue, Suite 500

  

Long Island City, New York 11101

  

Tel: (718) 482-2011

  

Fax: (718) 482-2323

  

Attention: Secretary and General Counsel

  

Email: jonathan.friedman@sirona.com

  



    

 | 90| 
---|---|--- 

 



    



  

with a copy to (for information purposes only):

  



  

Latham and Watkins LLP

  

330 North Wabash Avenue, Suite 2800

  

Chicago, Illinois 60611

  

Tel: (312) 876-7700

  

Fax: (312) 993-9767

  

Attention: Mark D. Gerstein

  

 Bradley C. Faris

  

Email: mark.gerstein@lw.com

  

  bradley.faris@lw.com

  



  

If to DENTSPLY or Merger Sub, addressed to it at:

  



  

DENTSPLY International Inc.

  

221 W. Philadelphia St., Suite 60W

  

York, Pennsylvania 17401

  

Tel: (717) 845-7511

  

Fax: (717) 849-4753

  

Attention: General Counsel

  

Email: CorporateSecretary@dentsply.com

  



  

with a copy to (for information purposes only):

  



  

Skadden, Arps, Slate, Meagher and Flom LLP

  

1440 New York Avenue, N.W.

  

Washington, DC 20005

  

Tel: (202) 371-7000

  

Fax: (202) 393-5760

  

Attention: Michael P. Rogan

  

 Pankaj K. Sinha

  

Email: michael.rogan@skadden.com

  

  pankaj.sinha@skadden.com

  



  

8.3 _Certain Definitions_. For purposes of this Agreement, the term:

  



  

" _Acceptable Confidentiality Agreement_ " means a confidentiality agreement
that contains confidentiality and standstill provisions that are no less
favorable in the aggregate to DENTSPLY or Sirona, as applicable, than those
contained in the Confidentiality Agreement;  _provided_ that such
confidentiality agreement may not include any provision calling for an
exclusive right to negotiate with any party to this Agreement or otherwise
conflicting with the obligations of any party under this Agreement.

  



  

" _affiliate_ " means a Person that directly or indirectly, through one or
more intermediaries, controls, is controlled by, or is under common control
with, the first-mentioned Person.

  



    

 | 91| 
---|---|--- 

 



    



  

" _Anti-corruption Laws_ " means Laws relating to anti-bribery or anti-
corruption (governmental or commercial) which apply to Sirona, DENTSPLY or
their respective Subsidiaries, including Laws that prohibit the corrupt
payment, offer, promise or authorization of the payment or transfer of
anything of value (including gifts or entertainment), directly or indirectly,
to any foreign Government Official or other Person to obtain a business
advantage, including the FCPA, the U.K. Bribery Act of 2010 and all national
and international Laws enacted to implement the OECD Convention on Combating
Bribery of Foreign Officials in International Business Transactions.

  



  

" _associate_ " has the meaning set forth in Section 203 of the DGCL.

  



  

" _beneficial ownership_ " (and related terms such as "beneficially owned" or
"beneficial owner") has the meaning set forth in Rule 13d-3 under the
Exchange Act.

  



  

" _Business Day_ " means any date except Saturday or Sunday on which
commercial banks are not required or authorized to close in New York, New
York, United States.

  



  

" _Code_ " means the Internal Revenue Code of 1986, as amended.

  



  

" _Contract_ " means any agreements, arrangements, commitments,
understandings, contracts, leases (whether for real or personal property),
powers of attorney, notes, bonds, mortgages, indentures, deeds of trust,
loans, evidences of indebtedness, purchase orders, letters of credit,
settlement agreements, franchise agreements, undertakings, covenants not to
compete, employment agreements, licenses, instruments, obligations,
commitments, understandings, policies, purchase and sales orders, quotations
and other commitments to which a Person is a party or to which any of the
assets of such Person or its Subsidiaries are subject, whether oral or
written, express or implied, including all amendments or modifications
thereto.

  



  

" _control_ " (including the terms "controlled by" and "under common control
with") means the possession, directly or indirectly or as trustee or
executor, of the power to direct or cause the direction of the management or
policies of a Person, whether through the ownership of stock or shares or as
trustee or executor, by Contract or otherwise.

  



  

" _DENTSPLY Disclosure Schedule_ " means the disclosure schedule delivered by
DENTSPLY to Sirona prior to the execution of this Agreement.

  



  

" _DENTSPLY Leased Real Property_ " means all real property leased,
subleased, or otherwise occupied pursuant to an occupancy agreement
by DENTSPLY or any of its Subsidiaries.

  



    

 | 92| 
---|---|--- 

 



    



  

" _DENTSPLY Material Adverse Effect_ " means any change, event, development,
condition, occurrence or effect that is, or would reasonably be expected to
be, materially adverse to the business, condition (financial or otherwise),
assets, liabilities or results of operations of DENTSPLY and its
Subsidiaries, taken as a whole; _provided_ , _however_ , that none of the
following shall be deemed in themselves, either alone or in combination, to
constitute, and none of the following shall be taken into account in
determining whether there has been or will be, a DENTSPLY Material Adverse
Effect: (i) any changes resulting from general market, economic, financial,
capital markets or political or regulatory conditions, (ii) any changes or
proposed changes of Law or GAAP (or, in each case, any authoritative
interpretations thereof), (iii) any changes resulting from any act of
terrorism, war, national or international calamity, or any worsening thereof,
(iv) any changes generally affecting the industries in which DENTSPLY and its
Subsidiaries conduct their businesses, (v) any changes resulting from the
execution of this Agreement or the announcement or the pendency of the
Merger, including any loss of employees or customers, any cancellation of or
delay in customer orders or any disruption in or termination of (or loss of
or other negative effect or change with respect to) customer, supplier,
distributor or similar business relationships or partnerships resulting from
the Transactions (provided, that this clause (v) does not apply in the
context of the representations and warranties set forth in _Section 4.4_),
(vi) changes in DENTSPLY's stock price or the trading volume of DENTSPLY's
stock or any change in the credit rating of DENTSPLY (but not, in each case,
the underlying cause of any such changes, unless such underlying cause would
otherwise be excepted from this definition), (vii) any changes or effects
resulting from any action required to be taken by the terms of this Agreement,
(viii) the failure to meet internal or analysts' expectations, projections or
results of operations (but not, in each case, the underlying cause of any
such changes, unless such underlying cause would otherwise be excepted from
this definition), or (ix) any Proceeding arising from or relating to the
Merger or the other Transactions; _provided_ , that in the case of clauses
(i), (ii), (iii) and (iv), if and only to the extent such changes do not have
a disproportionate impact on DENTSPLY and its Subsidiaries, taken as a whole,
as compared to other participants in the industries in which DENTSPLY and its
Subsidiaries conduct their businesses.

  



  

" _DENTSPLY Owned Real Property_ " means all real property owned or purported
to be owned (as reflected in the most recent DENTSPLY SEC
Financial Statements) by DENTSPLY or any of its Subsidiaries.

  



  

" _DENTSPLY Share Issuance_ " means the issuance of shares of DENTSPLY Common
Stock in the Merger pursuant to _Section 2.1_.

  



  

" _DENTSPLY Stock Plans_ " means, together, (i) the DENTSPLY 1998 Stock
Option Plan, (ii) the DENTSPLY 2002 Amended and Restated Equity Incentive
Plan and (iii) the DENTSPLY 2010 Amended and Restated Equity Incentive Plan.

  



  

" _DGCL_ " means the General Corporation Law of the State of Delaware, as
amended.

  



  

" _Disclosure Schedules_ " means the DENTSPLY Disclosure Schedule and the
Sirona Disclosure Schedule.

  



  

" _Environmental Claim_ " means any Proceeding, investigation, order, demand,
allegation, accusation or notice (written or oral) by any Person or entity
alleging actual or potential liability (including actual or potential
liability for investigatory costs, cleanup costs, response costs, natural
resources damages, property damages, personal injuries, attorneys' fees or
penalties) arising out of, based on, resulting from or relating to any
Environmental Laws, Environmental Permits or the presence, or Release
into the environment, of, or exposure to, any Hazardous Materials at any
location, but shall not include any claims relating to products liability.

  



    

 | 93| 
---|---|--- 

 



    



  

" _Environmental Laws_ " means any and all applicable, federal, state,
provincial, local or foreign Laws, statutes, ordinances,
regulations, treaties, policies, guidance, rules, judgments, orders, writs,
court decisions or rule of common law, stipulations, injunctions, consent
decrees, permits, restrictions and licenses, regulating or relating to
Hazardous Materials, pollution, protection of the environment (including
ambient air, surface water, ground water, land surface, subsurface strata,
wildlife, plants or other natural resources), and/or the protection of health
and safety of persons from exposures to Hazardous Materials in the
environment.

  



  

" _Environmental Permits_ " means any permit, certificate, approval,
identification number, license or other authorization required under, or
issued pursuant to, an Environmental Law.

  



  

" _Equity Interest_ " means any share, capital stock, partnership, member,
membership or similar interest in any Person, and any option, warrant,
right or security (including debt securities) convertible, exchangeable or
exercisable thereto or therefor.

  



  

" _ERISA_ " means the United States Employee Retirement Income Security Act
of 1974, as amended.

  



  

" _ERISA Affiliate_ " means any Person (whether or not incorporated) that,
together with DENTSPLY or Sirona, as applicable, is considered under
common control and treated as one employer under Section 414(b), (c), (m) or
(o) of the Code.

  



  

" _EU Merger Regulation_ " means the requirements of Council Regulation
139/2004 of the European Union, as amended.

  



  

" _Exchange Act_ " means the Securities Exchange Act of 1934, as amended, and
the rules and regulations promulgated thereunder.

  



  

" _Expenses_ " means, with respect to any Person, all reasonable and
documented out-of-pocket fees and expenses (including all fees and
expenses of counsel, accountants, financial advisors and investment bankers
of such Person and its affiliates), incurred by such Person or on its behalf
in connection with or related to the authorization, preparation, negotiation,
execution and performance of this Agreement and the Transactions, any
litigation with respect thereto, the preparation, printing, filing and mailing
of the Joint Proxy Statement or Form S-4, the filing of any required notices
under the HSR Act or foreign antitrust, competition, investment, trade
regulation or similar Laws, or in connection with other regulatory approvals,
and all other matters related to the Merger or the other Transactions.

  



  

" _GAAP_ " means generally accepted accounting principles as applied in the
United States.

  



    

 | 94| 
---|---|--- 

 



    



  

" _Government Official_ " means (i) any official, officer, employee,
representative or any person acting in an official capacity for or on behalf
of any Governmental Entity; (ii) any political party or party official or
candidate for political office; (iii) any public international organization
or any department or agency thereof; or (iv) any Person or other entity owned
in whole or in part, or controlled by any Person described in the foregoing
clauses (i), (ii) or (iii) of this definition.

  



  

" _Governmental Entity_ " means any national, federal, state, county,
municipal, local or foreign government, or other political
subdivision thereof, any entity exercising executive, legislative, judicial,
regulatory, taxing or administrative functions of or pertaining to
government, and any arbitrator or arbitral body or panel of competent
jurisdiction.

  



  

" _group_ " has the meaning ascribed to in the Exchange Act, except where the
context otherwise requires.

  



  

" _Hazardous Materials_ " means any pollutants, chemicals, contaminants or
wastes and any other toxic, infectious, carcinogenic, reactive, corrosive,
ignitable, flammable or otherwise hazardous substance, whether solid, liquid
or gas, that is subject to regulation, control or remediation under any
Environmental Laws, including any quantity of asbestos in any form, urea
formaldehyde, PCBs, radon gas, crude oil or any fraction thereof, all forms
of natural gas, petroleum products or by-products or derivatives.

  



  

" _Health Care Laws_ " means: (i) the Federal Food, Drug, and Cosmetic Act
and the regulations promulgated thereunder; (ii) the Controlled Substances
Act (21 U.S.C.  801 et seq.); (iii) the Public Health Service Act (42 U.S.C.
 201 et seq.); (iv) all applicable federal, state, local and all applicable
foreign health care related fraud and abuse, false claims, and anti-
kickback laws, including, without limitation, the U.S. Anti-Kickback Statute
(42 U.S.C.  1320a-7b(b)), the Stark law (42 U.S.C.  1395nn), the U.S.
Physician Payment Sunshine Act (42 U.S.C.  1320a-7h) and similar gift and
disclosure Laws, the U.S. Civil False Claims Act (31 U.S.C.  3729 et seq.),
the criminal False Claims Law (42 U.S.C.  1320a-7b(a)), all criminal laws
relating to health care fraud and abuse, including but not limited to 18
U.S.C.  286 and 287, and the health care fraud criminal provisions under
the U.S. Health Insurance Portability and Accountability Act of 1996 ("
_HIPAA_ ") (42 U.S.C.  1320d et seq.), the exclusion laws (42 U.S.C. 
1320a-7), the civil monetary penalties law (42 U.S.C.  1320a-7a), HIPAA, as
amended by the Health Information Technology for Economic and Clinical Health
Act (42 U.S.C.  17921 et seq.), Laws pertaining to privacy, data protection
and information security, and the regulations promulgated pursuant to such
statutes; (v) state Laws relating to the manufacture, sale and distribution of
dental and medical products; (vi) Medicare (Title XVIII of the Social
Security Act) and (vii) Medicaid (Title XIX of the Social Security Act).

  



  

" _HSR Act_ " means the Hart-Scott-Rodino Antitrust Improvements Act of 1976,
as amended, and the rules and regulations thereunder.

  



    

 | 95| 
---|---|--- 

 



    



  

" _Intellectual Property_ " means all domestic and foreign intellectual
property rights, including all (a) inventions (whether or not patentable and
whether or not reduced to practice), all improvements thereto, and all
patents, patent applications, and patent disclosures, together with all
provisionals, reissues, continuations, continuations-in-part, divisions,
revisions, extensions, and reexaminations thereof, (b) trademarks, service
marks, trade names, trade dress, logos, corporate names, brand names and other
source indicators, together with all translations, adaptations, derivations,
and combinations thereof, and all applications, registrations, and
renewals in connection therewith, (c) domain names, uniform resource locators
and other names and locators associated with the Internet, and all
registrations in connection therewith, (d) works of authorship (whether or not
published), and all copyrights, designs and mask works, and all
registrations, applications and renewals in connection therewith, (e) software
and all website content (including text, graphics, images, audio, video and
data) and (f) trade secrets, confidential business information, and other
proprietary information (including ideas, know-how, formulas, compositions,
processes and techniques, research and development information, data,
designs, drawings, specifications, research records, records of inventions,
test information, financial, marketing and business data, pricing and cost
information, business and marketing plans and proposals and customer and
supplier lists and information).

  



  

" _IRS_ " means the United States Internal Revenue Service.

  



  

" _IT Assets_ " means computers, software, servers, workstations, routers,
hubs, switches, circuits, networks, data communications lines and all other
information technology equipment.

  



  

" _Joint Proxy Statement_ " means a proxy statement or similar disclosure
document or circular relating to the DENTSPLY Shareholders Meeting and the
Sirona Shareholders Meeting.

  



  

" _Knowledge_ " and " _known_ " means the actual knowledge of the officers of
Sirona set forth in _Section 8.3(a)_ of the Sirona Disclosure Schedule or of
the officers of DENTSPLY set forth in _Section 8.3(a)_ of the DENTSPLY
Disclosure Schedule, as the case may be.

  



  

" _Law_ " means any federal, state, provincial, municipal, local or foreign
law, statute, code, ordinance, rule, regulation, circular, order, judgment,
writ, stipulation, award, injunction, decree or arbitration award or finding.

  



  

" _Lien_ " means any lien, mortgage, pledge, conditional or installment sale
agreement, encumbrance, defect in title, covenant, condition, restriction,
charge, option, right of first refusal, easement, security interest, deed of
trust, right-of-way, encroachment, community property interest or other claim
or restriction of any nature, whether voluntarily incurred or arising by
operation of Law (including any restriction on the voting of any security,
any restriction on the transfer of any security or other asset, and any
restriction on the possession, exercise or transfer of any other attribute of
ownership of any asset).

  



  

" _NASDAQ_ " means the NASDAQ Global Select Market.

  



  

" _Order_ " means any order, writ, injunction, decree, circular, judgment,
award, injunction, settlement or stipulation issued, promulgated, made,
rendered, entered into or enforced by or with any Governmental Entity (in each
case, whether temporary, preliminary or permanent).

  



  

" _Other Covered Party_ " means any political party or party official, or any
candidate for political office.

  



    

 | 96| 
---|---|--- 

 



    



  

" _Permitted Liens_ " means (i) Liens for current Taxes, or governmental
assessments, charges or claims of payment not yet past due or the amount or
validity of which is being contested in good faith by appropriate Proceedings
and for which adequate reserves in accordance with GAAP have been established
in the latest financial statements of DENTSPLY included in the DENTSPLY SEC
Documents or Sirona included in the Sirona SEC Documents, as the case may be,
(ii) mechanics', workmen's, repairmen's, warehousemen's and carriers' Liens
arising in the ordinary course of business consistent with past practice for
sums not yet due and payable, (iii) any such matters of record, Liens and
other imperfections of title that do not and would not reasonably be
expected to, individually or in the aggregate, materially impair the
continued ownership, use and operation of the assets to which they relate and
(iv) restrictions on transfers under applicable securities Laws.

  



  

" _Person_ " means an individual, corporation, limited company, limited
liability company, partnership, association, trust, unincorporated
organization, Governmental Entity, other entity or group (as defined in
Section 13(d) of the Exchange Act).

  



  

" _Proceeding_ " means any suit, action, proceeding, arbitration, mediation,
audit, hearing, inquiry or, to the Knowledge of the Person in
question, investigation (in each case, whether civil, criminal,
administrative, investigative, formal or informal) commenced, brought,
conducted or heard by or before, or otherwise involving, any Governmental
Entity.

  



  

" _Release_ " means disposing, discharging, injecting, spilling, leaking,
pumping, pouring, leaching, dumping, emitting, escaping or emptying into or
upon the indoor or outdoor environmental, including any soil, sediment,
subsurface strata, surface water, groundwater, ambient air, the atmosphere or
any other media.

  



  

" _Representatives_ " means, with respect to any Person, such Person's
officers, directors, employees, accountants, legal counsel, financial
advisors, consultants, financing sources and other advisors and
representatives.

  



  

" _SEC_ " means the Securities and Exchange Commission.

  



  

" _Securities Act_ " means the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder.

  



  

" _Sirona Disclosure Schedule_ " means the disclosure schedule delivered by
Sirona to DENTSPLY prior to the execution of this Agreement.

  



  

" _Sirona Leased Real Property_ " means all real property leased, subleased,
or otherwise occupied pursuant to an occupancy agreement by Sirona or any of
its Subsidiaries.

  



    

 | 97| 
---|---|--- 

 



    



  

" _Sirona Material Adverse Effect_ " means any change, event, development,
condition, occurrence or effect that is, or would reasonably be expected to
be, materially adverse to the business, condition (financial or otherwise),
assets, liabilities or results of operations of Sirona and its Subsidiaries,
taken as a whole; _provided_ , _however_ , that none of the following shall be
deemed in themselves, either alone or in combination, to constitute, and none
of the following shall be taken into account in determining whether there has
been or will be, a Sirona Material Adverse Effect: (i) any changes resulting
from general market, economic, financial, capital markets or political or
regulatory conditions, (ii) any changes or proposed changes of Law or GAAP
(or, in each case, authoritative interpretations thereof), (iii) any changes
resulting from any act of terrorism, war, national or international calamity,
or any worsening thereof, (iv) any changes generally affecting the industries
in which Sirona and its Subsidiaries conduct their businesses, (v) any
changes resulting from the execution of this Agreement or the announcement or
the pendency of the Merger, including any loss of employees or customers, any
cancellation of or delay in customer orders or any disruption in or
termination of (or loss of or other negative effect or change with respect to)
customer, supplier, distributor or similar business relationships or
partnerships resulting from the Transactions (provided, that this clause (v)
does not apply in the context of the representations and warranties set forth
in _Section 3.4_), (vi) changes in Sirona's stock price or the trading
volume of Sirona's stock or any change in the credit rating of Sirona (but
not, in each case, the underlying cause of any such changes, unless such
underlying cause would otherwise be excepted from this definition), (vii) any
changes or effects resulting from any action required to be taken by the
terms of this Agreement, (viii) the failure to meet internal or
analysts' expectations, projections or results of operations (but not, in
each case, the underlying cause of any such changes, unless such underlying
cause would otherwise be excepted from this definition), or (ix) any
Proceeding arising from or relating to the Merger or the other Transactions;
_provided_ , that in the case of clauses (i), (ii), (iii) and (iv), if and
only to the extent such changes do not have a disproportionate impact on
Sirona and its Subsidiaries, taken as a whole, as compared to other
participants in the industries in which Sirona and its Subsidiaries conduct
their businesses.

  



  

" _Sirona Owned Real Property_ " means all real property owned or purported
to be owned (as reflected in the most recent Sirona SEC Financial Statements)
by Sirona or any of its Subsidiaries.

  



  

" _Sirona Stock Plans_ " means, together, (i) the Sirona 2015 Long-Term
Incentive Plan, (ii) the Sirona 2006 Equity Incentive Plan, (iii) the Schick
Technologies 1997 Stock Option Plan for Non-Employee Directors and (iv) the
Schick Technologies 1996 Stock Option Plan.

  



  

" _Subsidiary_ " means, with respect to any Person, any corporation,
partnership, joint venture or other legal entity of which such Person
(either alone or through or together with any other Subsidiary), owns,
directly or indirectly, a majority of the stock or other Equity Interests the
holders of which are generally entitled to vote for the election of the board
of directors or other governing body of such corporation, partnership, joint
venture or other legal entity, or any Person that would otherwise be deemed a
"subsidiary" under Rule 12b-2 promulgated under the Exchange Act.

  



  

" _Tax Return_ " means any report, return (including information return),
claim for refund, election, estimated tax filing, declaration or
similar filing supplied or required to be supplied to any Governmental Entity
with respect to Taxes, including any election, notification, appendix
schedule or attachment thereto, and including any amendments thereof.

  



    

 | 98| 
---|---|--- 

 



    



  

" _Taxes_ " means any and all domestic or foreign, federal, state, local or
other taxes, of any kind (together with any and all interest,
penalties, additions to tax and additional amounts imposed with respect
thereto) imposed by any Governmental Entity, including taxes on or with
respect to income, franchise, windfall or other profits, gross receipts,
occupation, severance, alternative minimum, disability, estimated, property,
escheat or unclaimed property, sales, use, net worth, capital stock, payroll,
employment, social security, workers' compensation, unemployment
compensation, and taxes in the nature of excise, withholding, ad valorem,
stamp, transfer, value-added, gains tax and license, registration and
documentation fees, and other taxes, fees, levies, duties, tariffs,
imposts, assessments, obligations and charges of the same or a similar nature
to any of the foregoing.

  



  

" _Willful Breach_ " means a material breach of this Agreement that is the
consequence of an act or omission by a party with the actual knowledge
that the taking of such act or failure to take such action would be a
material breach of this Agreement.

  



  

8.4 _Terms Defined Elsewhere_. The following terms are defined
elsewhere in this Agreement, as indicated below: 

  



     " _Agreemen_ t"  |   | Preamble 
---|---|--- 
     |   | 
   " _Amended and Restated DENTSPLY Charter_ "  |   | Section 1.4(b) 
     |   | 
   " _Certificate of Merger_ "  |   | Section 1.3(a) 
     |   | 
   " _Closing_ "  |   | Section 1.2 
     |   | 
   " _Closing Date_ "  |   | Section 1.2 
     |   | 
   " _Common Shares Trust_ "  |   | Section 2.4(b) 
     |   | 
   " _Competing Proposal_ "  |   | Section 5.4(g)(i) 
     |   | 
   " _Competing Proposal Notice_ "  |   | Section 5.4(b) 
     |   | 
   " _Confidentiality Agreement_ "  |   | Section 5.5(a) 
     |   | 
   " _DENTSPLY_ "   |   | Preamble 
     |   | 
   " _DENTSPLY Adverse Recommendation Change_ "  |   | Section 5.3(c)(ii) 
     |   | 
   " _DENTSPLY Benefit Plan_ "  |   | Section 4.11(a) 
     |   | 
   " _DENTSPLY Board_ "  |   | Section 4.3(b) 
     |   | 
   " _DENTSPLY Business Personnel_ " __   |   | Section 4.12(a) 
     |   | 
   " _DENTSPLY Bylaws_ "  |   | Section 4.1 
     |   | 
   " _DENTSPLY Charter_ "  |   | Section 4.1 
  



    

 | 99| 
---|---|--- 

 



    



     " _DENTSPLY Common Stock_ "  |   | Section 2.1(b) 
---|---|--- 
     |   | 
   " _DENTSPLY Foreign Benefit Plan_ "  |   | Section 4.11(j) 
     |   | 
   " _DENTSPLY Material Contracts_ "  |   | Section 4.16(c) 
     |   | 
   " _DENTSPLY Material Intellectual Property_ "  |   | Section 4.17(d) 
     |   | 
   " _DENTSPLY Preferred Stock_ "  |   | Section 4.2(a) 
     |   | 
   " _DENTSPLY Real Property_ "  |   | Section 4.14(c) 
     |   | 
   " _DENTSPLY Recommendation_ "  |   | Section 4.3(b) 
     |   | 
   " _DENTSPLY Registered Intellectual Property_ "  |   | Section 4.17(a) 
     |   | 
   " _DENTSPLY RSU_ "  |   | Section 2.6(b) 
     |   | 
   " _DENTSPLY SEC Documents_ "  |   | Section 4.5(a) 
     |   | 
   " _DENTSPLY SEC Financial Statements_ "  |   | Section 4.5(c) 
     |   | 
   " _DENTSPLY Shareholder Approval_ "  |   | Section 4.3(c) 
     |   | 
   " _DENTSPLY Shareholders Meeting_ "  |   | Section 5.3(c)(i) 
     |   | 
   " _DENTSPLY Stock Option_ "  |   | Section 2.6(a) 
     |   | 
   " _DENTSPLY Tax Opinion_ "  |   | Section 6.2(d) 
     |   | 
   " _DENTSPLY Tax Opinion Materials_ "  |   | Section 5.14(b) 
     |   | 
   " _DENTSPLY Termination Fee_ "  |   | Section 7.3(b) 
     |   | 
   " _Divestiture_ "  |   | Section 5.6(c) 
     |   | 
   " _D andO Insurance_"  |   | Section 5.9(c) 
     |   | 
   " _Effective Time_ "  |   | Section 1.3(b) 
     |   | 
   " _Excess Shares_ "  |   | Section 2.4(a) 
     |   | 
   " _Exchange Agent_ "  |   | Section 2.5(a) 
  



    

 | 100| 
---|---|--- 

 



    



     " _Exchange Fund_ "  |   | Section 2.5(a) 
---|---|--- 
     |   | 
   " _Exchange Ratio_ "  |   | Section 2.1(b) 
     |   | 
   " _FCPA_ "  |   | Section 3.9(b) 
     |   | 
   " _FDA_ "  |   | Section 3.18(b) 
     |   | 
   " _FDA Permits_ "  |   | Section 3.18(b) 
     |   | 
   " _Form S-4_ "  |   | Section 3.7 
     |   | 
   " _Fractional Shares Cash Amount_ "  |   | Section 2.4(b) 
     |   | 
   " _Indemnitee_ "  |   | Section 5.9(a) 
     |   | 
   " _Intended Tax Treatment_ "  |   | Section 5.14(a) 
     |   | 
   " _Intervening Event_ "  |   | Section 5.4(g)(ii) 
     |   | 
   " _Merger_ "  |   | Section 1.1(a) 
     |   | 
   " _Merger Consideration_ "  |   | Section 2.1(b) 
     |   | 
   " _Merger Sub_ "  |   | Preamble 
     |   | 
   " _Multiemployer Plan_ "  |   | Section 3.11(e) 
     |   | 
   " _Negotiation Period_ "  |   | Section 5.4(b) 
     |   | 
   " _OFAC_ "  |   | Section 3.9(e) 
     |   | 
   " _Outside Date_ "  |   | Section 7.1(b)(ii) 
     |   | 
   " _Permits_ "  |   | Section 3.10 
     |   | 
   " _Safety Notices_ "  |   | Section 3.18(e) 
     |   | 
   " _Sarbanes-Oxley Act_ "  |   | Section 3.5(d) 
     |   | 
   " _Second Merger_ "  |   | Section 5.14(d) 
     |   | 
   " _Sirona_ "  |   | Preamble 
     |   | 
   " _Sirona Adverse Recommendation Change_ "  |   | Section 5.3(b)(ii) 
     |   | 
   " _Sirona Benefit Plan_ "  |   | Section 3.11(a) 
  



    

 | 101| 
---|---|--- 

 



    



     " _Sirona Board_ "  |   | Section 3.3(b) 
---|---|--- 
     |   | 
   " _Sirona Book-Entry Shares_ "  |   | Section 2.1(c) 
     |   | 
   " _Sirona Business Personnel_ "  |   | Section 3.12(a) 
     |   | 
   " _Sirona Bylaws_ "  |   | Section 3.1 
     |   | 
   " _Sirona Certificate_ "  |   | Section 2.1(c) 
     |   | 
   " _Sirona Charter_ "  |   | Section 3.1 
     |   | 
   " _Sirona Common Stock_ "  |   | Section 2.1 
     |   | 
   " _Sirona Foreign Benefit Plan_ "  |   | Section 3.11(j) 
     |   | 
   " _Sirona Material Contract_ "  |   | Section 3.16(c) 
     |   | 
   " _Sirona Material Intellectual Property_ "  |   | Section 3.17(d) 
     |   | 
   " _Sirona Performance Units_ "  |   | Section 3.2(a) 
     |   | 
   " _Sirona Preferred Stock_ "  |   | Section 3.2(a) 
     |   | 
   " _Sirona Real Property_ "  |   | Section 3.14(c) 
     |   | 
   " _Sirona Recommendation_ "  |   | Section 3.3(b) 
     |   | 
   " _Sirona Registered Intellectual Property_ "  |   | Section 3.17(a) 
     |   | 
   " _Sirona RSU_ "  |   | Section 2.6(b) 
     |   | 
   " _Sirona SEC Documents_ "  |   | Section 3.5(a) 
     |   | 
   " _Sirona SEC Financial Statements_ "  |   | Section 3.5(c) 
     |   | 
   " _Sirona Shareholder Approval_ "  |   | Section 3.3(c) 
     |   | 
   " _Sirona Shareholders Meeting_ "  |   | Section 5.3(b)(i) 
     |   | 
   " _Sirona Stock Option_ "  |   | Section 2.6(a) 
     |   | 
   " _Sirona Tax Opinion_ "  |   | Section 6.3(d) 
     |   | 
   " _Sirona Tax Opinion Materials_ "  |   | Section 5.14(c) 
  



    

 | 102| 
---|---|--- 

 



    



     " _Sirona Termination Fee_ "  |   | Section 7.3(d) 
---|---|--- 
     |   | 
   " _Superior Proposal_ "  |   | Section 5.4(g)(iii) 
     |   | 
   " _Surviving Corporation_ "  |   | Section 1.1(a) 
     |   | 
   " _Transactions_ "  |   | Section 1.1(a) 
  



  

8.5 _Headings_. The headings contained in this Agreement are for
reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.

  



  

8.6 _Severability_. If any term or other provision of this Agreement
is invalid, illegal or incapable of being enforced by any rule of Law or
public policy, all other conditions and provisions of this Agreement shall
nevertheless remain in full force and effect so long as the economic or legal
substance of the Transactions is not affected in any manner materially adverse
to any party. Upon such determination that any term or other provision is
invalid, illegal or incapable of being enforced, the parties shall negotiate
in good faith to modify this Agreement so as to effect the original intent of
the parties as closely as possible in an acceptable manner to the end that
the Transactions are fulfilled to the extent possible.

  



  

8.7 _Entire Agreement_. This Agreement (together with the Exhibits,
the DENTSPLY Disclosure Schedules, the Sirona Disclosure Schedules and the
other documents delivered pursuant hereto) and the Confidentiality Agreement
constitute the entire agreement of the parties and supersede all prior
agreements and undertakings, both written and oral, among the parties, or any
of them, with respect to the subject matter hereof and, except as otherwise
expressly provided herein or therein, are not intended to confer upon any
other Person any rights or remedies hereunder or thereunder.

  



  

8.8 _Assignment_. Neither this Agreement nor any of the rights,
interests or obligations hereunder shall be assigned by any of the parties
hereto, in whole or in part (whether by operation of law or otherwise),
without the prior written consent of the other parties, and any attempt to
make any such assignment without such consent shall be null and void. Subject
to the preceding sentence, this Agreement will be binding upon, inure to the
benefit of and be enforceable by the parties and their respective successors
and assigns.

  



  

8.9 _Parties in Interest_. This Agreement shall be binding upon and
inure solely to the benefit of the parties and their respective
successors and assigns, and nothing in this Agreement, express or implied,
other than pursuant to _Section 5.9_ , is intended to or shall confer upon
any other Person any right, benefit or remedy of any nature whatsoever under
or by reason of this Agreement.

  



    

 | 103| 
---|---|--- 

 



    



  

8.10 _Mutual Drafting; Interpretation_. Each party has participated in
the drafting of this Agreement, which each party acknowledges is the result
of extensive negotiations between the parties. If an ambiguity or question of
intent or interpretation arises, this Agreement shall be construed as if
drafted jointly by the parties, and no presumption or burden of proof shall
arise favoring or disfavoring any party by virtue of the authorship of any
provision. For purposes of this Agreement, whenever the context requires: the
singular number shall include the plural, and vice versa; the masculine
gender shall include the feminine and neuter genders; the feminine gender
shall include the masculine and neuter genders; and the neuter gender shall
include masculine and feminine genders. As used in this Agreement, the words
"include" and "including," and variations thereof, shall not be deemed to be
terms of limitation, but rather shall be deemed to be followed by the words
"without limitation." As used in this Agreement, references to a "party" or
the "parties" are intended to refer to a party to this Agreement or the
parties to this Agreement. Except as otherwise indicated, all references in
this Agreement to "Sections," "Exhibits," "Annexes" and "Schedules" are
intended to refer to Sections of this Agreement and Exhibits, Annexes
and Schedules to this Agreement. All references in this Agreement to "$" are
intended to refer to U.S. dollars. Unless otherwise specifically provided for
herein, the term "or" shall not be deemed to be exclusive. In this Agreement,
when determining whether an item is "material" to DENTSPLY or its Subsidiary
or Sirona or its Subsidiary, the term "material" shall be interpreted to
mean, as applicable, "material to the business of DENTSPLY and its
Subsidiaries, taken as a whole" or "material to the business of Sirona and
its Subsidiaries, taken as a whole."

  



  

8.11 _Governing Law; Consent to Jurisdiction; Waiver of Trial by
Jury_.

  



  

(a) This Agreement shall be governed by, and construed in accordance
with, the Laws of the State of Delaware, without regard to laws that may be
applicable under conflicts of laws principles (whether of the State of
Delaware or any other jurisdiction) that would cause the application of the
Laws of any jurisdiction other than the State of Delaware.

  



  

(b) Each of the parties hereby irrevocably and unconditionally
submits, for itself and its property, to the exclusive jurisdiction of
the Court of Chancery of the State of Delaware or, if such court shall not
have jurisdiction, any federal court of the United States of America, sitting
in Delaware, and any appellate court from any thereof, in any Proceeding
arising out of or relating to this Agreement or the transactions contemplated
hereby or for recognition or enforcement of any judgment relating thereto, and
each of the parties hereby irrevocably and unconditionally (i) agrees not to
commence any such Proceeding except in such courts, (ii) agrees that any
claim in respect of any such Proceeding may be heard and determined in the
Court of Chancery of the State of Delaware or, to the extent permitted by
Law, in such federal court, (iii) waives, to the fullest extent it may
legally and effectively do so, any objection which it may now or hereafter
have to the laying of venue of any such Proceeding in any such court, and
(iv) waives, to the fullest extent permitted by Law, the defense of an
inconvenient forum to the maintenance of such Proceeding in any such court.
Each of the parties agrees that a final judgment in any such Proceeding shall
be conclusive and may be enforced in other jurisdictions by suit on the
judgment or in any other manner provided by Law. Each party to this
Agreement irrevocably consents to service of process in the manner provided
for notices in _Section 8.2_. Nothing in this Agreement will affect the right
of any party to this Agreement to serve process in any other manner permitted
by Law.

  



    

 | 104| 
---|---|--- 

 



    



  

(c) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH
MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND
DIFFICULT ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY
WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION
DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT AND ANY OF
THE AGREEMENTS DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS
CONTEMPLATED HEREBY OR THEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I)
NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED,
EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT
OF LITIGATION, SEEK TO ENFORCE EITHER OF SUCH WAIVERS, (II) IT UNDERSTANDS
AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVERS, (III) IT MAKES SUCH
WAIVERS VOLUNTARILY, AND (IV) IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT
BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS
_SECTION 8.11(c)_.

  



  

8.12 _Counterparts_. This Agreement may be executed in one or more
counterparts, and by the different parties hereto in separate counterparts,
each of which when executed shall be deemed to be an original but all of
which taken together shall constitute one and the same agreement.

  



  

8.13 _Delivery by Facsimile or Email_. This Agreement, and any
amendments hereto, waivers hereof or consents or notifications hereunder,
to the extent signed and delivered by facsimile or by email with scan
attachment, shall be treated in all manner and respects as an original
contract and shall be considered to have the same binding legal effects as if
it were the original signed version thereof delivered in person. At the
request of any party, each other party shall re-execute original forms thereof
and deliver them to all other parties. No party shall raise the use of
facsimile or email to deliver a signature or the fact that any signature
or Contract was transmitted or communicated by facsimile or email with scan
attachment as a defense to the formation of a legally binding contract, and
each such party forever waives any such defense.

  



  

8.14 _Specific Performance_. The parties agree that irreparable damage
would occur in the event that any of the provisions of this Agreement were
not performed in accordance with their specific terms or were otherwise
breached. It is accordingly agreed that the parties shall be entitled to an
injunction or injunctions to prevent actual or threatened breaches of this
Agreement and to enforce specifically the terms and provisions hereof in any
court of the United States or any state or foreign jurisdiction having
jurisdiction, this being in addition to any other remedy to which they are
entitled at Law or in equity. The parties waive, in connection with
any action for specific performance or injunctive relief, the defense of
adequacy of remedies at Law and any requirement under Law to post a bond or
other security as a prerequisite to obtaining equitable relief.

  



  

8.15 _Disclosure Schedules_. The parties acknowledge and agree that
(a) the inclusion of any items or information in the Disclosure
Schedules that are not required by this Agreement to be so included is solely
for the convenience of parties, (b) the disclosure by the parties of any
matter in the Disclosure Schedules shall not be deemed to constitute an
acknowledgement by any party that the matter is required to be disclosed by
the terms of this Agreement or that the matter is material or significant, (c)
if any section of the Disclosure Schedules lists an item or information in
such a way as to make its relevance to the disclosure required by or
provided in another section of the Disclosure Schedules or the statements
contained in any Section of this Agreement reasonably apparent, the matter
shall be deemed to have been disclosed in or with respect to such other
section, notwithstanding the omission of an appropriate cross-reference to
such other section or the omission of a reference in the particular
representation and warranty to such section of the Disclosure Schedules, (d)
except as provided in clause (c) above, headings have been inserted in the
Disclosure Schedules for convenience of reference only, (e) the Disclosure
Schedules are qualified in their entirety by reference to specific provisions
of this Agreement and (f) the Disclosure Schedules and the information and
statements contained therein are not intended to constitute, and shall not be
construed as constituting, representations or warranties of the parties except
as and to the extent provided in this Agreement.

  



  

 _[Remainder of page left intentionally blank]_

  



    

 | 105| 
---|---|--- 

 



    



  

IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to
be executed as of the date first written above by their respective
officers thereunto duly authorized.

  



       | DENTSPLY INTERNATIONAL INC. 
---|--- 
     |   | 
     | By:  | 
   

       | Name:  | 
---|---|--- 
     | Title:  | 
     |   | 
   

       | SIRONA DENTAL SYSTEMS, INC. 
---|--- 
     |   | 
     | By:  | 
   

       | Name:  | 
---|---|--- 
     | Title:  | 
     |   | 
   

       | DAWKINS MERGER SUB INC. 
---|--- 
     |   | 
     | By:  | 
   

       | Name:  | 
---|---|--- 
     | Title:  | 
  



  

[Signature Page to Merger Agreement]

  



  

   



 



    



  

 _Exhibit A_

  



  

FORM OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

  



  

OF

  



  

SIRONA DENTAL SYSTEMS, INC.

  



  

 _FIRST_ : The name of the Corporation is Sirona Dental Systems, Inc. (the "
_Corporation_ ").

  



  

 _SECOND_ : The address of the registered office in the State of Delaware is
Corporation Trust Center, 1209 Orange Street, in the City of Wilmington,
County of New Castle, Delaware 19801. The name of its registered agent at
such address is The Corporation Trust Company.

  



  

 _THIRD_ : The purpose of the Corporation is to engage in any lawful act or
activity for which a corporation may be organized under the General
Corporation Law of the State of Delaware as set forth in Title 8 of the
Delaware Code (the " _GCL_ ").

  



  

 _FOURTH_ : The total number of shares of stock which the Corporation shall
have authority to issue is one thousand (1,000) shares of Common Stock, each
having a par value of one cent ($0.01) per share.

  



  

 _FIFTH_ : The following provisions are inserted for the management of the
business and the conduct of the affairs of the Corporation, and for further
definition, limitation and regulation of the powers of the Corporation and of
its directors and stockholders:

  



  

(1) The business and affairs of the Corporation shall be managed by
or under the direction of the Board of Directors of the Corporation (the "
_Board of Directors_ ").

  



  

(2) The directors shall have concurrent power with the stockholders
to make, alter, amend, change, add to or repeal the By-Laws of
the Corporation.

  



  

(3) The number of directors of the Corporation shall be as from time
to time fixed by, or in the manner provided in, the By-Laws of
the Corporation. Election of directors need not be by written ballot unless
the By-Laws so provide.

  



  

(4) A director shall not be personally liable to the Corporation or
the stockholders for monetary damages for breach of fiduciary duty as a
director, except (i) for any breach of the duty of loyalty of such director to
the Corporation or such holders, (ii) for acts or omissions not in good faith
or which involve intentional misconduct or a knowing violation of law, (iii)
under Section 174 of the GCL and (iv) for any transaction from which such
director derives an improper personal benefit. If the GCL is hereafter
amended to authorize corporate action further eliminating or limiting the
personal liability of directors, then the liability of a director shall be
eliminated or limited to the fullest extent permitted by the GCL, as so
amended. No repeal or modification of this Article FIFTH shall adversely
affect any right of or protection afforded to a director prior to such repeal
or modification.

  



    



 



    



  

(5) In addition to the powers and authority hereinbefore or by
statute expressly conferred upon them, the directors are hereby empowered to
exercise all such powers and do all such acts and things as may be exercised
or done by the Corporation, subject, nevertheless, to the provisions of the
GCL, this Certificate of Incorporation, and any By-Laws adopted by the
stockholders; provided, however, that no By-Laws hereafter adopted by the
stockholders shall invalidate any prior act of the directors which would have
been valid if such By-Laws had not been adopted.

  



  

 _SIXTH_ : Meetings of stockholders may be held within or without the State
of Delaware, as the By-Laws may provide. The books of the Corporation may be
kept (subject to any provision contained in the GCL) outside the State of
Delaware at such place or places as may be designated from time to time by
the Board of Directors or in the By-Laws of the Corporation.

  



  

 _SEVENTH_ : The Corporation reserves the right to amend, alter, change or
repeal any provision contained in this Certificate of Incorporation, in the
manner now or hereafter prescribed by statute, and all rights conferred upon
stockholders herein are granted subject to this reservation.

  



    



 



    



  

 _Exhibit B_

  



  

FORM OF SECOND AMENDED AND RESTATED CERTIFICATE OF 
 INCORPORATION OF

  

DENTSPLY INTERNATIONAL INC.

  



  

The present name of the corporation is DENTSPLY International Inc. (the "
_Corporation_ "). The name under which the Corporation was originally
incorporated is Gendex Corporation. The date of filing of the Corporation's
original Certificate of Incorporation with the Secretary of State of the
State of Delaware was February 15, 1983. The Corporation's Amended
and Restated Certificate of Incorporation was duly adopted in accordance with
the provisions of Sections 242 and 245 of the General Corporation Law of the
State of Delaware and it amended and restated the provisions of the
Certificate of Incorporation of the Corporation. The date of filing of the
Corporation's Amended and Restated Certificate of Incorporation with the
Secretary of State of the State of Delaware was July 11, 2013.

  



  

This Second Amended and Restated Certificate of Incorporation of the
Corporation, which restates and integrates and also further amends the
provisions of the Corporation's Amended and Restated Certificate of
Incorporation, was duly adopted in accordance with the provisions of Sections
242 and 245 of the General Corporation Law of the State of Delaware.

  



  

The Amended and Restated Certificate of Incorporation is hereby amended,
integrated and restated to read in its entirety as follows:

  



   | 1.| The name of the corporation is DENTSPLY SIRONA Inc. 
---|---|--- 
  



   | 2.| The address of its registered office in the State of Delaware is
Corporation Trust Center, 1209 Orange Street, in the City of Wilmington,
County of New Castle, Delaware 19801. The name of the registered agent at such
address is The Corporation Trust Company. 
---|---|--- 
  



   | 3.| The nature and business or purposes to be conducted or promoted
is: To engage in any lawful act or activity for which corporations may be
organized under the General Corporation Law of the state of Delaware. 
---|---|--- 
  



   | 4A.| _Number of Shares and Classes_. The aggregate number  of shares
of stock which the Corporation shall have authority to issue is Four Hundred 
Million Two Hundred Fifty Thousand (400,250,000) shares, which shall be
divided into  two classes as follows: 
---|---|--- 
  



   | (1)| Four Hundred Million (400,000,000) shares of Common Stock, par
value One Cent ($.01) per share; and 
---|---|--- 
  



    



 



    



   | (2)| Two Hundred Fifty Thousand (250,000) shares of Preferred Stock,
par value One Dollar ($1.00) per share. 
---|---|--- 
  



   | 4B.| _Preferred Stock_. The Corporation's board of directors  is
hereby expressly authorized to provide by resolution or resolutions from time
to time  for the issue of the Preferred Stock in one or more series, the
shares of each of which  series may have such voting powers, full or limited,
or no voting powers, and such designations,  preferences and relative,
participating, optional or other special rights, and qualification, 
limitations or restrictions thereof, as shall be permitted under the General
Corporation  Law of the State of Delaware and as shall be stated in the
resolution or resolutions  providing for the issue of such stock adopted by
the board of directors pursuant to the  authority expressly vested in the
board of directors hereby. 
---|---|--- 
  



   | 4C.| _Common Stock_. 
---|---|--- 
  



   | (1)| _Voting_. Except as otherwise required by the General
Corporation Law of the State of Delaware, this Second Amended and Restated
Certificate of Incorporation or any series of Preferred Stock designated by
the board of directors, all of the voting power of the Corporation shall be
vested in the holders of the Common Stock and each holder of the Common Stock
shall have one (1) vote for each share of such Common Stock held by him of
record on all matters voted upon by the Stockholders. 
---|---|--- 
  



   | (2)| _Dividends_. Subject to the terms of any series of Preferred
Stock, the board of directors of the Corporation may declare a dividend on
the Common Stock out of the remaining unreserved and unrestricted surplus of
the Corporation, and the holders of the Common Stock shall share ratably in
such dividend in proportion to the number of shares of such Common Stock held
by each. 
---|---|--- 
  



   | (3)| _Liquidation_. Except as otherwise required by any series of
Preferred Stock designated by the board of directors, in the event of any
voluntary or involuntary liquidation, dissolution or winding up of the
Corporation, after distribution in full of the preferential amounts to be
distributed to the holders of any series of Preferred Stock, the remaining
assets of the Corporation shall be distributed ratably among the holders of
the Common Stock in proportion to the number of shares of such Common Stock
held by each. 
---|---|--- 
  



    



 



    



   | 5.| The business and affairs of the Corporation shall be managed  by
or under the direction of a board of directors consisting of such number of
directors  as is determined from time to time by resolution adopted by
affirmative vote of a majority  of the entire board of directors or such
higher vote as may be required by the Corporation's  by-laws; provided,
however, that in no event shall the number of directors be less than  three
(3) nor more than thirteen (13). Any additional director elected to fill a
vacancy  resulting from an increase in the number of directors shall hold
office until the next  annual meeting of stockholders, but in no case will a
decrease in the number of directors  shorten the term of any incumbent
director. A director shall hold office until the annual  meeting and until
his or her successor shall be elected and shall qualify, subject, however, 
to prior death, resignation, incapacitation or removal from office. Except as
otherwise  required by law, any newly created directorship shall be filled
only by the affirmative  vote of a majority of the board of directors then in
office or such higher vote as may  be required by the Corporation's by-laws,
provided that a quorum is present, and  any vacancy occurring in the board of
directors shall be filled by a majority of the  directors then in office or
such higher vote as may be required by the Corporation's  by-laws, even if
less than a quorum, or by a sole remaining director. 
---|---|--- 
  



   | 6.| The Corporation is to have perpetual existence. 
---|---|--- 
  



   | 7.| Notwithstanding any other provision of this Second Amended and
Restated Certificate of Incorporation or the Corporation's by-laws (and
notwithstanding the fact that some lesser percentage may be specified by law,
this Second Amended and Restated Certificate of Incorporation or the
Corporation's by-laws), the Corporation's by-laws may be amended, altered or
repealed, and new by-laws enacted, only by the affirmative vote of not less
than two-thirds (2/3) in voting power of the outstanding shares of capital
stock of the Corporation entitled to vote at a meeting of stockholders duly
called for such purpose, or by a vote of not less than a majority of the
entire board of directors then in office; _provided_ that, during the period
beginning at the Effective Time (as defined in the Agreement and Plan of
Merger, dated as of September 15, 2015, among the Corporation, Sirona
Dental Systems, Inc., and Dawkins Merger Sub Inc.) and ending on the third
(3rd) anniversary of the Effective Time, the provisions of Article VII of the
Corporation's by-laws may be modified, amended or repealed by the board of
directors, and any by-law provision or other resolution inconsistent with
Article VII of the Corporation's by-laws may be adopted by the board of
directors, only by an affirmative vote of the greater of (i) at least seventy
percent (70%) of the entire board of directors and (ii) eight (8) directors. 
---|---|--- 
  



    



 



    



   | 8.| Elections of directors need not be by written ballot unless  the
by-laws of the Corporation shall so provide. 
---|---|--- 
  



   | 9.| A director of the Corporation shall not be personally liable to
the Corporation or its stockholders for monetary damages for breach of
fiduciary duty as a director except for liability (i) for any breach of the
director's duty of loyalty to the Corporation or its stockholders, (ii) for
acts or omissions not in good faith or which involve intentional misconduct or
knowing violation of law, (iii) under Section 174 of the General Corporation
Law of the State of Delaware, or (iv) for any transaction from which the
director derived any improper personal benefit. If the General Corporation Law
of the State of Delaware is hereafter amended to authorize corporate action
further eliminating or limiting the personal liability of directors, then the
liability of a director shall be eliminated or limited to the fullest extent
permitted by the General Corporation Law of the State of Delaware, as so
amended. No repeal or modification of this Section 9 shall adversely affect
any right of or protection afforded to a director prior to such repeal or
modification. 
---|---|--- 
  



   | 10.| The stockholders of the Corporation shall have no authority  to
call a special meeting of the stockholders. 
---|---|--- 
  



   | 11.| No action required to be taken or which may be taken at any
annual or special meeting of stockholders of the Corporation may be taken
without a meeting, and the power of the stockholders to consent in writing,
without a meeting, to the taking of any action is specifically denied. 
---|---|--- 
  



    



 



    



  

IN WITNESS WHEREOF, the undersigned has executed this Second Amended and
Restated Certificate of Incorporation on this [_______] day of [________],
201[__].

  



       | DENTSPLY SIRONA Inc.  | 
---|---|--- 
     |   | 
     | By:   |   | 
     | Name:   |   | 
     | Title:   |   | 
  



    



 



    



 

  

 _Exhibit C_

  



  

[_________], 201[]

  



  

DENTSPLY SIRONA INC.

  



  

FORM OF SECOND AMENDED AND RESTATED BY-LAWS

  



  

BY-LAWS INDEX

  



  

TABLE OF CONTENTS

  



       |   | PAGE 
---|---|--- 
     |   | 
   ARTICLE I STOCKHOLDERS' MEETINGS  | 1 
     | 
   Section 1.  | Annual Meetings.  | 1 
     |   | 
   Section 2.  | Special Meetings.  | 1 
     |   | 
   Section 3.  | Place of Meeting.  | 1 
     |   | 
   Section 4.  | Notice of Meeting.  | 1 
     |   | 
   Section 5.  | Fixing of Record Date.  | 2 
     |   | 
   Section 6.  | Quorum.  | 2 
     |   | 
   Section 7.  | Proxies.  | 2 
     |   | 
   Section 8.  | Voting of Shares.  | 2 
     |   | 
   Section 9.  | List of Stockholders.  | 3 
     |   | 
   Section 10.  | Waiver of Notice by Stockholders.  | 3 
     |   | 
   Section 11.  | Advance Notice of Stockholder-Proposed Business at Annual
Meetings.  | 3 
     |   | 
   Section 12.  | Procedure for Nomination of Directors.  | 5 
     |   | 
   Section 13.  | Election of Directors.  | 7 
     |   | 
   ARTICLE II BOARD OF DIRECTORS  | 7 
     | 
   Section 1.  | General Powers.  | 7 
     |   | 
   Section 2.  | Number of Directors, Tenure and Qualifications.  | 7 
     |   | 
   Section 3.  | Regular Meetings.  | 8 
   

  



   

i

 



    

  



     Section 4.  | Special Meetings.  | 8 
---|---|--- 
     |   | 
   Section 5.  | Notice.  | 8 
     |   | 
   Section 6.  | Quorum.  | 8 
     |   | 
   Section 7.  | Manner of Acting.  | 9 
     |   | 
   Section 8.  | Vacancies.  | 9 
     |   | 
   Section 9.  | Compensation.  | 9 
     |   | 
   Section 10.  | Presumption of Assent.  | 9 
     |   | 
   Section 11.  | Committees.  | 9 
     |   | 
   Section 12.  | Action of the Board by Written Consent.  | 10 
     |   | 
   Section 13.  | Conferences.  | 10 
     |   | 
   ARTICLE III OFFICERS  | 10 
     | 
   Section 1.  | Number.  | 10 
     |   | 
   Section 2.  | Election and Term of Office.  | 10 
     |   | 
   Section 3.  | Removal.  | 11 
     |   | 
   Section 4.  | Executive Chairman of the Board.  | 11 
     |   | 
   Section 5.  | Lead Independent Directors.  | 11 
     |   | 
   Section 6.  | Chief Executive Officer.  | 11 
     |   | 
   Section 7.  | Senior Vice President and Vice Presidents.  | 11 
     |   | 
   Section 8.  | Secretary and Assistant Secretaries.  | 12 
     |   | 
   Section 9.  | Treasurer and Assistant Treasurer.  | 12 
     |   | 
   Section 10.  | Salaries.  | 12 
     |   | 
   Section 11.  | Representation in Other Companies.  | 12 
     |   | 
   ARTICLE IV STOCK AND TRANSFER OF STOCK  | 13 
     | 
   Section 1.  | Shares of Stock.  | 13 
     |   | 
   Section 2.  | Transfer of Shares.  | 13 
   



  

   

ii

 



    

  



     ARTICLE V INDEMNIFICATION OF DIRECTORS, OFFICERS,  | 14 
---|--- 
     | 
   Section 1.  | Indemnification Generally.  | 14 
     |   | 
   Section 2.  | Indemnification in Actions By or In the Right Of the
Corporation.  | 14 
     |   | 
   Section 3.  | Success on the Merits; Indemnification Against Expenses. 
| 15 
     |   | 
   Section 4.  | Determination that Indemnification is Proper.  | 15 
     |   | 
   Section 5.  | Insurance; Indemnification Agreements.  | 15 
     |   | 
   Section 6.  | Advancement of Expenses.  | 15 
     |   | 
   Section 7.  | Rights Not Exclusive.  | 16 
     |   | 
   Section 8.  | Severability.  | 16 
     |   | 
   Section 9.  | Modification.  | 16 
     |   | 
   ARTICLE VI EXCLUSIVE FORUM  | 16 
     | 
   ARTICLE VII CERTAIN GOVERNANCE MATTERS  | 17 
     | 
   Section 1.  | Definitions.  | 17 
     |   | 
   Section 2.  | Composition of the Board.  | 17 
     |   | 
   Section 3.  | Chairman, Chief Executive Officer, Lead Independent
Director.  | 18 
     |   | 
   Section 4.  | Required Committees.  | 18 
     |   | 
   Section 5.  | Amendments.  | 19 
  



    

iii

 



    



  

SECOND AMENDED AND RESTATED BY-LAWS

  



  

OF

  



  

DENTSPLY SIRONA INC.

  



  

(formerly DENTSPLY International Inc.)

  



  

ARTICLE I

  


  _STOCKHOLDERS ' MEETINGS_

  



  

Section 1. _Annual Meetings_ __. The annual meeting of the
stockholders, for the purpose of electing directors and for the transaction
of such other business as may properly come before the meeting, shall be held
on such date and at such time as shall be designated from time to time by the
Board of Directors.

  



  

Section 2. _Special Meetings_ __. Except as otherwise required by
law and subject to the rights of the holders of any class or series of
capital stock having a preference over the common stock as to dividends or
upon liquidation, special meetings of stockholders of the corporation may be
called only upon the request of the Chairman of the Board or the
Chief Executive Officer and approved by a resolution adopted by the Board of
Directors.

  



  

Section 3. _Place of Meeting_ __. The Board of Directors may
designate any place, either within or without the State of Delaware, as the
place of meeting for any annual meeting, or for any special meeting called
pursuant to Article I, Section 2, above. A waiver of notice signed by all
stockholders entitled to vote at a meeting may designate any place, either
within or without the State of Delaware, as the place for the holding of such
meeting. If no designation is made, or if a special meeting shall be
otherwise called, the place of meeting shall be the principal office of the
corporation.

  



  

Section 4. _Notice of Meeting_. Written notice stating the place,
date and hour of the meeting and, in the case of a special meeting, the
purpose or purposes for which the meeting is called, shall be delivered not
less than ten (10) nor more than sixty (60) days before the date of the
meeting either personally or by mail, by or at the discretion of the Chief
Executive Officer or the officer or persons calling the meeting. If mailed,
such notice shall be deemed to be delivered when deposited in the United
States mail, addressed to the stockholder at his address as it appears on the
stock record books of the corporation, with postage thereon prepaid.

  



    



 



    



  

Section 5. _Fixing of Record Date_.

  



  

(a) For the purpose of determining stockholders entitled to notice
of or to vote at any meeting of stockholders or any adjournment thereof, the
Board of Directors of the corporation may fix, in advance, a date as the
record date for any such determination of stockholders, such date in any case
to be not more than sixty (60) nor less than ten (10) days prior to the date
of any proposed meeting of stockholders. In no event shall the stock transfer
books be closed. When a determination of stockholders entitled to vote at any
meeting of stockholders has been made as provided in this Section, such
determination shall be applied to any adjournment thereof.

  



  

(b) For the purpose of determining stockholders entitled to receive
payment of any dividend or other distribution or allotment of any rights, or
in order to make a determination of stockholders for any other lawful purpose,
the Board of Directors of the corporation may fix a date as the record date
for any such determination of stockholders, which record date shall not
precede the date upon which the resolution fixing the record date is adopted,
and which record date shall be not more than sixty (60) days prior to such
action. In no event shall the stock transfer books be closed.

  



  

Section 6. _Quorum_ __. A majority of the outstanding shares of
the corporation entitled to vote, represented in person or by proxy, shall
constitute a quorum at a meeting of stockholders. Provided that a meeting has
been duly convened in accordance herewith, any meeting of the stockholders
may be adjourned from time to time without further notice. At any adjourned
meeting at which a quorum shall be present or represented, any business may
be transacted which might have been transacted at the meeting as originally
notified. Any meeting (a) at which all of the outstanding shares are present
in person or represented by proxy and at which none of such shares attend for
the purpose of objecting, at the beginning of the meeting, to the transaction
of any business thereat because the meeting was not lawfully called or
convened, or (b) at which all of the outstanding stock has waived notice, or
(c) for which notice shall have been duly given as provided herein, shall be
deemed a properly constituted meeting of the stockholders.

  



  

Section 7. _Proxies_ __. At all meetings of stockholders, a
stockholder entitled to vote may vote by proxy appointed in writing by the
stockholder or by his duly authorized attorney in fact. Such proxy shall be
filed with the Secretary of the corporation before or at the time of
the meeting. An instrument appointing a proxy shall, unless the contrary is
stated thereon, be valid only at the meeting for which it has been given or
any adjournment thereof.

  



  

Section 8. _Voting of Shares_ __. At each meeting of stockholders,
every stockholder entitled to vote thereat shall be entitled to vote in
person or by a duly authorized proxy, which proxy may be appointed by an
instrument in writing executed by such stockholder or his duly authorized
attorney or through electronic means, if applicable, such as the internet.
Subject to the provisions of applicable law and the corporation's Certificate
of Incorporation, each holder of common stock shall be entitled to one (1)
vote for each share of stock standing registered in his name at the close of
business on the day fixed by the Board of Directors as the record date for
the determination of the stockholders entitled to notice of and vote at such
meeting. Shares standing in the name of another corporation may be voted by
any officer of such corporation or any proxy appointed by any officer of such
corporation in the absence of express notice of such corporation given in
writing to the Secretary of this corporation in connection with the
particular meeting, that such officer has no authority to vote such shares.

  



    

 | 2| 
---|---|--- 

 



    



  

Section 9. _List of Stockholders_ __. A complete list of the
stockholders entitled to vote at the ensuing meeting, arranged in
alphabetical order and showing the address of each stockholder and the number
of shares registered in the name of each stockholder, shall be prepared by
the Secretary, or other officer of the corporation having charge of
said stock ledger. Such list shall be open to the examination of any
stockholder during ordinary business hours, for a period of at least ten (10)
days prior to the meeting, either at a place within the city where the meeting
is to be held, which place shall be specified in the notice of the meeting,
or, if not so specified, at the place where said meeting is to be held, and
the list shall be produced and kept at the time and place of the meeting
during the whole time thereof, and shall be subject to the inspection of any
stockholder who may be present.

  



  

Section 10. _Waiver of Notice by Stockholders_ __. Whenever any
notice whatever is required to be given to any stockholder of the corporation
under the provisions of these By-Laws or under the provisions of the
Certificate of Incorporation or under the provisions of any statute, a waiver
thereof in writing, signed at any time, whether before or after the time of
meeting, by the stockholder entitled to such notice, shall be deemed
equivalent to the giving of such notice.

  



  

Section 11. _Advance Notice of Stockholder-Proposed Business at
Annual Meetings_ __. No business may be transacted at an annual meeting of
stockholders, other than business that is either (a) specified in the notice
of meeting (or any supplement thereto) given by or at the direction of the
Board of Directors (or any duly authorized committee thereof), (b) otherwise
properly brought before the annual meeting by or at the direction of the Board
of Directors (or any duly authorized committee thereof), or (c) otherwise
properly brought before the annual meeting by any stockholder of the
corporation (i) who is a stockholder of record on the date of the giving of
the notice provided for in this Section 11 and on the record date for the
determination of stockholders entitled to notice of and to vote at such annual
meeting and (ii) who complies with the notice procedures set forth in this
Section 11.

  



  

In addition to any other applicable requirements, for business to be properly
brought before an annual meeting by a stockholder, such stockholder must have
given timely notice thereof in proper written form to the Secretary of the
corporation.

  



    

 | 3| 
---|---|--- 

 



    



  

To be timely, a stockholder's notice to the Secretary must be delivered to or
mailed and received at the principal executive offices of the corporation not
less than ninety (90) days nor more than one hundred twenty (120) days prior
to the anniversary date of the immediately preceding annual meeting of
stockholders; provided, however, that in the event that the annual meeting is
called for a date that is not within twenty-five (25) days before or after
such anniversary date, notice by the stockholder in order to be timely must be
so received not later than the close of business on the tenth (10th) day
following the day on which such notice of the date of the annual meeting
was mailed or such public disclosure of the date of the annual meeting was
made, whichever first occurs.

  



  

To be in proper written form, a stockholder's notice to the Secretary must
set forth as to each matter such stockholder proposes to bring before the
annual meeting (i) a brief description of the business desired to be brought
before the annual meeting, the reasons for conducting such business at the
annual meeting and any material interest in such business of such stockholder
and any Stockholder Associated Person (as defined below), individually or in
the aggregate, including any anticipated benefit to the stockholder or the
Stockholder Associated Person therefrom, (ii) the name and record address of
such stockholder, (iii) as to the stockholder giving the notice and any
Stockholder Associated Person, (A) the class, series and number of all shares
of stock of the corporation which are owned by such stockholder and by
such Stockholder Associated Person, if any, (B) the nominee holder for, and
number of, shares owned beneficially but not of record by such stockholder
and by any such Stockholder Associated Person, and (C) any derivative
positions held or beneficially held by the stockholder and by any such
Stockholder Associated Person and whether and the extent to which any hedging
or other transaction or series of transactions has been entered into by or on
behalf of, or any other agreement, arrangement or understanding
(including any short position or any borrowing or lending of shares) has been
made, the effect or intent of which is to mitigate loss to or manage risk or
benefit of share price changes for, or to increase or decrease the voting
power of, such stockholder or any such Stockholder Associated Person with
respect to any share of stock of the corporation; (iv) as to the stockholder
giving the notice and any Stockholder Associated Person covered by clause
(iii) of this paragraph, the name and address of such stockholder, as
they appear on the corporation's stock ledger, and current name and address,
if different, and of such Stockholder Associated Person; (v) a description of
all proxy, contract, arrangement, understanding, or relationship between such
stockholder and any other person or persons (including their names) in
connection with the proposal of such business by such stockholder; and (vi) a
representation that such stockholder intends to appear in person or by proxy
at the annual meeting to bring such business before the meeting.

  



    

 | 4| 
---|---|--- 

 



    



  

Notwithstanding anything in these By-Laws to the contrary, no business shall
be conducted at the annual meeting except business brought before the annual
meeting in accordance with the procedures set forth in this Section 11;
provided, however, that, once business has been properly brought before the
annual meeting in accordance with such procedures, nothing in this Section 11
shall be deemed to preclude discussion by any stockholder of any such
business. If the chairman of an annual meeting determines that business was
not properly brought before the annual meeting in accordance with the
foregoing procedures, the chairman shall declare to the meeting that the
business was not properly brought before the meeting and such business shall
not be transacted.

  



  

For purposes of this Section 11 and of Section 12 of this Article I,
"Stockholder Associated Person" of any stockholder shall mean (i) any person
controlling, directly or indirectly, or acting in concert with, such
stockholder, (ii) any beneficial owner of shares of stock of the corporation
owned of record or beneficially by such stockholder and (iii) any person
controlling, controlled by or under common control with such Stockholder
Associated Person.

  



  

Section 12. _Procedure for Nomination of Directors_. Only persons
who are nominated in accordance with the following procedures shall be
eligible for election as directors of the corporation, except as may be
otherwise provided in the Certificate of Incorporation with respect to the
right of holders of preferred stock of the corporation to nominate and
elect a specified number of directors in certain circumstances. Nominations
of persons for election to the Board of Directors may be made at any annual
meeting of stockholders, or at any special meeting of stockholders called for
the purpose of electing directors, (a) subject to Article VII of these By-
laws, by or at the direction of the Board of Directors (or any duly authorized
committee thereof) or (b) by any stockholder of the corporation (i) who is a
stockholder of record on the date of the giving of the notice provided for in
this Section 12 and on the record date for the determination of stockholders
entitled to notice of and to vote at such meeting and (ii) who complies with
the notice procedures set forth in this Section 12.

  



  

In addition to any other applicable requirements, for a nomination to be made
by a stockholder, such stockholder must have given timely notice thereof in
proper written form to the Secretary of the corporation.

  



  

To be timely, a stockholder's notice to the Secretary must be delivered to or
mailed and received at the principal executive offices of the corporation (a)
in the case of an annual meeting, not less than ninety (90) days nor more
than one hundred twenty (120) days prior to the anniversary date of the
immediately preceding annual meeting of stockholders; provided, however, that
in the event that the annual meeting is called for a date that is not within
twenty-five (25) days before or after such anniversary date, notice by the
stockholder in order to be timely must be so received not later than the
close of business on the tenth (10th) day following the day on which such
notice of the date of the annual meeting was mailed or such public disclosure
of the date of the annual meeting was made, whichever first occurs; and (b)
in the case of a special meeting of stockholders called for the purpose of
electing directors, not later than the close of business on the tenth (10th)
day following the day on which notice of the date of the special meeting was
mailed or public disclosure of the date of the special meeting was made,
whichever first occurs.

  



    

 | 5| 
---|---|--- 

 



    



  

To be in proper written form, a stockholder's notice to the Secretary must
set forth (a) as to each person whom the stockholder proposes to nominate for
election as a director (i) the name, age, business address and residence
address of the person, (ii) the principal occupation or employment of the
person, (iii) the class or series and number of shares of capital stock of
the corporation which are owned beneficially or of record by the person and
(iv) any other information relating to the person that would be required to be
disclosed in a proxy statement or other filings required to be made in
connection with solicitations of proxies for election of directors pursuant to
Section 14 of the Exchange Act of 1934, as amended (the "Exchange Act"), and
the rules and regulations promulgated thereunder; and (b) as to the
stockholder giving the notice and any Stockholder Associated Person, (i) the
name and record address of such stockholder, (ii) the class, series and
number of all shares of stock of the corporation which are owned by such
stockholder and by such Stockholder Associated Person, if any, (iii) the
nominee holder for, and number of, shares owned beneficially but not
of record by such stockholder and by any such Stockholder Associated Person,
(iv) any derivative positions held or beneficially held by the stockholder
and by any such Stockholder Associated Person and whether and the extent to
which any hedging or other transaction or series of transactions has been
entered into by or on behalf of, or any other agreement, arrangement or
understanding (including any short position or any borrowing or lending of
shares) has been made, the effect or intent of which is to mitigate loss to
or manage risk or benefit of share price changes for, or to increase or
decrease the voting power of, such stockholder or any such Stockholder
Associated Person with respect to any share of stock of the corporation, (v) a
description of all arrangements or understandings between such stockholder or
any such Stockholder Associated Person and each proposed nominee and any other
person or persons (including their names) pursuant to which the nomination(s)
are to be made by such stockholder, (vi) as to the stockholder giving the
notice, a representation that such stockholder intends to appear in person or
by proxy at the meeting to nominate the persons named in its notice and (vii)
any other information relating to the stockholder giving the notice that would
be required to be disclosed in a proxy statement or other filings required to
be made in connection with solicitations of proxies for election of
directors pursuant to Section 14 of the Exchange Act and the rules and
regulations promulgated thereunder. Such notice must be accompanied by a
written consent of each proposed nominee to being named as a nominee and to
serve as a director if elected.

  



    

 | 6| 
---|---|--- 

 



    



  

No person shall be eligible for election as a director of the corporation
unless nominated in accordance with the procedures set forth in this Section
12. If the Chairman of the meeting determines that a nomination was not made
in accordance with the foregoing procedures, the Chairman shall declare to
the meeting that the nomination was defective and such defective nomination
shall be disregarded.

  



  

Section 13. _Election of Directors_. Except as provided in Section
8 of Article II of these By-laws, a nominee for director shall be elected to
the Board of Directors if the votes cast for such nominee's election exceed
the votes cast against such nominee's election; provided, however, that
directors shall be elected by a plurality of the votes cast at any meeting of
stockholders for which (i) the Secretary of the Corporation receives a notice
that a stockholder has nominated a person for election to the Board of
Directors in compliance with the advance notice requirements for stockholder
nominees for director set forth in Article I, Section 12 of these By-laws and
(ii) such nomination has not been withdrawn by such stockholder on or prior
to the fourteenth day before the date the Corporation first mails to the
stockholders its notice of such meeting.  If directors are to be elected by a
plurality of the votes cast, stockholders shall not be permitted to vote
against a nominee, but only to withhold their vote.

  



  

ARTICLE II

  



  

 _BOARD OF DIRECTORS_

  



  

Section 1. _General Powers_ __. The business and affairs of the
corporation shall be managed by its Board of Directors. Except as otherwise
provided in and subject to Article VII of these By-laws, the Board of
Directors may adopt, amend or repeal by-laws adopted by the Board or by the
stockholders.

  



  

Section 2. _Number of Directors, Tenure and Qualifications_ __.
Except as otherwise provided in and subject to Article VII of these By-laws
or fixed pursuant to the Certificate of Incorporation, the number of members
of the Board of Directors shall be not less than three (3) nor more than
thirteen (13), as determined from time to time by the Board of Directors. The
directors need not be stockholders of the corporation. Any additional director
elected to fill a vacancy resulting from an increase in the number of
directors shall hold office until the next annual meeting of stockholders, but
in no case will a decrease in the number of directors shorten the term of any
incumbent director. Each director shall hold office until the next annual
meeting of stockholders and until his or her successor shall be elected and
shall qualify, subject, however, to prior death, resignation, incapacitation
or removal from office, in the manner provided in these By-laws, including
Article VII, and except as otherwise required by law. In the event such
election is not held at the annual meeting of stockholders, it shall be held
at any adjournment thereof or a special meeting.

  



    

 | 7| 
---|---|--- 

 



    



  

Section 3. _Regular Meetings_ __. Regular meetings of the Board of
Directors shall be held without any other notice than this By-Law immediately
after, and at the same place as, the annual meeting of stockholders, and each
adjourned session thereof. The Board of Directors may designate the time and
place, either within or without the State of Delaware, for the holding of
additional regular meetings without other notice than such designation.

  



  

Section 4. _Special Meetings_ __. Special meetings of the Board of
Directors may be called by or at the request of the Chairman of the Board,
the Chief Executive Officer or by members of the Board of Directors
constituting no less than three-fourths (3/4) of the total number of
directors then in office. The person or persons authorized to call
special meetings of the Board of Directors may fix any place either within or
without the State of Delaware, as the place for holding any special meeting
of the Board of Directors called by them.

  



  

Section 5. _Notice_. Notice of any special meeting shall be given
at least five (5) days previously thereto by written notice delivered or
mailed to each director at his last known address, or at least forty-eight
(48) hours previously thereto by personal delivery or by facsimile to a
telephone number provided to the corporation. If mailed, such notice shall be
deemed to be delivered when deposited in the United States mail so addressed,
with postage thereon prepaid. If notice is given by facsimile, such notice
shall be deemed to be delivered when transmitted with receipt confirmed.
Whenever any notice whatever is required to be given to any director of the
corporation under the provisions of these By-Laws or under the provisions of
the Certificate of Incorporation or under the provisions of any statute, a
waiver thereof in writing, signed at any time, whether before or after the
time of meeting, by the director entitled to such notice, shall be deemed
equivalent to the giving of such notice. The attendance of a director at a
meeting shall constitute a waiver of notice of such meeting except where a
director attends a meeting and objects thereat to the transaction of any
business because the meeting is not lawfully called or convened. Neither the
business to be transacted at, nor the purpose of, any regular or special
meeting of the Board of Directors need be specified in the notice or waiver of
notice of such meeting.

  



  

Section 6. _Quorum_ __. During the Specified Period (as defined in
Article VII of these By-Laws), two-thirds (2/3rds) of the total number of
directors which the corporation would have if there were no vacancies on the
Board of Directors of the corporation shall constitute a quorum for the
transaction of business at any meeting of the Board of Directors. In the event
a quorum is not present at a duly called meeting of the Board of Directors, a
majority of the directors present at such duly called meeting may adjourn the
meeting and, upon delivery of a notice in accordance with Article II, Section
5 to the director(s), reschedule such meeting for an alternative date, and,
at such rescheduled meeting, a majority of the total number of directors shall
constitute a quorum.

  



    

 | 8| 
---|---|--- 

 



    



  

Section 7. _Manner of Acting_ __. The act of the majority of the
directors then in office shall be the act of the Board of Directors, unless
the act of a greater number is required by these By-Laws, including Article
VII.

  



  

Section 8. _Vacancies_ __. Except as otherwise required by law or
Article VII of these By-laws, any vacancy on the Board of Directors that
results from an increase in the number of directors shall be filled only by a
majority of the Board of Directors then in office, provided that a quorum is
present, and any other vacancy occurring on the Board of Directors shall be
filled by a majority of the directors then in office, even if less than a
quorum, or by a sole remaining director. Any director elected to fill a
vacancy not resulting from an increase in the number of directors shall have
the same remaining term as that of his or her predecessor. The resignation of
a director shall be effective upon receipt by the corporation, unless some
subsequent time is fixed in the resignation, and then from that time.
Acceptance of such resignation by the corporation shall not be required.

  



  

Section 9. _Compensation_ __. The Board of Directors, by
affirmative vote of a majority of the directors, and irrespective of any
personal interest of any of its members, may establish reasonable
compensation of all directors for services to the corporation as directors,
officers or otherwise, or may delegate such authority to an appropriate
committee.

  



  

Section 10. _Presumption of Assent_ __. A director of the
corporation who is present at a meeting of the Board of Directors or a
committee thereof at which action on any corporate matter is taken shall be
presumed to have assented to the action taken unless his dissent shall be
entered in the minutes of the meeting or unless he shall file his written
dissent to such action with the person acting as the secretary of the meeting
before the adjournment thereof. Such right to dissent shall not apply to a
director who voted in favor of such action.

  



  

Section 11. _Committees_ __. Except as otherwise provided in and
subject to Article VII of these By-laws, the Board of Directors by resolution
may designate one (1) or more committees, each committee to consist of one
(1) or more directors elected by the Board of Directors, which to the
extent provided in such resolution, as initially adopted, and as thereafter
supplemented or amended by further resolution adopted by a like vote, shall
have and may exercise, when the Board of Directors is not in session, the
powers of the Board of Directors in the management of the business and
affairs of the corporation, except action with respect to amendment of the
Certificate of Incorporation or By-Laws, adoption of an agreement of merger
or consolidation (other than the adoption of a Certificate of Ownership and
Merger in accordance with Section 253 of the General Corporation Law of the
State of Delaware, as such law may be amended or supplemented),
recommendation to the stockholders of the sale, lease or exchange of all or
substantially all of the corporation's property or assets, recommendation to
the stockholders of the dissolution or the revocation of a dissolution of the
corporation, election of officers or the filling of vacancies on the Board of
Directors or on committees created pursuant to this Section or declaration of
dividends. Except as otherwise provided in and subject to Article VII of these
By-laws, the Board of Directors may elect one (1) or more of its members as
alternate members of any such committee who may take the place of any absent
or disqualified member or members at any meeting of such committee, upon
request by the Chairman of the Board or the Chief Executive Officer or upon
request by the chairman of such meeting. Each such committee may fix its own
rules governing the conduct of its activities and shall make such reports to
the Board of Directors of its activities as the Board of Directors may
request.

  



    

 | 9| 
---|---|--- 

 



    



  

Section 12. _Action of the Board by Written Consent_ __. Any action
required or permitted to be taken at any meeting of the Board of Directors or
any committee thereof may be taken without a meeting of the Board of
Directors or any committee thereof if prior to such action a written consent
thereto is signed by all members of the Board or of the committee, as the
case may be, and such written consent is filed with the minutes of the
proceedings of the Board or the committee.

  



  

Section 13. _Conferences_ __. Members of the Board of Directors or
any committee designated by the Board may participate in a meeting of such
Board or committee by means of conference telephone or similar communications
equipment by means of which all persons participating in the meeting can hear
each other, and participation in a meeting pursuant to this Section 13 shall
constitute presence in person at such meeting.

  



  

ARTICLE III

  



  

 _OFFICERS_

  



  

Section 1. _Number_ __. The officers of the corporation shall
consist of an Chairman of the Board and a Chief Executive Officer. The Board
of Directors may appoint as officers such number of Senior Vice Presidents
and Vice Presidents, a Secretary, a Treasurer, one (1) or more
Assistant Treasurers, one (1) or more Assistant Secretaries, and such other
officers as are created by the Board from time to time. The same person may
hold two (2) or more of such offices.

  



  

Section 2. _Election and Term of Office_ __. Except as otherwise
provided in and subject to Article VII of these By-laws, the Chairman of the
Board shall be elected by the directors from among their own number; other
officers need not be directors. In addition to the powers conferred upon them
by these By-Laws, except as otherwise provided in and subject to Article VII
of these By-Laws, all officers elected or appointed by the Board of Directors
shall have such authority and shall perform such duties as from time to time
may be prescribed by the Board of Directors by resolution.

  



    

 | 10| 
---|---|--- 

 



    



  

Section 3. _Removal_ __. Except as otherwise provided in and
subject to Article VII of these By-laws, any officer or agent elected or
appointed by the Board of Directors may be removed by the Board of Directors,
whenever in its judgment the best interests of the corporation will be served
thereby, but such removal shall be without prejudice to the contract rights,
if any, of the person so removed. Election or appointment shall not of itself
create contract rights.

  



  

Section 4. _Executive Chairman of the Board_. The Executive
Chairman of the Board shall have the duties as set forth in the Corporate
Governance Guidelines/Policies of the corporation.

  



  

Section 5. _Lead Independent Directors_. The Lead Independent
Director shall have the duties as set forth in the Corporate Governance
Guidelines/Policies of the corporation and such other duties as from time to
time may be assigned to him by the Board of Directors.

  



  

Section 6. _Chief Executive Officer_ __. The Chief Executive
Officer shall be the principal executive officer of the corporation and shall
have the general charge of and control over the business, affairs, and
personnel of the corporation, subject to the authority of the Board of
Directors. The Chief Executive Officer may, together with the Secretary, sign
all certificates for shares of the capital stock of the corporation. Except as
may be specified by the Board of Directors, the Chief Executive Officer shall
have the power to enter into contracts and make commitments on behalf of the
corporation and shall have the right to execute deeds, mortgages, bonds,
contracts and other instruments necessary or proper to be executed
in connection with the corporation's regular business and may authorize any
other officer of the corporation, to sign, execute and acknowledge such
documents and instruments in his place and stead.

  



  

Section 7. _Senior Vice President and Vice Presidents_ __. Each
Senior Vice President or Vice President shall perform such duties and have
such authority as from time to time may be assigned to him by the Board of
Directors (so long as such duties are, and such authority is, subordinate to
the Chief Executive Officer) or the Chief Executive Officer.

  



    

 | 11| 
---|---|--- 

 



    



  

Section 8. _Secretary and Assistant Secretaries_ __. The Secretary
shall have custody of the seal of the corporation and of all books, records
and papers of the corporation, except such as shall be in the charge of the
Treasurer or some other person authorized to have custody and be in
possession thereof by resolution of the Board of Directors. The
Secretary shall record the proceedings of the meetings of the stockholders
and of the Board of Directors in books kept by him for that purpose and may,
at the direction of the Board of Directors, give any notice required by
statute or by these By-Laws of all such meetings. The Secretary shall,
together with the Chief Executive Officer, sign certificates for shares of the
capital stock of the corporation. Any Assistant Secretaries elected by the
Board of Directors, in order of their seniority, shall, in the absence or
disability of the Secretary, perform the duties and exercise the powers of
the Secretary as aforesaid. The Secretary or any Assistant Secretary may,
together with the Chief Executive Officer or any other authorized officer,
execute on behalf of the corporation any contract which has been approved by
the Board of Directors, and shall perform such other duties as the Board of
Directors or the Chief Executive Officer shall prescribe.

  



  

Section 9. _Treasurer and Assistant Treasurer_ __. The Treasurer
shall keep accounts of all moneys of the corporation received and disbursed,
and shall deposit all monies and valuables of the corporation in its name and
to its credit in such banks and depositories as the Board of Directors shall
designate. Any Assistant Treasurers elected by the Board of Directors, in
order of their seniority, shall, in the absence or disability of the
Treasurer, perform the duties and exercise the powers of the Treasurer, and
shall perform such other duties as the Board of Directors or the Chief
Executive Officer shall prescribe.

  



  

Section 10. _Salaries_ __. The salaries of the officers shall be
fixed from time to time by the Board of Directors and no officer shall be
prevented from receiving such salary by reason of the fact that he is also a
director of the corporation.

  



  

Section 11. _Representation in Other Companies_ __. Unless
otherwise ordered by the Board of Directors, the Chief Executive Officer or a
Vice President designated by the Chief Executive Officer or the Board of
Directors shall have full power and authority on behalf of the corporation to
attend and to act and to vote at any meetings of security holders
of corporations in which the corporation may hold securities, and at such
meetings shall possess and may exercise any and all rights and powers
incident to the ownership of such securities, and which as the owner thereof
the corporation might have possessed and exercised, if present. The Board of
Directors by resolution from time to time may confer like powers upon any
other person or persons.

  



    

 | 12| 
---|---|--- 

 



    



  

ARTICLE IV

  



  

 _STOCK AND TRANSFER OF STOCK_

  



  

Section 1. _Shares of Stock_ __. The shares of capital stock of
the corporation shall be represented by a certificate, unless and until the
Board of Directors of the corporation adopts a resolution permitting shares to
be uncertificated. Notwithstanding the adoption of any such resolution
providing for uncertificated shares, every holder of capital stock of
the corporation theretofore represented by certificates and, upon request,
every holder of uncertificated shares, shall be entitled to have a
certificate for shares of capital stock of the corporation signed by the Chief
Executive Officer and by the Secretary. To the extent that shares are
represented by certificates, the certificates shall be in such form as shall
be determined by the Board of Directors and shall be consecutively numbered
or otherwise identified. The name and address of the person to whom
the shares represented thereby are issued, with the number of shares and date
of issue, shall be entered on the stock transfer books of the corporation.
With respect to certificated shares of stock, all certificates surrendered to
the corporation for transfer shall be canceled and no new certificate or
uncertificated shares shall be issued until the former certificate for a like
number of shares shall have been surrendered and canceled, except that in
case of a lost, destroyed or mutilated certificate, a new certificate or
uncertificated shares may be issued therefor upon such terms and indemnity to
the corporation as the Board of Directors may prescribe.

  



  

Section 2. _Transfer of Shares_ __. Stock of the corporation shall
be transferable in the manner prescribed by applicable law and in these By-
Laws. Transfers of stock shall be made on the books of the corporation, and in
the case of certificated shares of stock, only by the person named in the
certificate or by such person's attorney lawfully constituted in writing and
upon the surrender of the certificate therefor, properly endorsed for transfer
and payment of all necessary transfer taxes; or, in the case of
uncertificated shares of stock, upon receipt of proper transfer instructions
from the registered holder of the shares or by such person's attorney
lawfully constituted in writing, and upon payment of all necessary
transfer taxes and compliance with appropriate procedures for transferring
shares in uncertificated form; provided, however, that such surrender and
endorsement, compliance or payment of taxes shall not be required in any case
in which the officers of the corporation shall determine to waive such
requirement. Prior to due presentment for registration of transfer of a
certificate representing shares of capital stock of the corporation or of
proper transfer instructions with respect to uncertificated shares, the
corporation may treat the registered owner of such shares as the person
exclusively entitled to vote, to receive notifications and otherwise to
exercise all the rights and powers of an owner. Where a certificate for shares
is presented to the corporation with a request to register for transfer, the
corporation shall not be liable to the owner or any other person suffering
loss as a result of such registration of transfer if (a) there were on or
with the certificate the necessary endorsements, and (b) the corporation
had no duty to inquire into adverse claims or has discharged any such duty.
The corporation may require reasonable assurance that said endorsements are
genuine and effective and in compliance with such other regulations as may be
prescribed under the authority of the Board of Directors.

  



    

 | 13| 
---|---|--- 

 



    



  

ARTICLE V

  



  

 _INDEMNIFICATION OF DIRECTORS, OFFICERS,_

  



  

 _EMPLOYEES AND AGENTS_

  



  

Section 1. _Indemnification Generally_ __. The corporation shall
indemnify any person who was or is a party or is threatened to be made a
party to any threatened, pending or completed action, suit or proceeding,
whether civil, criminal, administrative or investigative (other than an
action by or in the right of the corporation), by reason of the fact that he
or she is or was a director, officer, employee or agent of the corporation,
or is or was serving at the request of the corporation as a director,
officer, employee or agent of another corporation, partnership, joint venture,
trust or other enterprise, or is alleged to have violated the Employee
Retirement Income Security Act of 1974, as amended, against expenses
(including attorneys' fees), judgments, fines, penalties, and amounts paid in
settlement actually and reasonably incurred by him or her in connection with
such action, suit or proceeding if he or she acted in good faith and in a
manner he or she reasonably believed to be in or not opposed to the best
interests of the corporation, and, with respect to any criminal action or
proceeding, had no reasonable cause to believe his or her conduct was
unlawful. The termination of any action, suit or proceeding by judgment,
order, settlement, conviction, or upon plea of nolo contendere or its
equivalent shall not, of itself, create a presumption that the person did
not act in good faith and in a manner which he or she reasonably believed to
be in or not opposed to the best interests of the corporation, and, with
respect to any criminal action or proceeding, had reasonable cause to believe
that his or her conduct was unlawful.

  



  

Section 2. _Indemnification in Actions By or In the Right Of the
Corporation_ __. The corporation shall indemnify any person who was or is a
party or is threatened to be made a party to any threatened, pending or
completed action or suit by or in the right of the corporation to procure a
judgment in its favor by reason of the fact that he or she is or was a
director, officer, employee or agent of the corporation, or is or was serving
at the request of the corporation as a director, officer, employee or agent
of another corporation, partnership, joint venture, trust or other enterprise
against expenses (including attorneys' fees) actually and reasonably incurred
by him or her in connection with the defense and settlement of such action or
suit if he or she acted in good faith and in a manner he or she reasonably
believed to be in or not opposed to the best interests of the corporation and
except that no indemnification shall be made in respect of any claim, issue or
matter as to which such person shall have been adjudged to be liable to the
corporation unless and only to the extent that the Delaware Court of
Chancery or the court in which such action or suit was brought shall
determine upon application that, despite the adjudication of liability but in
view of all the circumstances of the case, such person is fairly and
reasonably entitled to indemnity for such expenses which the Delaware Court
of Chancery or such other court shall deem proper.

  



    

 | 14| 
---|---|--- 

 



    



  

Section 3. _Success on the Merits; Indemnification Against
Expenses_ __. To the extent that a director, officer, employee or agent of
the corporation has been successful on the merits or otherwise in defense of
any action, suit or proceeding referred to in Section 1 or Section 2 of this
Article V, or in defense of any claim, issue or matter therein, he or she
shall be indemnified against expenses (including attorneys' fees) actually and
reasonably incurred by him or her in connection therewith.

  



  

Section 4. _Determination that Indemnification is Proper_ __. Any
indemnification under Section 1 or Section 2 of this Article V, unless
ordered by a court, shall be made by the corporation only as authorized in the
specific case upon a determination that indemnification of the director,
officer, employee or agent is proper in the circumstances under the standard
of conduct set forth in such Section 1 or Section 2 of this Article V, as the
case may be. Such determination shall be made:

  



  

(a) By the Board of Directors by a majority vote of a quorum
consisting of directors who were not parties to such action, suit or
proceeding;

  



  

(b) If such a quorum is not obtainable, or, even if obtainable if a
quorum of disinterested directors so directs, by independent legal counsel in
a written opinion; or

  



  

(c) By the stockholders.

  



  

Section 5. _Insurance; Indemnification Agreements_ __. The
corporation may, but shall not be required to, supplement the right of
indemnification under this Article V by any lawful means, including, without
limitation by reason of enumeration, (i) the purchase and maintenance of
insurance on behalf of any one or more of such indemnitees, whether or not the
corporation would be obligated to indemnify such person under this Article V
or otherwise, and (ii) individual or group indemnification agreements with
any one or more of such indemnities.

  



  

Section 6. _Advancement of Expenses_. Expenses (including
attorneys' fees) incurred by an indemnitee in defending any civil, criminal,
administrative or investigative action, suit or proceeding shall be paid by
the corporation in advance of the final disposition of such action, suit or
proceeding upon receipt of an undertaking by or on behalf of the
indemnitee to repay such amount if it shall ultimately be determined that he
or she is not entitled to be indemnified by the corporation as to such
amounts.

  



    

 | 15| 
---|---|--- 

 



    



  

Section 7. _Rights Not Exclusive_ __. The indemnification and
advancement of expenses provided by this Article V shall be not deemed
exclusive of any other right to which an indemnified person may be entitled
under Section 145 of the General Corporation Law of the State of Delaware (or
any successor provision) or otherwise under applicable law, or under any
agreement, vote of stockholders or disinterested directors or otherwise, both
as to action in his or her official capacity and as to action in another
capacity while holding such office and shall continue as to a person who has
ceased to be a director, officer, employee or agent and shall inure to the
benefit of the heirs, executors and administrators of such a person.

  



  

Section 8. _Severability_ __. To the extent that any court of
competent jurisdiction shall determine that the indemnification provided under
this Article V shall be invalid as applied to a particular claim, issue or
matter, the provisions hereof shall be deemed amended to allow
indemnification to the maximum extent permitted by law.

  



  

Section 9. _Modification_ __. This Article V shall be deemed to be
a contract between the corporation and each previous, current or future
director, officer, employee or agent. The provisions of this Article V shall
be applicable to all actions, claims, suits or proceedings, commenced after
the adoption hereof, whether arising from any action taken or failure to act
before or after such adoption. No amendment, modification or repeal of this
Article V shall diminish the rights provided hereby or diminish the right to
indemnification with respect to any claim, issue or matter in any then
pending or subsequent proceeding which is based in any material respect from
any alleged action or failure to act prior to such amendment, modification or
repeal.

  



  

ARTICLE VI

  



  

 _EXCLUSIVE FORUM_

  



  

Unless the corporation consents in writing to the selection of an alternative
forum, the sole and exclusive forum for (i) any derivative action or
proceeding brought on behalf of the corporation, (ii) any action asserting a
claim of breach of a fiduciary duty owed by any director or officer or other
employee of the corporation to the corporation or the corporation's
stockholders, (iii) any action asserting a claim against the corporation or
any director or officer or other employee of the corporation arising pursuant
to any provision of the Delaware General Corporation Law or the corporation's
Certificate of Incorporation or By-Laws (as either may be amended from time to
time), or (iv) any action asserting a claim against the corporation or any
director or officer or other employee of the corporation governed by the
internal affairs doctrine shall be a state court located within the State of
Delaware (or, if no state court located within the State of Delaware has
jurisdiction, the federal district court for the District of Delaware).

  



    

 | 16| 
---|---|--- 

 



    



  

ARTICLE VII

  



  

 _CERTAIN GOVERNANCE MATTERS_

  



  

Section 1. _Definitions_. The following definitions shall apply to
this Article VII and otherwise as applicable in these By-laws:

  



  

(a) " _Effective Time_ " has the meaning specified in the Merger
Agreement.

  



  

(b) " _Entire Board of Directors_ " shall mean a total of eleven
(11) directors; provided, however, that if a vacancy has not been filled
pursuant to Article VII, Section 2 below and the remaining directors
determine, by action of a majority of the directors then in office, in the
good faith exercise of their fiduciary duties, that immediate action is
required to avoid material harm to the corporation, then the "Entire Board of
Directors" shall mean the remaining directors (even if less than a quorum) or
the sole remaining director.

  



  

(a) " _Entire Corporate Governance and Nominating Committee_ " shall
mean a total of four (4) directors on the Corporate Governance and Nominating
Committee.

  



  

(b) " _Merger Agreement_ " shall mean the Agreement and Plan of
Merger, dated as of September 15, 2015, by and among DENTSPLY
International Inc., Sirona Dental Systems, Inc., and Dawkins Merger Sub Inc.,
as amended from time to time.

  



  

(c) " _Specified Period_ " shall mean the period beginning at the
Effective Time and ending on the third (3rd) anniversary of the Effective
Time.

  



  

Section 2. _Composition of the Board._

  



  

(a) Following the Effective Time, the Board shall be comprised of
eleven (11) members. The specific composition of the Board as of the
Effective Time shall be as set forth in the Merger Agreement. Any re-
nomination of a director or nomination of an individual to a seat held by an
existing director shall be filled only by the approval of at least a majority
of the Entire Board of Directors (even if less than a quorum, or by the sole
remaining director) acting solely upon the recommendation of at least a
majority of the Entire Corporate Governance and Nominating Committee. In the
event of a deadlock among the members of the Corporate Governance and
Nominating Committee concerning such re-nomination or nomination, as
applicable, or failure of the Board to approve such recommendation of the
Entire Corporate Governance and Nominating Committee, the incumbent director
shall be re-nominated if willing to serve.

  



    

 | 17| 
---|---|--- 

 



    



  

(b) Vacancies resulting from the cessation of service by, including
removal of, any director shall be filled only by the approval of at least a
majority of the Entire Board of Directors (even if less than a quorum, or by
the sole remaining director) acting solely upon the unanimous recommendation
of the Corporate Governance and Nominating Committee.

  



  

Section 3. _Chairman, Chief Executive Officer, Lead Independent
Director_. During the Specified Period, the Board may only replace, remove,
alter the responsibilities and authorities (as set forth in the Corporate
Governance Guidelines/Policies of the corporation or these By-laws), or grant
conflicting responsibilities or authorities of the Chairman, the Chief
Executive Officer, or the Lead Independent Director, as applicable, by the
affirmative vote of the greater of (i) at least seventy percent (70%) of the
Entire Board of Directors and (ii) eight (8) directors.

  



  

Section 4. _Required Committees_.

  



  

(a) From the Effective Date, the Board shall have the following
three committees, in addition to any other committees as determined by
the Board from time to time by the affirmative vote of the greater of (i) at
least seventy percent (70%) of the Entire Board of Directors and (ii) eight
(8) directors: Audit and Finance Committee, Corporate Governance and Nominating
Committee, and Human Resources Committee (the " _Required Committees_ ").

  



  

(b) Vacancies in any Required Committee resulting from the cessation
of service by, including removal of, any director or any subsequent
director shall be filled only by the approval of at least a majority of the
Entire Board of Directors (even if less than a quorum, or by a sole remaining
director) acting solely upon the unanimous recommendation of the Corporate
Governance and Nominating Committee.

  



  

(c) The chairman of the Required Committees as of the Effective Time
shall be as set forth in the Merger Agreement. Any change to or
replacement of the chairman of any Required Committee shall be determined by
the Board from time to time by the affirmative vote of the greater of (i) at
least seventy percent (70%) of the Entire Board of Directors and (ii) eight
(8) directors.

  



  

(d) Each Required Committee shall have the responsibilities set
forth in the charter of such Required Committee as of the Effective
Time, except as modified from time to time by the affirmative vote of the
greater of (i) at least seventy percent (70%) of the Entire Board of
Directors and (ii) eight (8) directors.

  



    

 | 18| 
---|---|--- 

 



    



  

Section 5. _Amendments_. During the Specified Period, the
provisions of this Article VII and the Corporate Governance
Guidelines/Policies of the corporation may be modified, amended or repealed
by the Board of Directors, and any By-law provision or other resolution
inconsistent with this Article VII or the Corporate Governance
Guidelines/Policies of the corporation may be adopted by the Board of
Directors, only by an affirmative vote of the greater of (i) at least seventy
percent (70%) of the Entire Board of Directors and (ii) eight (8) directors.
In the event of any inconsistency between any other provision of these By-laws
and any provision of this Article VII, the provisions of this Article VII
shall control. Following the end of the Specified Period, this Article VII
shall automatically and without further action become void and be of no
further force and effect.

  



  

[ _Remainder of Page Intentionally Left Blank_ ]

  



    

   

 | 19| 
---|---|--- 

 



    

  



  

 _Exhibit D_

  



  

FORM OF

  



  

DENTSPLY SIRONA INC.

  



  

CORPORATE GOVERNANCE GUIDELINES/POLICIES

  



    



 



    



  

 _TABLE OF CONTENTS_

  



  

     I.  | Functions/Responsibilities of the Board of Directors  | 1 
---|---|--- 
     |   | 
   II.  | Selection/Service of Board Members  | 2 
     | A.  | Identification  | 2 
     | B.  | Non-Discrimination  | 2 
     | C.  | Independence  | 2 
     | D.  | Criteria for the Nomination  | 2 
     | E.  | Number of Board Seats  | 3 
     | F.  | Size of Board  | 4 
     |   | 
   III.  | Term  | 4 
     | A.  | Normal Terms  | 4 
     | B.  | Management Director Resignation  | 4 
     | C.  | Term Limits  | 4 
     | D.  | Retirement  | 4 
     |   |   | 
   IV.  | Stock Ownership of Directors  | 4 
     |   | 
   V.  | Board Meetings  | 4 
     | A.  | Scheduling of Meetings  | 4 
     | B.  | Agenda  | 5 
     | C.  | Management Presentations  | 5 
     | D.  | Executive Sessions  | 5 
     |   | 
   VI.  | Attendance  | 5 
     | A.  | Board Meetings  | 5 
     | B.  | Annual Stockholders Meeting  | 5 
     |   | 
   VII.  | Chairman of the Board  | 5 
     |   | 
   VIII.  | Roles and Responsibilities: Executive Chairman and Chief
Executive Officer  | 5 
     |   | 
   IX.  | Lead Independent Director  | 6 
     |   | 
   X.  | Board Committees  | 6 
     | A.  | Generally  | 6 
     | B.  | Charters  | 6 
     | C.  | Advisors  | 7 
     | D.  | Committee Assignments  | 7 
     | E.  | Committee Meetings  | 7 
     |   | 
   XI.  | Compensation  | 7 
     |   | 
   XII.  | Self-Evaluation by the Board  | 7 
     |   | 
   XIII.  | Director Education  | 8 
     |   | 
   XIV.  | Expenses  | 8 
     |   | 
   XV.  | Capital Expenditures and Acquisitions  | 8 
     |   | 
   XVI.  | Communications  | 9 
     | A.  | Communications With Management  | 9 
     | B.  | Communications to Board  | 9 
     | C.  | Communications with Third Parties  | 9 
     | D.  | Director Nominations  | 9 
  

  



    

 | i| 
---|---|--- 

 



    



  

DENTSPLY SIRONA INC. 
 CORPORATE GOVERNANCE GUIDELINES/POLICIES

  



  

The following Corporate Governance Guidelines have been adopted by the Board
of Directors of DENTSPLY SIRONA Inc. (the " _Company_ ") to assist the Board
in the exercise of its responsibilities. These Corporate Governance Guidelines
reflect the Board's commitment to monitor the effectiveness of policy and
decision making both at the Board and management level. These Corporate
Governance Guidelines shall be reviewed by the Board, through the Corporate
Governance and Nominating Committee (or successor thereof) (the " _Governance
Committee_ "), on a periodic basis and are subject to modification from time
to time by the Board in accordance with the By-Laws of the Company.

  



   | I.| _Functions/Responsibilities of the Board of Directors_   
---|---|--- 
  



  

The Directors oversee and direct the management of the business and affairs
of the Company in accordance with the Delaware General Corporation Law and as
set forth in the Company's By-Laws. Directors shall discharge the duties of
their positions in good faith, in a manner reasonably believed to be in the
best interests of the Company and with such care, skill and diligence,
including reasonable inquiry as a person of ordinary prudence would use under
similar circumstances. The responsibility of the Board of Directors is to
supervise and direct the management of the Company. To that end, the role of
the Board of Directors (references to the Board include the Committees of the
Board, as applicable) shall include, but not be limited to:

  



   | (1)| The selection, appointment and regular evaluation of
the performance, and approval of the compensation of, the Chief Executive
Officer and, with the advice of the Chief Executive Officer, the principal
senior executives;  
---|---|--- 
  



   | (2)| The development of plans for succession with respect to the
position of Executive Chairman and Chief Executive Officer, and monitoring
succession planning for other key executives;  
---|---|--- 
  



   | (3)| Oversight of the conduct of the Company's business and
evaluation of whether the business is being properly managed;  
---|---|--- 
  



   | (4)| Review and, where appropriate, approval of the
Company's objectives, plans and actions, including its longer term strategic
plans;  
---|---|--- 
  



   | (5)| Review of the Company's financial statements;  
---|---|--- 
  



   | (6)| Assessment of major risk factors relating to the Company and its
performance, and review of measures taken or intended to be taken to address
and mitigate such risks; and  
---|---|--- 
  



   | (7)| Evaluation of whether appropriate systems and processes are in
place to support the effective management of the Company in accordance with
applicable legal requirements and the Company's Code of Business Conduct and
Ethics.  
---|---|--- 
  



    

 | 1| 
---|---|--- 

 



    



  

II. _Selection/Service of Board Members_

  



   | A.| _Identification_. The responsibility for the selection of new
Directors resides with the Board and stockholders. The identification,
screening and recommendation process has been delegated to the Governance
Committee, which reviews candidates for election as Directors, recommends
candidates to the Board to fill vacant Board seats and annually recommends a
slate of Directors for approval by the Board and election by the stockholders
of the Company.  
---|---|--- 
  



   | B.| _Non-Discrimination_. Potential candidates for membership on the
Board and Committees of the Board shall not be denied consideration by reason
of race, gender, religion, color or ethnicity, nor shall any candidate be
approached or selected solely because of any such reason.  
---|---|--- 
  



   | C.| _Independence_. The Board shall be comprised of a majority of
independent Directors, and no less than are required by NASDAQ or applicable
law. Independence shall be defined as provided by the rules and regulations
of NASDAQ and the Securities Exchange Commission (" _SEC_ ") law. The
Board, in consultation with the Company's Secretary, shall undertake an
annual review of the independence of all non-employee Directors. In advance
of the meeting at which this review occurs, each non-employee Director shall
provide to the Company for presentation to the Board, full information
regarding the Director's business and other relationships with the Company and
its affiliates, and with senior management and their affiliates, to enable
the Board to evaluate the Director's independence.  
---|---|--- 
  



  

Directors have an affirmative obligation to inform the Board of any material
changes in their circumstances or relationships that may impact their
designation by the Board as "independent." This obligation includes all
business relationships between Directors, their immediate families and
organizations in which they perform a material function, and the Company and
its affiliates or members of senior management and their affiliates, whether
or not such business relationships are subject to the approval requirement set
forth elsewhere in these Guidelines.

  



   | D.| _Criteria for the Nomination_ :  
---|---|--- 
  



   | 1.| The Governance Committee shall consider for selection
as Directors those persons:  
---|---|--- 
  



   | a.| who possess strong personal and professional ethics, and high
standards of integrity and values;  
---|---|--- 
  



   | b.| who have the proven ability and experience to bring
informed, thoughtful and well-considered opinions to corporate management and
the Board;  
---|---|--- 
  



   | c.| who have the competence, maturity and integrity to monitor and
evaluate the Company's management, performance and policies;  
---|---|--- 
  



    

 | 2| 
---|---|--- 

 



    



   | d.| who have the willingness, commitment and availability to devote
the necessary time and effort required for service on the Board;  
---|---|--- 
  



   | e.| who have the capacity to provide additional strength
and diversity of view to the Board and its activities;  
---|---|--- 
  



   | f.| who have the necessary measure of communication skills and self-
confidence to ensure ease of participation in Board discussion;  
---|---|--- 
  



   | g.| who hold or have held a senior position with a
significant business enterprise or a position of senior leadership in an
educational, medical, religious, or other non-profit institution or
foundation of significance; and  
---|---|--- 
  



   | h.| who meet the requirements of Article VII of the Company's By-
Laws.  
---|---|--- 
  



   | 2.| Persons who have attained the age of 75 shall not be eligible for
election or reelection as a Director.  
---|---|--- 
  



   | 3.| Any Director who (i) retires from; or (ii) discontinues their
active employment with the business or other enterprise with which they were
primarily affiliated at the time of their most recent election to the Board;
or (iii) incurs a significant change in responsibilities, title or activities
since their most recent election to the Board, shall submit their resignation
upon the occurrence of any of the aforesaid events. The Governance
Committee will review the effects of this change upon the interests of the
Company and recommend to the Board whether to accept such resignation. If
such resignation is not accepted, it shall be deemed rejected.  
---|---|--- 
  



   | 4.| It is the responsibility of each Director to advise the Corporate
Secretary of any actual or potential conflict of interest, as well as any
affiliation with public or privately held enterprises, including for profit
and non-profit entities, that may create a potential conflict of interest,
embarrassment to the Company or inconsistency with the Company's policies or
values.  
---|---|--- 
  



   E.| | _Number of Board Seats_.  
---|---|--- 
  



   | 1.| The Company does not have a policy specifying a maximum number of
other company boards upon which a Director may sit. However, it is recognized
that other activities of Board members, including service on multiple Boards,
could affect the ability of a Director to effectively serve on the Company's
Board and therefore, no director shall accept a position on another Board
which would result in the Director sitting on more than three (3) Boards,
without prior review and approval of the Governance Committee.  
---|---|--- 
  



   | 2.| Directors are expected to advise the Chairman of the Board and
the Chairman of the Governance Committee in advance of accepting any other
company directorship or any assignment to the audit committee or compensation
committee of the board of directors of any other company.  
---|---|--- 
  



    

 | 3| 
---|---|--- 

 



    



   | F.| _Size of Board_. The By-laws of the Company provide that the
size of the Board of Directors shall consist of not more than thirteen (13)
Directors. The Board shall determine the number of Directors as deemed
appropriate by the Board, subject to the Company's By-laws.  
---|---|--- 
  



   III.| | _Term_   
---|---|--- 
  



   | A.| _Normal Terms_. Directors shall hold office from the time of
their election and qualification and shall serve until the next annual meeting
of stockholders and until the election and qualification of their successor
or until such Director's earlier death, resignation, disqualification or
removal. Any open Director position in the Board for any reason, including a
vacancy resulting from an increase in the specific size of the Board, may be
filled by action of the Board of Directors in accordance with the By-Laws of
the Company.  
---|---|--- 
  



   | B.| _Management Director Resignation_. A Director who also is an
officer of the Company, who either resigns or retires their officer position,
shall simultaneously submit their resignation as a Director, acceptance of
which shall be at the discretion of the Board.  
---|---|--- 
  



   | C.| _Term Limits_. The Board does not believe it should establish
term limits. While term limits could help ensure that there are fresh ideas
and viewpoints available to the Board, they hold the disadvantage of losing
the contribution of Directors who have been able to develop, over a period of
time, increasing insight into the Company and its operations and, therefore,
provide an increasing contribution to the Board as a whole.  
---|---|--- 
  



   | D.| _Retirement_. A Director who attains the age of 75 shall be
required to retire from the Board at the next Annual Stockholders' meeting.  
---|---|--- 
  



   | IV.| _Stock Ownership of Directors_   
---|---|--- 
  



   | | It is the policy of the Board that all Directors hold an equity
interest in the Company.  Toward this end, the Board expects that all
Directors own, or acquire within five years of first becoming a Director,
shares  of common stock of the Company (including share units held under the
Company's Board of Directors Deferred Compensation  Plan, or any successor
plan, and restricted stock units, but not including stock options) having a
market value of at least  five times the annual retainer paid to Board
members. The Board recognizes that exceptions to this policy may be necessary
or  appropriate in individual cases, and may approve such exceptions from
time to time as it deems appropriate.  
---|---|--- 
  



   | V.| _Board Meetings_   
---|---|--- 
  



   | A.| _Scheduling of Meetings_. The Chairman, in consultation with
other members of the Board, shall determine the timing and length of the
meetings of the Board. The Board expects that five to six meetings per year
at appropriate intervals are generally desirable for the performance of the
Board's responsibilities. In addition to regularly scheduled meetings,
additional Board meetings may be called upon appropriate notice at any time to
address specific needs of the Company. A special meeting of the Board may be
called at any time by the Chief Executive Officer, the Chairman or by members
of the Board of Directors constituting no less than three-fourths (3/4) of the
total number of directors then in office. Participation in meetings may be by
means of conference telephone with the prior authorization from the
Chairman.  
---|---|--- 
  



    

 | 4| 
---|---|--- 

 



    



   | B.| _Agenda_. The Chairman and Chief Executive Officer, in
conjunction with the Lead Independent Director, shall establish the agenda for
each Board meeting. Each Director shall be entitled to suggest the inclusion
of items on the agenda, request the presence of any member of the Company's
senior management, or at any Board meeting raise subjects that are not on the
agenda for that meeting. Subject to reasonable exception, Directors shall be
advised of significant agenda items and shall be furnished with appropriate
supporting materials, including minutes of Board and Committee meetings, in
advance of meetings of the Board and Committees of the Board.  
---|---|--- 
  



   | C.| _Management Presentations_. Management shall make presentations
to the Board on the performance, operations, strategies and significant
activities of the Company.  
---|---|--- 
  



   | D.| _Executive Sessions_. The Board will generally meet in Executive
Session at each meeting and in any event, in Executive Sessions of the
independent Directors no less than twice a year. Executive Sessions of the
independent Directors will be chaired by the Lead Independent Director.  
---|---|--- 
  



   | VI.| _Attendance_   
---|---|--- 
  



   | A.| _Board Meetings_. It is expected that Board Members will make
every effort to attend every Board Meeting and meetings of their respective
Committees.  
---|---|--- 
  



   | B.| _Annual Stockholders Meeting_. It is expected that Board Members
will attend the Annual Stockholders Meeting, except when exceptional
circumstances prevent such attendance.  
---|---|--- 
  



   | VII.| _Chairman of the Board_   
---|---|--- 
  



   | A.| Subject to and in accordance with the By-laws of the Company, the
Chairman of the Board shall be elected by and serve at the pleasure of the
Board of Directors. The Board has no policy restricting the Chief Executive
Officer from serving as the Chairman.  
---|---|--- 
  



   | B.| The Chairman shall schedule board meetings and call meetings.  
---|---|--- 
  



   | C.| The Executive Chairman shall be designated the Chairman of the
Board until such time as the Board determines otherwise in accordance with
Section 3 of Article VII of the By-Laws of the Company (if such provision is
applicable at such time).  
---|---|--- 
  



   | VIII.| _Roles and Responsibilities: Executive Chairman and
Chief Executive Officer_   
---|---|--- 
  



   | A.| The roles and responsibilities of the Executive Chairman and the
Chief Executive Officer are set forth in the By-laws of the Company and on
Exhibit A to these Corporate Governance Guidelines.  
---|---|--- 
  



    

 | 5| 
---|---|--- 

 



    



   | IX.| _Lead Independent Director_   
---|---|--- 
  



  

An independent Director shall act in a lead capacity to perform certain
functions (" _Lead Independent Director_ ") as outlined below. Except as
otherwise provided in and subject to the By-laws of the Company, for so long
as the Chairman of the Board is also an officer or employee of the Company
(i.e., an Executive Chairman), or for any other reason is not an independent
director, then the independent directors of the Board of Directors shall
annually elect one of the independent directors to serve as the Lead
Independent Director and shall fill any vacancy in the position of Lead
Independent Director, when applicable, at such time and in such manner as
the independent directors of the Board of Directors shall determine, provided
that the Lead Independent Director may only be selected from among the
independent directors.

  



  

The Lead Independent Director's responsibilities are to:

  



   | (a)| call for and preside at Executive Sessions of the
independent Directors;  
---|---|--- 
  



   | (b)| provide the Chairman with input into the agenda for
Board meetings, and on other matters as deemed appropriate by the Board, or
on behalf of the independent Directors, and recommend the agenda for
Executive Sessions of independent Directors, to the extent deemed necessary;
and  
---|---|--- 
  



   | (c)| be available for consultation with other Directors, and apprise
the Chairman and the Chief Executive Officer, as appropriate, of activities of
the Board in Executive Sessions of the independent directors.  
---|---|--- 
  



   | X.| _Board Committees_   
---|---|--- 
  



   | A.| _Generally_. Standing and/or temporary committees may be
appointed by the Board from time to time. The Board may vest committees with
such power and authority as the Board determines appropriate, subject to such
limitations as are set forth in the Delaware General Corporation Law and the
Company's Certificate of Incorporation and By-Laws. In general, Committees of
the Board focus on issues that may require more in-depth time or
attention than could be consistently provided by the full Board. There are
currently three standing committees:  
---|---|--- 
  



  

Audit and Finance Committee (" _Audit Committee_ ")

  



  

Human Resources Committee (" _HR Committee_ ")

  



  

Corporate Governance and Nominating Committee (" _Governance Committee_ ")

  



   | B.| _Charters_. Each standing Committee shall have a written charter
of responsibilities, duties and authorities, which shall periodically be
reviewed by the Board. Each Committee shall report to the full Board with
respect to its activities, findings and recommendations.  
---|---|--- 
  



    

 | 6| 
---|---|--- 

 



    



   | C.| _Advisors_. Each Committee shall have full power and authority
to retain the services of such advisors and experts, including counsel, as the
Committee deems necessary or appropriate with respect to specific matters
within its purview.  
---|---|--- 
  



   | D.| _Committee Assignments_. Subject to and in accordance with the
By-laws of the Company, the Governance Committee, after consideration of the
desires, experience and expertise of individual Directors, shall recommend to
the Board the assignment of Directors to Committees, including the designation
of Committee Chairs. In acting upon such recommendation and report, the full
Board shall give consideration to the following objectives:  
---|---|--- 
  



   | *| the target size of each Committee is three or more members, unless
circumstances call for an exception;  
---|---|--- 
  



   | *| a Committee Chair shall stay on the Committee for one year after
stepping down as the Chair;  
---|---|--- 
  



   | *| the Audit, Human Resources and Governance Committees shall be
composed entirely of independent Directors.  
---|---|--- 
  



   | E.| _Committee Meetings_. Each Committee Chair, in consultation with
the Chairman of the Board, Committee members and management of the Company
shall establish agendas and set meetings at the frequency and length
appropriate and necessary to carry out the Committee's responsibilities. Any
Director who is not a member of a particular Committee may attend any
Committee meeting with the concurrence of the Committee Chair or a majority
of the members of the Committee.  
---|---|--- 
  



   | XI.| _Compensation_   
---|---|--- 
  



  

Directors who are not also officers of the company shall be appropriately
compensated for their service on the Board. This compensation shall take into
consideration the amount of time required to be devoted to Board activities,
the fiduciary responsibility of such positions and the competitiveness of the
compensation levels. Compensation is subject to change at the discretion of
the Board. The current composition of compensation paid to Outside Directors
shall be comprised of an annual Board retainer fee, annual Committee retainer
fees, Committee Chair and Lead Independent Director fees, all paid quarterly;
and an equity incentive component under the Company's Equity
Incentive Plan(s). The Company has adopted a deferred compensation plan which
allows Directors to defer payment of their Board compensation. This plan and
Director compensation may be changed from time to time by action of the Board.

  



   | XII.| _Self-Evaluation by the Board_   
---|---|--- 
  



  

The Governance Committee will manage a self-assessment process of the Board's
performance as well as follow up on self-assessments performed by the
Committees of the Board, the results of which will be discussed with the full
Board, including reviewing and recommending to the Board changes identified
by the Committees. The Governance Committee will also utilize the results of
this self-evaluation process in assessing and determining the characteristics
and critical skills required of prospective candidates for election to the
Board.

  



    

 | 7| 
---|---|--- 

 



    



   | XIII.| _Director Education_   
---|---|--- 
  



  

The Company shall assist the Board by providing appropriate orientation
programs for new Directors, which shall be designed both to familiarize new
Directors with the full scope of the Company's businesses and to assist them
in developing and maintaining skills necessary or appropriate for the
performance of their responsibilities. The Board and the Company's management
shall similarly work together to develop and periodically implement
appropriate continuing education programs for Board members.

  



   | XIV.| _Expenses_   
---|---|--- 
  



  

Directors shall be reimbursed for ordinary, necessary and reasonable expenses
incident to their service on the Board and to their attendance at meetings of
the Board, Committees of the Board and the annual stockholders meeting.
Requests for reimbursement for expenses over $75.00 must be accompanied by a
receipt for such expenses. Directors shall be reimbursed for air travel
expenses not exceeding the first-class commercial air travel rate. All such
requests are to be forwarded to the Secretary of the Company for processing.

  



   | XV.| _Capital Expenditures and Acquisitions_  
---|---|--- 
  



  

Management shall submit to the Board an Annual Capital Expenditure Budget for
Board approval at the same time the Annual Operating Budget is submitted.

  



  

While the Capital Expenditure Budget will outline anticipated projects, the
projects may change at the discretion of management as long as total annual
capital expenditures do not exceed the total Annual Budget and subject to the
individual expenditure approval levels established by the Board. If
management anticipates that expenditures will exceed the amount budgeted, it
must obtain Board approval for amounts that exceed the approved budget.

  



  

Management authority to approve funding for individual capital expenditures,
sale of assets and acquisitions is as follows:

  



     Up to $15 million  | Chief Executive Officer, and other executives
with the direction of the Chief Executive Officer 
---|--- 
     | 
   Greater than $15 million  | Board of Directors 
  



    

 | 8| 
---|---|--- 

 



    



   | XVI.| _Communications_   
---|---|--- 
 

  



   | A.| _Communications With Management_. As the role of the Board is
oversight of management and not directing the operations of the Company, in
general, Board members should communicate principally with the Chief
Executive Officer and other senior management of the Company. Board members
should carefully consider any communications with Company employees to ensure
it is an appropriate subject for communication.  
---|---|--- 
  



   | B.| _Communications to Board_. All Board members, including their
Committee assignments, are identified each year in the Company's Proxy
Statement. Communications which are intended for Board members can be sent to
the Company's Secretary at the Company's Headquarters for delivery to
individual Board members. Mail received will be delivered to the respective
Board member to which the communication is addressed. Mail addressed to
"Outside Directors" or "Non-Management Directors" will be forwarded or
delivered to the Chairman of the Governance Committee. Mail addressed to the
"Board of Directors" will be forwarded or delivered to the Chairman of the
Board.  
---|---|--- 
  



   | C.| _Communications with Third Parties_. To help shield directors
from general questions from media representatives and others, it is the
Company's policy that directors should respond by indicating that, as a
general matter, the Company's spokesmen are the Chairman or the Chief
Executive Officer or their designees and that comments on behalf of the
Company would come from such a person. Directors should at all times
maintain the confidentiality of sensitive or proprietary Company
information.  
---|---|--- 
  



   | D.| _Director Nominations_. The Directors welcome and are willing to
consider  recommendations from stockholders for Director nominations.
Stockholders desiring to make candidate recommendations for the  Board may do
so by submitting nominations to the Company or the Company's Governance
Committee, in accordance with the  Company's Bylaws and addressed to the
Corporate Secretary or to the Chairman of the Governance Committee at the 
following address: DENTSPLY SIRONA Inc., 221 West Philadelphia Street, York,
Pennsylvania 17405-0872.  
---|---|--- 
  



  

THESE GUIDELINES/POLICIES, INCLUDING ANY EXHIBITS ATTACHED HERETO, SHALL BE
SUBJECT TO CHANGE AS REQUIRED BY LAW OR AS DEEMED APPROPRIATE BY THE BOARD OF
DIRECTORS IN ACCORDANCE WITH THE BY-LAWS OF THE COMPANY.

  



    

 | 9| 
---|---|--- 

 



    



  

 _Exhibit A to Corporate Governance Guidelines/Policies_

  



  

Roles and Responsibilities: Executive Chairman and Chief Executive Officer

  



  

The role of the Executive Chairman will require a level of active engagement
in the Company to remain informed and knowledgeable of the operations of the
Company, including the integration efforts. This engagement cannot undermine
the authority of the CEO, but must be developed in concert with the CEO to
accomplish the goals of the Company. The CEO will have the general charge and
control over the business, affairs and personnel of the Company, having
authority and responsibility for the core operational, strategic and
organizational aspects of the business.

  



  

Subject to the foregoing principles the Roles and Responsibilities of the
Executive Chairman shall be as follows:

  



  

The Executive Chairman leads the Board of Directors of the Company. The CEO
reports to the Board of Directors through and in consultation with the
Executive Chairman. The Executive Chairman is an employee of the Company and
will take an active role in matters beyond the Board of Directors, in
partnership with the CEO. The two executives will develop a supportive and
collaborative relationship that will be driven by shared chemistry and strong
trust, and utilize the strengths and talents of both executives to advance the
strategic priorities of the Company.

  



  

The Executive Chairman will support the CEO's leadership of the company and
work in partnership with the CEO: (i) in the development and monitoring
of the strategic direction of the Company, (ii) in connection with MandA and
capital allocation and financial structure matters and (iii) regarding the
integration and synergy achievement of the combined Company, including the
Company's One Initiative efficiency program, while maintaining the best
attributes of each Company.

  



  

The Executive Chairman will remain knowledgeable of and informed on
operational matters, and will provide guidance and input on such matters,
provided that the involvement does not undermine the authority of the CEO.
The Executive Chairman will work closely with the CEO to merge the talent and
cultures of the combined Companies. The Executive Chairman will work together
with the CEO and provide counsel in the CEO's selection of senior management,
including the structure of the management team of the Company (segments,
etc.). The Executive Chairman will provide mentoring to senior management, as
requested by the CEO.

  



  

The Executive Chairman will participate in and collaborate with and support
the CEO in matters concerning: (i) industry relationships, (ii) investor
relations and (iii) communications with shareholders and the financial
community, as agreed to by the CEO and Executive Chairman.

  



  

The Executive Chairman will (i) oversee meetings of the Board and lead the
annual meeting of the Company's shareholders, (ii) set the Board agenda with
regard to all matters within the purview of the Board and develop the Board
meeting schedule in concert with the CEO, (iii) attend Committee meetings in
the Executive Chairman's discretion, (iv) facilitate discussions among Board
members and foster a collaborative meeting environment, (v) ensure Board
members receive accurate, timely and clear information, (vi) oversee a program
for Board performance, (vii) lead executive sessions among outside directors,
(viii) meet with the CEO one on one to discuss executive session and provide
feedback and critique to the CEO and (ix) advise the Board on the CEO
succession plan, if relevant.

  



    

 A-1

    

     '

